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I 
RESUME EN FRANÇAIS 
Introduction 
La réponse inflammatoire est un ensemble complexe de processus biologiques et 
biochimiques impliquant des cellules du système immunitaire et une pléthore de médiateurs 
biologiques. La réponse inflammatoire implique le relâchement séquentiel de médiateurs 
solubles, le recrutement de leucocytes circulants, qui deviennent activés au site inflammatoire, 
expriment de nouvelles molécules à surface, et relâchent davantage de médiateurs solubles. 
Dans la plupart des cas cette réponse se termine par le relâchement de médiateurs anti-
inflammatoires ainsi que par l’accumulation de facteurs régulateurs négatifs intracellulaires et 
finalement par l’élimination des cellules inflammatoires. L’inflammation peut être 
caractérisée d’aiguë ou de chronique. Est considérée comme chronique, une inflammation de 
durée prolongée (quelques semaines ou quelques mois) pendant laquelle l’inflammation reste 
active et où les processus de destruction et de réparation tissulaire sont actifs simultanément. 
Bien qu’elle puisse succéder à une inflammation aiguë, l’inflammation chronique commence 
fréquemment de manière insidieuse, par une réponse de moindre degré, latente et souvent 
asymptomatique. Plus spécifiquement, se sont l’accumulation et l’activation persistante des 
leucocytes qui caractérisent une inflammation chronique, et représentent, de ce fait, sa 
distinction majeure de l’inflammation aiguë.  
Les molécules de communication cellule-cellule - collectivement appelées cytokines - 
jouent un rôle extrêmement important de médiateurs dans les processus inflammatoires. Les 
cytokines sont des glycoprotéines de faible poids moléculaire (5-50 kDa) produites par une 
grande variété de cellules immunes ou non-immunes possédant des fonctions pro-
inflammatoires et/ou anti-inflammatoires. L’inflammation progresse en fonction de l’action 
de cytokines pro-inflammatoires, dont l’interleukine-1 (IL-1), et le facteur nécrosant des 
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tumeurs (TNF). La réponse inflammatoire se termine par le relâchement de cytokines anti-
inflammatoires, telles que la forme soluble de l’antagoniste du récepteur à l’IL-1 (sIL-1Ra), 
ainsi que par l’accumulation de facteurs régulateurs intracellulaires capables d’abroger la 
réponse en inhibant les voies de transmission du signal pro-inflammatoire. Les cytokines sont 
synthétisées transitoirement après l’activation cellulaire. Leurs autres caractéristiques sont le 
pléiotropisme, la redondance, la synergie, et le travail en réseau de cascades. Les cytokines 
ont souvent un faible rayon d’action, agissant sur leur propre cellule d’origine (influence 
autocrine) ou sur une cellule cible voisine (influence paracrine). Les cytokines se lient à des 
récepteurs membranaires et, par un processus d’activation de voies de signalisation 
impliquant des enzymes intracellulaires et des facteurs de transcription, peuvent induire, 
augmenter ou inhiber leurs gènes-cibles. Parce que les cytokines sont des régulateurs de 
mécanismes homéostatiques telles que les réponses immunitaires, l’inflammation et la 
réparation tissulaire, des variations de leurs niveaux d’expression et de production sont 
associées à des processus pathologiques et peuvent contribuer à leur pathogenèse. Ainsi, une 
production excessive et/ou une inhibition insuffisante des cytokines pro-inflammatoires 
seraient associées aux effets délétères observés dans des maladies inflammatoires chroniques 
comme l’arthrite rhumatoïde et la sclérose en plaques. En effet, dans ces maladies, l’IL-1 et le 
TNF conjuguent leurs actions pour exacerber la maladie, alors que le sIL-1Ra (entre autres) 
tente de réduire l’inflammation et de promouvoir la guérison. Toutefois, il n’est pas encore 
établi qu’un tel déséquilibre est la cause première de la maladie ou ne représente que le reflet 
d’un changement secondaire à l’établissement le la chronicité de l’inflammation. Bien que des 
recherches se poursuivent visant à établir les causes infectieuses possibles de l’arthrite 
rhumatoïde et de la sclérose en plaques, l’inflammation per se reste une des cibles 
thérapeutiques principales de ces maladies. 
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Lors d’une réponse inflammatoire aiguë, c’est-à-dire lorsque l’organisme est le sujet 
d’un dommage mécanique et d’une infection, les cytokines pro-inflammatoires, dont l’IL-1 et 
le TNF, jouent un rôle primordial dans l’élimination des agents pathogènes et donc dans la 
guérison. Les principales cellules qui produisent l’IL-1 et le TNF appartiennent à la lignée 
monocytaire, et seront appelées monocyte/macrophages dans ce résumé. Traditionnellement, 
dans les études in vitro, la production de ces cytokines est induite par les endotoxines de type 
lipopolysaccharides (LPS) qui sont les composants principaux  de la paroi des bactéries 
Gram-. Cependant, dans les maladies inflammatoires chroniques telles que l’arthrite 
rhumatoïde et la sclérose en plaques, la présence d’agents pathogènes (bactéries, virus) n’est 
usuellement pas décelée. La question du mécanisme d’induction de l’IL-1 et du TNF dans ces 
dernières conditions est donc importante. 
Dans l’arthrite rhumatoïde et la sclérose en plaques, l’inflammation est caractérisée par 
une infiltration importante dans les tissus cibles de cellules immunes, telles que des 
lymphocytes T et B, et des cellules phagocytaires, principalement des neutrophiles et des 
monocyte/macrophages. Dans ces conditions d’inflammation stérile, les 
monocyte/macrophages apparaissent également jouer un rôle clé puisque ce sont eux aussi qui 
produisent de préférence l’IL-1 et le TNF. L’hypothèse prédominante quant à la pathogenèse 
de l’inflammation chronique suggère que les lymphocytes T aient un effet pathogénique 
puisque l’infiltration de ces cellules dans le tissu cible précède les dommages tissulaires. Cette 
hypothèse a reçu confirmation par des expériences dans des modèles animaux qui ont permis 
de démontrer que l’injection de lymphocytes T, isolés de souris atteintes soit d’encéphalite 
allergique expérimentale (EAE, modèle animal de la sclérose en plaques) soit d’une arthrite 
induite au collagène (CIA, modèle animal de l’arthrite rhumatoïde), induisait ces maladies 
chez des souris saines. Très rapidement après les lymphocytes T, des monocyte/macrophages 
arrivent au site inflammatoire et des interactions se produisent entre ces types cellulaires. A 
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l’instar de cellules d’autres systèmes, celles du système immunitaire peuvent interagir les unes 
avec les autres par l’intermédiaire de cytokines mais également en établissant des contacts 
cellulaires directs. Ce dernier mécanisme (le contact cellulaire) semble jouer un rôle important 
dans l’inflammation chronique puisque in vitro, dans des conditions stériles, c’est-à-dire dans 
des conditions ressemblant à l’inflammation chronique, l’activation par le contact direct avec 
les lymphocytes T stimulés est capable d’induire par lui-même la production de TNF et d’IL-
1 dans les monocyte/macrophages et dans des cellules de la lignée monocytaire. Ceci suggère 
que ce mécanisme puisse être hautement important dans la pathogenèse et la persistance de 
l’inflammation chronique dans des maladies telles que l’arthrite rhumatoïde et la sclérose en 
plaques.  
Buts de l’étude 
L’objectif général de cette thèse est de caractériser les bases moléculaires du contact 
cellulaire comme une stratégie biologique générale, par laquelle les monocyte/macrophages 
sont activés pour produire des cytokines par le truchement du contact cellulaire avec des 
lymphocytes T stimulés. Pour aborder cette problématique, quatre aspects cruciaux de ce 
mécanisme ont été investigués, et ont fait, pour les trois premiers d’entre eux, l’objet de 
publications qui sont intégrées dans cette thèse. Le dernier aspect de ce projet fait 
actuellement l’objet d’un manuscrit en préparation, qui figure également dans cette thèse. Par 
ailleurs, cet écrit de thèse comporte une revue récemment publiée par notre groupe qui recadre 
mon travail de thèse dans une perspective plus générale des processus inflammatoires tels 
qu’ils sont considérés dans le cadre des pathologies inflammatoires, plus particulièrement 
dans l’arthrite rhumatoïde. Cette revue a pour titre “Des récepteurs cellulaires aux voies de 
transduction-transcription pour les cytokines : à quel niveau cibler l’inhibition de 
l’inflammation ?” 
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Résultats 
L’induction différentielle de l’IL-1b et du TNF par le ligand du CD40 ou par le contact 
cellulaire avec des lymphocytes T stimulés dépend du stade de maturation des 
monocytes humains 
Une des questions fondamentales que pose le modèle d’activation des 
monocyte/macrophages par le contact cellulaire avec les lymphocytes T stimulés est la 
caractérisation des molécules de surface responsables de ce processus sur les deux cellules 
impliquées. En effet, le contact cellulaire avec des lymphocytes T stimulés induit fortement la 
production des cytokines dans les monocyte/macrophages, un mécanisme qui joue 
probablement un rôle important dans l’inflammation chronique. Bien que l’identité des 
molécules de surface impliquées dans ce processus reste inconnue à ce jour, il a été suggéré 
que le CD40 et son ligand le CD40L, soient impliqués, car tous deux sont exprimés au site 
inflammatoire. En plus d’une expression aberrante de CD40, associée aux maladies auto-
immunes inflammatoires comme l’arthrite rhumatoïde et la sclérose en plaques, l’expression 
de CD40L est augmentée dans les lymphocytes T au site inflammatoire et dans le sang 
périphérique des patients. Pour s’assurer de l’implication du CD40L dans l’induction des 
cytokines par le contact cellulaire entre lymphocytes T stimulés et monocyte/macrophages, 
nous avons comparé l’activation de trois types différents de cellules monocytaires : des 
monocytes fraîchement isolés, des monocytes différenciés par de l’interféron (IFN)-g (IFNg-
macrophages), et des cellules de la lignée THP-1, comme modèle de macrophages dérivés de 
monocytes. L’approche technique consistait à activer ces cellules monocytaires par des 
membranes isolées de lymphocytes T stimulés, afin d’imiter le contact cellulaire, ou par un 
trimère synthétique du CD40L (CD40LT), la forme la plus active du CD40L. Les résultats ont 
démontré que la production d’IL-1b et de TNF était induite par les membranes de cellules T 
stimulées chez les trois types de cellules cibles, alors que le CD40LT induisait la production 
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de TNF seulement chez les IFNg-macrophages. Des résultats similaires ont été obtenus avec 
des extraits solubles de membranes de lymphocytes T, démontrant que la différence entre les 
membranes et le CD40LT n’était pas due à la forme particulaire des membranes. Chez les 
monocytes, le CD40LT n’induisait ni l’ARN messager, ni la protéine des cytokines, alors que 
chez les IFNg-macrophages, les messagers de l’IL-1b et du TNF ont pu être mesurés, bien que 
seul le TNF fut exprimé dans les surnageants de culture. Finalement, des anticorps anti-
CD40L bloquants n’ont pas été capables d’inhiber la production d’IL-1b et de TNF induite 
chez les IFNg-macrophages par des membranes solubilisées, alors que la production de TNF 
induite par le CD40LT était inhibée. Cette étude a donc démontré que le CD40L n’était pas 
nécessaire à l’induction de la production de TNF et d’IL-1b lors de l’activation des 
monocyte/macrophages par le contact cellulaire direct avec des lymphocytes T stimulés, bien 
que le CD40LT per se induise la production de TNF chez les IFNg-macrophages. 
Effets opposés de l’IFNb sur l’homéostasie des cytokines produites par les monocytes 
humains activés par des LPS ou par contact cellulaire direct avec des lymphocytes T 
stimulés 
L’administration d’IFNb montre une certaine efficacité thérapeutique chez les patients 
atteints de la forme rémittente-progressive de la sclérose en plaques et pourrait également être 
potentiellement bénéfique dans l’arthrite rhumatoïde. L’IFNb peut induire directement la 
production de la forme soluble de l’antagoniste du récepteur à l’IL-1 (sIL-1Ra) chez les 
monocytes humains, ceci en l’absence de production d’IL-1b et de TNF. Cette propriété anti-
inflammatoire pourrait être en partie responsable des effets bénéfiques de l’IFNb en thérapie. 
Par ailleurs, un autre travail de notre laboratoire a récemment démontré que l’IFNb inhibait la 
production d’IL-1b et de TNF chez les monocytes humains activés par le contact avec des 
lymphocytes T stimulés, alors que la production de sIL-1Ra était augmentée. Dans la mesure 
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où les patients traités par l’IFNb ne développent pas plus d’infection que les contrôles, nous 
avons comparé les effets modulateurs de l’IFNb sur la production des cytokines pro-
inflammatoires (IL-1b, IL-1a, TNF et IL-6) et de sIL-1Ra par les monocytes humains 
stimulés par les LPS et des membranes plasmiques isolées de lymphocytes T stimulés (msT), 
qui, reflètent l’activation des monocytes dans l’inflammation aiguë et chronique, 
respectivement. Les résultats ont montré que chez les monocytes activés par les LPS ou les 
msT, l’IFNb ne modulait pas la sécrétion de l’IL-1a et de l’IL-6, mais augmentait la 
production de sIL-1Ra en fonction de la dose. Toutefois, dans les monocytes activés par les 
msT, l’expression de l’IL-1a associée à la cellule et intracellulaire était inhibée par l’IFNb, 
correspondant à l’inhibition du messager de l’IL-1a. Confirmant les résultats déjà publiés, 
l’IFNb inhibait l’expression du messager et la production de la protéine de l’IL-1b et du TNF 
chez les monocytes activés par les msT. Chez les monocytes activés par les LPS, le contraire 
se produisait, l’IFNb augmentait l’expression et la production d’IL-1b et de TNF, démontrant 
qu’il n’exprimait pas d’effets anti-inflammatoires dans ces conditions d’inflammation aiguë. 
En conclusion, cette étude a démontré que l’IFNb a des effets opposés selon le type 
d’activation des monocytes humains. Il peut donc affecter des mécanismes inflammatoires de 
manière différente, ayant des effets anti-inflammatoires dans des conditions imitant 
l’inflammation chronique et des effets pro-inflammatoires dans des conditions relevant de 
l’inflammation aiguë. Ces observations pourraient expliquer pourquoi les infections ne sont 
pas des effets secondaires courants dans le traitement de la sclérose en plaques par l’IFNb. 
La production du sIL-1Ra chez les monocytes humains stimulés par l’IFNb dépend de 
l’activation de la phosphatidylinositol 3-kinase mais pas de STAT1 
De façon canonique, l’IFNb, après sa liaison avec son récepteur, active la voie dite 
« JAnus kinase/transducteur du signal et activateur de la transcription » ou plus 
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communément, la voie des JAk/STAT, bien que la voie des phosphatidylinositol 3-kinases 
(PI3Ks) et de la protéine kinase activée par le mitogène (MAPK) soient également 
impliquées. Nous avons donc étudié le rôle des PI3Ks, de la MAPK kinase MEK1, et de 
STAT1 dans la production de sIL-1Ra induite par l’IFNb chez des monocytes humains 
fraîchement isolés du sang périphérique. Des expériences recourant à des inhibiteurs 
respectifs des PI3Ks et de MEK1, Ly294002 et PD98059, ont révélé que l’activation des 
PI3Ks, mais pas celle de MEK1, était essentielle à la production du sIL-1Ra chez les 
monocytes traités à l’IFNb. L’utilisation de la cycloheximide (un bloqueur de la synthèse des 
protéines) et de l’actinomycine D (un bloqueur de la transcription) ont montré que le sIL-1Ra 
était un gène précoce immédiatement induit par l’IFNb et que les PI3Ks en contrôlaient la 
transcription. Les inhibiteurs des PI3Ks et de MEK1 diminuaient la phosphorylation de la 
sérine 727 de STAT1 induite par l’IFNb, mais seul le Ly294002 inhibait la production de sIL-
1Ra, suggérant que STAT1 ne soit pas impliqué dans l’induction du gène du sIL-1Ra. Ce 
résultat fut confirmé car l’inhibition de la phosphorylation de la sérine 727 de STAT1 par le 
Ly294002 n’affectait pas la translocation de STAT1. Pour établir plus solidement que le 
STAT1 n’était pas impliqué dans l’induction du sIL-1Ra par l’activation des monocytes, ces 
derniers ont été transfectés par des petits ARN interférants (siRNA) ciblant spécifiquement 
STAT1. Les monocytes dans lesquels l’interférence par le siRNA était efficace à plus de 90% 
répondaient totalement à l’IFNb, d’après la production de sIL-1Ra. En conclusion, ces 
données démontrent que l’induction par l’IFNb de la transcription du gène du sIL-1Ra et de 
sa production chez les monocytes humains impliquait l’activation des PI3Ks mais pas celle de 
STAT1. 
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Les phosphatidylinositide 3-kinases régulent de manière opposée la production d’IL-1b 
et du sIL-1Ra chez les monocytes humains: implication dans l’inflammation 
aiguë/infectieuse et chronique/stérile. 
Après avoir démontré que les PI3Ks contrôlaient la production d’sIL-1Ra chez les 
monocytes humains activés par l’IFNb et dans la mesure où ce dernier modulait de manière 
différentielle la production d’sIL-1Ra et d’IL-1b chez ces mêmes cellules activées par les LPS 
ou les msT, nous avons donc entrepris d’étudier le rôle des PI3Ks dans l’induction de la 
production d’IL-1b et de sIL-1Ra chez les monocytes humains dans des conditions 
apparentées à l’inflammation aiguë ou chronique. Chez des monocytes activés soit par les 
LPS, soit par les par un extrait soluble des msT (CEsHUT), l’inhibiteur des PI3Ks, le 
Ly294002, inhibait l’expression du messager de l’sIL-1Ra et rabaissait la production d’sIL-
1Ra au niveau basal. Ceci démontrait que les PI3Ks contrôlaient la transcription du gène du 
sIL-1Ra. Par contre, le Ly294002 augmentait la production de la protéine de l’IL-1b, aussi 
bien chez les monocytes activés par les LPS que par le CEsHUT. Cependant, chez les 
monocytes activés par le CEsHUT, l’augmentation de la production d’IL-1b était de 10 à 15 
fois plus importante que celle induite par l’activation au LPS. L’augmentation de la 
production d’IL-1b n’était pas due à des changements des niveaux à l'état stationnaire du 
messager de l’IL-1b ni à des effets sur la stabilité de ces derniers. La régulation de la 
production d’IL-1b pouvant également se faire au niveau de la sécrétion, nous avons mesuré 
simultanément la production de la cytokine dans des surnageants de culture et dans des lysats 
cellulaires. Les résultats montrent que parallèlement aux niveaux augmentés d’IL-1b dans les 
surnageants de culture cellulaire, l’inhibition des PI3Ks diminuait la quantité d’IL-1b associée 
à la cellule, suggérant que les PI3Ks soient impliquées dans le contrôle du relâchement de 
l’IL-1b. La régulation différentielle de la production de l’IL-1b et du sIL-1Ra était spécifique 
X 
de la voie des PI3Ks, car elle était également observée avec un inhibiteur de l’Akt, le substrat 
le plus étudié en aval des PI3Ks. Les messagers de l’IL-1b induits par les msT étaient 
beaucoup plus instables que ceux induits par les LPS. Dans l’ensemble, ces résultats 
démontraient que les PI3Ks étaient impliquées dans la répression de la production d’IL-1b et 
dans l’induction de la production de sIL-1Ra chez des monocytes humains en régulant 
différents mécanismes. Ainsi les PI3Ks représentent des effecteurs-clés qui pourraient être 
dérégulés dans des conditions pathologiques telles que l’arthrite rhumatoïde et la sclérose en 
plaques, dans lesquelles la production déséquilibrée/incontrôlée des cytokines pro- et anti-
inflammatoires exerce un rôle pathogénique important. 
Conclusions 
Dans ce travail de thèse nous avons en premier lieu écarté l’implication controversée 
de l’interaction CD40L-CD40 dans l’activation des monocyte/macrophages par le contact 
cellulaire avec les lymphocytes T stimulés, un mécanisme qui semblerait jouer un rôle 
important dans le déclenchement et la persistance des maladies chroniques/stériles telles que 
l’arthrite rhumatoïde et la sclérose en plaques. Etant donnée la difficulté dans l’avenir de 
préciser l’identité des molécules de surface impliquées dans ce mécanisme, nous avons dès 
lors investigué les effets de l’IFNb, une médication pour la sclérose en plaques et 
probablement l’arthrite rhumatoïde, sur les fonctions inflammatoires des monocytes activés 
par le contact cellulaire. Parallèlement, afin de comparer deux types de condition 
inflammatoire, nous avons également étudié les effets de l’IFNb sur les fonctions 
inflammatoires des monocytes dans des conditions d’activation correspondant à celles de 
l’inflammation aiguë/infectieuse. Nous avons démontré que l’IFNb orientait la fonction des 
monocytes vers un statut anti-inflammatoire dans des conditions d’activation correspondant à 
l’inflammation chronique, mais pas aiguë. Ainsi, nos observations ont à la fois permis de 
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renforcer la pertinence in vivo du contact cellulaire, et de fournir une explication quant à la 
rareté des cas rapportés d’épisodes infectieux chez des patients atteints de sclérose en plaques 
sous traitement à l’IFNb. Par ailleurs, puisque l'induction de la production de sIL-1Ra 
représente une caractéristique primordiale de l’IFNb, nous nous sommes alors penchés sur les 
voies de transduction impliquées dans cette synthèse. Curieusement, nos résultats ont permis 
d’écarter toute implication du facteur de transcription STAT1, et donc sa nécessité aux effets 
initiés par l’IFNb. Au contraire, nous avons mis en lumière le rôle crucial des PI3Ks dans la 
régulation transcriptionnelle du gène du sIL-1Ra. Ces observations nous ont conduit 
finalement à déterminer la fonction des PI3Ks dans la production des cytokines pro- et anti-
inflammatoires par les monocytes dans des conditions d’activation relatives à l’inflammation 
stérile ou infectieuse. Ainsi dans cette dernière étude, nous avons établi que les PI3Ks 
représentaient des effecteurs-clés qui pourraient être déréglés dans des conditions 
pathologiques. 
Les approches cliniques actuelles pour le traitement de l’inflammation se focalisent 
principalement sur l’inhibition de l’activité des médiateurs pro-inflammatoires et par la 
suppression de l’initiation de la réponse inflammatoire. Toutefois, relativement peu 
d’attention a été consacrée à la manière dont les réactions inflammatoires se résolvent et si ces 
mécanismes endogènes de contrôle de l’inflammation pouvaient être exploités de façon 
thérapeutique. Ainsi, la capacité d’auto-résolution des réactions inflammatoires pourrait 
nécessiter l’activité des PI3Ks, dont l’activation se produirait de manière cyclique dans des 
maladies inflammatoires chroniques, telles que l’arthrite rhumatoïde et la sclérose en plaques, 
qui montrent souvent des périodes de rémission.  
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FOREWORD 
Inflammation was originally defined by Celsus around 40 AD as “rubor, calor, dolor, and 
tumor” (redness, heat, pain and swelling) and further completed in 1858 by Rudolf Virchow by 
means of the feature “functio laesa” (dysfunction of the organs involved), and represents an 
intellectually attractive problem in biology and signal transduction systems. Inflammation could be 
depicted as the normal response of living tissues to mechanical injury, invasion by microorganisms, 
and chemical toxins. It is important to pinpoint that inflammation is a normal response and, as such, 
is expected to take place when tissue is injured. Indeed, if a damaged tissue did not exhibit signs of 
inflammation this would be abnormal. The major goal of the inflammatory response is to localize 
and remove the causative agent or substance and repair the surrounding tissues that were damaged by 
trauma. It is imperative however to emphasize that while inflammation stand for an essential 
physiological response that contributes to normal healing and repair, it represents a double-edged 
sword, because inflammatory responses elicited by hypersensitivity reactions and autoimmune injury 
mediate significant tissue damage due to the host response.  
In the course of inflammatory reactions, pro-inflammatory mechanisms are important to 
guarantee elimination of causative infectious, toxic, or allergenic agents. Once induced, 
inflammatory processes do not go up but are again down-regulated to allow healing. Therefore, pro-
inflammatory and anti-inflammatory mechanisms have to be activated spatially and temporally in a 
finely tuned manner. This is emphasized by deregulation of the inflammatory processes seen in 
sepsis. In such a case, the causative agent is a microbial agent; and considerable production of 
inflammatory mediators, including cytokines such as tumor necrosis factor (TNF) or interleukin (IL)-
1 actually mediates the detrimental developments. On a second time, the septic organism tries to 
counteract the effects of these pro-inflammatory cytokines, e.g. via the production of IL-1 receptor 
antagonist (IL-1Ra). This is the reason why septic shock may not only be due to an aberrant 
overwhelming pro-inflammatory reaction, but can also be caused by dysfunction or failure of anti-
inflammatory control mechanisms(14). TNF and IL-1 play an important part in chronic inflammatory 
destructive diseases. For convenience, examples of chronic inflammatory destructives diseases will 
be limited in this thesis to rheumatoid arthritis (RA) and multiple sclerosis (MS). While both diseases 
are of unknown etiology, they may possibly result from the excess production of pro-inflammatory 
cytokines as well as the inadequate production of anti-inflammatory cytokines(15). Thus, pro-
inflammatory reactions are closely interconnected with counter-regulatory anti-inflammatory 
pathways.  
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The pathogenesis of organ-specific chronic inflammatory diseases such as RA and MS 
assumes for a long-time the traditional autoimmune prototype, which supports that T cells respond to 
a specific antigen(s) in a target organ. Such current concept is evolving in light of the literature 
showing the importance of contact-mediated activation of monocytic lineage cells by stimulated T 
cells(4;16). Such cell-cell contact interactions do not presume any specific response and depend only 
on the localization of stimulated T cells adjacent to cells capable to produce inflammatory and 
destructor mediators. Noticeably, direct contact-mediated cognate interactions between stimulated T 
lymphocytes and monocyte/macrophages or microglial cells, trigger massive up-regulation of the 
pro-inflammatory cytokines TNF and IL-1(4).  
Overall, this thesis attempts to characterize the molecular mechanisms of cell-cell contact, 
whereby monocyte/macrophages are turn on to produce cytokines upon cellular contact with 
stimulated T cells, underlying inflammatory reactions elicited in the context of chronic and 
destructive inflammatory diseases exemplified here by RA and MS. Investigations were purchased 
exclusively on human monocyte/macrophages since they play critical accessory, inflammatory, and 
effector roles in non-septic T cell-mediated chronic inflammatory diseases and are present 
throughout the inflammatory process. Alternatively, because monocyte/macrophages are exquisitely 
responsive to microbial infection and play important roles in the induction of acute inflammatory 
reactions(17), this thesis aspires as well to highlight the divergences and similarities of 
monocyte/macrophage biology in acute/infectious and chronic/sterile systems, at both cellular and 
molecular levels.  
The experimental part of this thesis is presented in the form of three papers already published 
and one manuscript envisioned for publication, all comprising their own set of references. The 
general background is treated in the introduction, which is composed of different sections intending 
to summarize the current knowledge about inflammation, the role of inflammation in T cell-mediated 
autoimmune diseases such as RA and MS, the regulatory systems of inflammation including 
cytokine and signal transduction networks, and the molecular therapeutic targets in inflammation. 
This latter part is a review from our group and comprises its own set of references. The significance 
of these results already discussed in the different publications will be the object of the last section. 
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INTRODUCTION 
1. Inflammation 
In contrast to the immune response that is characterized by a high degree of specificity and 
memory, the inflammatory response is unspecific and does not possess memory. Consequently, 
regardless the type of exposure or number of exposures to the same stimulus, the inflammatory 
response is always the same. Inflammation has been categorized as acute and chronic. The main 
distinction between the two types is question of duration, since a long-lasting acute inflammation is 
considered chronic. Indeed, although difficult to define precisely, chronic inflammation is considered 
to be inflammation of prolonged duration (weeks or months) in which active inflammation, tissue 
destruction, and attempts at repair are proceeding simultaneously. Although it may follow acute 
inflammation, chronic inflammation frequently begins insidiously, as a low-grade, smoldering, often 
asymptomatic response. A central difference between acute and chronic inflammation also occurs at 
the cellular level in the types of cells that prevail, because there is an abundance of phagocytic cells 
(mainly neutrophils and macrophages) in acute inflammation, and a dominance of lymphocytes (T 
and B) and monocyte/macrophages in chronic inflammation(18).  
Three foremost actions take place during the inflammatory response: the blood supply to the 
affected area is augmented significantly, capillary permeability is increased, and leucocytes migrate 
from the capillary vessels into the surrounding interstitial space to the site of inflammation or injury 
 
Figure 1. Bacterial infection triggers an inflammatory response. Phagocytic cells of the innate immune system, such as macrophages are able 
to recognize and bind conserved constituents of microorganisms by means of surface receptors. Bacterial molecules, for instance, once bound to 
these receptors trigger the macrophage to engulf the bacterium and also to secrete biologically active molecules such as cytokines and 
chemokines. These factors then initiate the process known as inflammation. Cytokines enhance the adhesive properties of the endothelium, 
causing circulating leukocytes to migrate to the site of infection, to which they are attracted by chemokines.  
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(Figure 1). Such intricate biological and biochemical processes involved cells of the immune system 
and a plethora of bioactive mediators. Particularly, cell-to-cell communication molecules known as 
cytokines play an essential role in mediating this process. Cytokines have complex, pleiotropic 
effects and interact with many cell types to amplify the inflammatory response. Taken as a whole, an 
inflammatory response consists of the sequential release of inflammatory mediators and the 
recruitment of circulating leukocytes, which become activated at the inflammatory site and release 
further mediators. In most cases, however, an inflammatory response is resolved by the release of 
endogenous anti-inflammatory mediators as well as by the accumulation of intracellular negative 
regulatory factors(19). Therefore the regulation of inflammation is a crucial event, and its alteration 
determines severe tissue damages, such as those observed in severe sepsis and chronic inflammatory 
autoimmune diseases (e.g. rheumatoid arthritis (RA), multiple sclerosis (MS)) or infectious diseases 
(e.g. tuberculosis, leprosy). Overall, there is a general consensus that the regulation of inflammation 
results from a balance between pro-inflammatory and anti-inflammatory pathways. This concept, 
which is fundamental to cytokine biology and also to clinical medicine, claims that some cytokines 
primarily function to induce inflammation (pro-inflammatory) whereas others repress inflammation 
(anti-inflammatory). Particularly, inflammation progresses by the action of pro-inflammatory 
cytokines, such as interleukin (IL)-1, tumor necrosis factor (TNF), IL-6 and interferon (IFN)-γ, and 
resolves by anti-inflammatory cytokines, including IL-4, IL-10, IL-13, IL-1 receptor antagonist (IL-
1Ra), IFN-α/b and transforming growth factor (TGF)-b(19).  
Because deregulation of the inflammatory processes is linked to both acute and chronic 
inflammatory diseases, pharmacological intervention is often necessary to attenuate cellular 
inflammatory pathways(20). For several important diseases, whose the primary pathogenetic events 
are unidentified, such as RA and MS, the control of inflammation is considered as the next best 
alternative. Nevertheless the number of diseases previously declared as “inflammatory” may 
diminish since infectious causes continue to be demonstrated for some of them, as recently revealed 
for Helicobacter pylori-dependent chronic gastritis(21). However, within these specific and 
numerous other infectious diseases, the inflammatory response may be more harmful than the 
microbe itself. Therefore, while the search is maintained for potential infectious causes of RA and 
MS, inflammation per se represents a major therapeutic target.  
2. Cytokines 
Cytokines play crucial roles in inflammation being the cause of many signs and symptoms, 
since they are implicated in the regulation of the magnitude, nature, and duration of the inflammatory 
response. Cytokines are nonstructural proteins or glycoproteins functioning as overlapping and 
interdependent molecules with important roles in the homeostatic control of the immune system and 
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other organs, upon physiological and pathological conditions(22). These mediators form a complex 
network of molecules that may act systemically as well as locally in an auto- or paracrine manner. 
Other cytokine features are pleiotropism, synergism, and redundancy. Most cytokines are often 
similar in size (5 and 50 kD) and charge(23). The active form of cytokines may be monomeric (e.g. 
IL-1b)(24), whereas noncovalent associations are required between monomers to form homodimers 
(e.g. IFNb)(25), homotrimers (e.g. TNF)(26), or higher oligomers (e.g. IL-16) to produce the active 
form. A small number of cytokines are active as heteromers (e.g. IL-12)(27). Cytokines mainly 
function as soluble mediators between cells and act via the interaction with specific cell surface 
receptors in the nano- to picomolar range. Cytokine receptors are generally expressed at low levels 
on resting cells but their expression can be up-regulated during activation. Many cytokine receptors 
share common signal transducing receptor components, which could partly explain the functional 
redundancy of cytokines(28). Although the majority of cytokines are secreted (e.g. IFNb), 
membrane-bound cytokines (e.g. IL-1a, TNF), cytokines associated with the extracellular matrix 
(IFNg) and cytokines stored inside cells (e.g. intracellular IL-1Ra (icIL-1Ra)), have also been 
described. The tight regulation of cytokine expression takes place at multiple levels being usually 
synthesized transiently after cell stimulation in response to an induction signal, although constitutive 
expression has also been observed(29). Cytokine expression could be regulated at the level of 
transcription, translation, and processing. The modulation of mRNA half-life by the selective 
degradation of transcripts, and particularly those containing specific RNA-destabilizing elements 
such as adenylate uridylate (AU)-rich elements (AREs), appears to be one of the mechanisms 
allowing transient expression of cytokines. The 3’ untranslated regions of inflammatory cytokines 
encode AREs that control mRNA stability and translationnal efficiency. These cis-elements recruit a 
family of trans-acting factors that determine whether individual transcripts are translated or 
degraded(30-32). Additionally, while most cytokines are secreted by cells through the classical 
endoplasmic reticulum-to-Golgi exocytic pathway, some cytokines devoid of secretory signal 
sequence are released by alternative pathways (e.g. IL-1b)(33;34).  
Because cytokines play an important role in the homeostatic regulation of the immune 
system, other organs (reproductive cycle, sleep) and inflammation, being important components of 
defence and repair systems(35), they could also be harmful mediators of infectious and immuno-
inflammatory reactions. More specifically, the excessive production of pro-inflammatory cytokines 
can be even more dangerous than the original stimulus, overcoming the normal regulation of the 
immune response and producing pathological inflammatory disorders. In this context, it is likely that 
a deregulated cytokine function can subsequently promote or sustain chronic inflammation, such as 
RA and MS. There are a number of homeostatic mechanisms that may regulate inflammatory 
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processes and numerous mediators may act as immune deactivators. For instance, the synthesis of 
pro-inflammatory cytokines may be inhibited by IL-4, IL-10 and IFNb(22;36-40), i.e. anti-
inflammatory cytokines. The activity of pro-inflammatory cytokines could be also modified by 
complex formation between cytokines and their receptors which are shed from activated cells in a 
soluble form, e.g. soluble TNF receptors (TNFsRs) and soluble Type II IL-1 receptor (sIL-
1RII))(22;41-43). The action of cytokines may also be inhibited at the receptor level. This is well 
illustrated by secreted IL-1Ra (sIL-1Ra), a naturally occurring peptide structurally related to IL-1b 
and IL-1a, that bind to the transducing IL-1 receptor (IL-1RI) without causing activation of target 
cells, thereby blocking the biological activities of IL-1 agonists (See Figure 3 in section 2.2.1)(44). 
Lastly, pro-inflammatory cytokines could be sequestered by decoy receptors (e.g. IL-1RII) and 
therefore prevented from interacting with the functional receptor (See Figure 3 in section 2.2.1)(45).  
Because the activity of IL-1 and TNF, major pro-inflammatory cytokines, is correlated with 
the severity of T cell mediated diseases such as RA and MS, the following sections aim at defining 
their system.  
2.1. Tumor necrosis factor-alpha (TNF) 
Human TNF is a non-glycosylated protein of 17 kD, which belongs to a family of peptide 
ligands that activate a corresponding set of structurally related receptors(46;47). The soluble 17-kD 
form of TNF is generated by the cleaveage of an the 26-kD trans-membrane precursor devoid of a 
classic signal peptide by TNF-a-converting enzyme (TACE)(48). TACE is an adamalysin, a member 
of membrane-associated enzymes that contain both disintegrin and matrix metalloproteinase 
domains(49). The biological activity of both the cell-associated 26-kD and secreted 17-kD forms of 
TNF requires trimerization (51 kD homotrimers), and the cell-associated form is often thought to be 
responsible for juxtacrine signaling secondary to cell-to-cell contact(50). Biological responses of 
TNF are mediated by specific binding either via a Type I (TNFR1) or a Type II (TNFR2) 
receptor(51). Soluble and membrane-bound forms of TNF have different affinities for the two 
receptors(52). It has been proposed that the main ligand for TNFR1 is the soluble form of TNF, 
whereas the membrane-bound form is the primary ligand for TNFR2. These two receptors are 
expressed on the surface of many cell types, and a recent model of receptor-mediated signaling 
proposes that TNFR1 is expressed on cells susceptible to the cytotoxic action of TNF, whereas 
TNFR2 is strongly expressed on stimulated B and T cells(53). The ratio of TNFR1/TNFR2 dictates 
the final outcome of the cellular response upon TNF stimulation. Binding of TNF to its receptors 
results in activation of intracellular signaling processes that lead to a remarkably diverse set of 
cellular responses, including differentiation, activation, and release of pro-inflammatory mediators 
and apoptosis(54). The extracellular domain of the two TNF receptors can be cleaved by TACE 
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forming TNFsRs (soluble TNF receptors) that are free to bind to trimolecular TNF rendering it 
biologically inactive, resulting in diminished cellular signaling of TNF and thus acting as soluble 
natural inhibitors of TNF bioactivity in vivo. 
TNF is produced by several pro-inflammatory cells, mainly by tissue macrophages, but also 
monocytes, DCs, and T cells, and structural cells such as fibroblasts. TNF is generated in response to 
bacteria or parasitic proteins, but all potentially deleterious stimuli ranging from physical, chemical 
to immunological can rapidly induce TNF production. Moreover, TNF is also produced as a 
consequence of stimulation of a wide range of pro-inflammatory cytokines including TNF itself. Its 
inflammatory properties are characteristically mediated by means of a wide variety of inflammatory 
cytokines, including IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IFNg and TGF-b, generated mainly through 
nuclear factor (NF)-kB activation(55). Besides influencing innate immune responses, TNF is 
essential for the induction of adaptive immunity by promoting DCs differentiation from CD34+ 
progenitors but also from CD14+ blood precursors(56). 
Because TNF is potentially harmful to the host, its activity is tightly regulated at several 
levels to ensure the silence of its gene in the absence of cell stimulation, or in tissue that are not 
programmed to synthesize the protein. Therefore, besides to be barely produced in quiescent cells, 
but sharply increased within 15 to 30 minutes after cell activation, TNF production is also controlled 
at the post-transcriptional level as demonstrated by the presence of AREs. These sequences control 
the suppression of TNF transcripts translation but also the derepression that follows stimulation of 
monocyte/macrophages with bacterial components(57).  
An inappropriately sustained production TNF production is linked to chronic inflammatory 
and autoimmune diseases, such as RA and MS(58;59). There is ample evidence to support a central 
pathogenic role of TNF in synovial inflammation(60), as either monoclonal antibodies against TNF 
or soluble TNF receptor–immunoglobulin constructs markedly ameliorates arthritis. TNF has also 
been determined to be immunosuppressive in patients with RA because a single infusion of TNF 
antibodies was sufficient to restore peripheral T cell responses to recall antigens and/or 
mitogens(61). The same process of suppression can be demonstrated in the joints of patients with RA 
since hyporesponsiveness of synovial T cells has been reported to be due, at least in part, to chronic 
exposure to TNF(62). Hyporesponsive synovial T cells could maintain the chronic inflammatory 
process through a mechanism less dependent on antigen signals which include the overproduction of 
pro-inflammatory cytokines(63-70) during cell-cell contact with infiltrating monocyte/macrophages 
and resident cells such as macrophages(71-74). Because TNF has the capability to induce the 
expression of pro-inflammatory cytokines, it is likely that TNF both directly mediates RA 
progression and acts through the expression of other cytokines(75). In rodent models of RA, there is 
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evidence indicating that the arthritic changes in response to antigenic stimulation and dependence on 
TNF signaling are mediated in part by IL-1(76). In genetically altered mice over-expressing TNF, the 
erosive arthritis that develops is dependent on IL-1 signaling, as passive immunization with an 
antibody against the type I IL-1 receptor attenuates the development of synovial hyperplasia(77). 
Studies in animal models of inflammatory arthritis suggest that TNF plays a more important role in 
promoting inflammation, whereas IL-1 is more important in causing cartilage and bone destruction. 
These differential activities have not been found in clinical trials, in which TNF and IL-1 
neutralization correspondingly lessen clinical signs and symptoms of RA as well as slow 
radiographic evidence of disease progression(78). 
Because TNF production in central nervous system (CNS) damages the blood-brain barrier 
(BBB) integrity due to its cytotoxic effect on the endothelium and, therefore, favors an important 
leukocyte infiltration(79;80), identifying TNF as a mediator of CNS tissue injury(81), TNF 
inhibition was consequently investigated as a treatment in MS. However, while pharmacological 
inhibition of TNF in experimental animal models of MS disease display some efficacy, in MS 
patients TNF neutralization worsened MS disease activity(82;83). Therefore, it is becoming evident 
that TNF has a far from simple part in inflammatory CNS demyelination. Noticeably, TNF might 
promote proliferation of oligodendrocyte progenitors and remyelination(84;85). 
2.2. The IL-1 family 
The IL-1 family of molecules consists of two agonists, IL-1a and IL-1b, a specific receptor 
antagonist called IL-1Ra, and two different receptors, IL-1R type I (IL-1RI) and IL-1R type II (IL-
1RII)(44;86). The genes for IL-1Ra, IL-1a, and IL-1b are located together in the human 
chromosome 2q14 region, with their structures indicating an origin by gene duplication(87;88). 
Cytokines of the IL-1 family take an important part in inflammation. The agonists IL-1a and IL-1b 
trigger pro-inflammatory events via IL-1RI. The signaling of IL-1 is regulated by two inhibitory 
mechanisms, a nonsignaling decoy receptor IL-1RII, and IL-1Ra, a naturally occurring inhibitory 
form of IL-1. IL-1Ra competitively inhibits the binding of IL-1 to IL-1RI but does not induce signal 
transduction (see Figure 3 in section 2.2.1)(35).  
2.2.1. Interleukin-1 agonists 
Both IL-1a and IL-1b bind to the same receptors, and there are no significant differences in 
the spectrum of activities of recombinant IL-1a or IL-1b when studied in vitro or in vivo in diverse 
experimental systems. IL-1 is a highly potent pro-inflammatory cytokine. Intravenous injection of 
only few hundred nanograms of IL-1b into humans, induces fever, leukocytosis, thrombocytosis, 
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hypotension, and the release and production of cytokines such as IL-6 which, in turn, trigger the 
synthesis of the hepatic acute-phase proteins serum amyloid A and C-reactive protein(12;89).  
IL-1a and IL-1b are synthesized as 31–33 kD precursors lacking signal peptides, and 
proteolytic processing, by the membrane-associated cysteine proteases, calpains(90) and IL-1-
converting enzyme (ICE)/caspase-1(91;92), respectively, generates the 17.5 kD carboxyl-terminal 
fragments. Whereas IL-1b precursor is inactive, IL-1b is active in its secreted form. Mononuclear 
cells display the strongest secretory capacity of IL-1b, whereas diverse nonphagocytic cells generally 
secrete low levels of IL-1b. Although circulating levels of IL-1b are measurable, these levels are 
usually in the low pg/ml range, even in sepsis. In humans, IL-1a is mainly active intracellularly or in 
its membrane-associated form (23 kD) when it engages the IL-1 surface receptor by a mechanism of 
activation commonly termed “juxtacrine”(93;94), but is only marginally active as a secreted 17.5 kD 
molecule. IL-1a may be secreted by activated macrophages. It is not commonly detected in blood or 
in body fluids, except during severe diseases, in which case the cytokine may be released from dying 
cells. Processing of the IL-1a precursor form (pIL-1a) to the mature form appear to be deficient in a 
variety of cells(89), leaving the intracellular precursor form in abundance. The IL-1a amino-terminal 
propiece (ppIL-1a) includes a latent nuclear localization sequence that is functional after cleavage of 
the precursor(95). In fact, ppIL-1a translocates to the nucleus in a variety of cells in response to 
cytokines and Toll-like receptor (TLR) ligands, and this appears to be necessary for specific 
downstream events(96). More specifically, overexpression of intracellular IL-1a is often seen in 
chronic diseases. In such context, it has been proposed that ppIL-1a might play a pivotal role in the 
pathogenesis and maintenance of chronicity via the activation of the transcriptional machinery 
together with the synthesis of pro-inflammatory cytokines(97).  
IL-1a and IL-1b differ from most other cytokines by lacking a signal sequence, thus they do 
not traffick through the endoplasmic reticulum-Golgi pathway. To date the mechanisms of IL-1 
secretion is still an ill-defined process. Following the synthesis by TLR ligands of the IL-1b 
precursors, a part moves into specialized secretory lysosomes to co-localize with procaspase-1, while 
most reside in the cytosol(98). It is generally believed that in resting cells, procaspase-1 is bound to a 
large inhibitor molecule, which prevents its activation, and that through initiation of IL-1b 
production, there is activation of caspase-1 by a complex of proteins termed the "IL-1b 
inflammasome", which then processes the IL-1b precursor form into a mature form ready for 
secretion(12;99) (Figure 2). Many studies have shown the requirement of P2X7 receptors for ATP-
induced caspase-1 activation and subsequent IL-1β release(100;101). P2X7 receptor activation is 
supposed to mimic a hypotonic stress situation. Hence, to date, at least two systems are able to cause 
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activation of caspase-1, one as a result of bacterial agents and the other following alterations in the 
intracellular ionic environment.  
Because IL-1β production is critical for the control of infections and that excessive cytokine 
production is harmful to the host, it is therefore not surprising that IL-1β activity is controlled at 
several levels. These include the regulation gene transcription(102-109), mRNA turnover (presence 
of AREs)(110;111) and translation(112;113). As stated above, IL-1b activity is furthermore 
regulated by the post-translational processing of the protein precursor by caspase-1(92), secretion, 
and receptor association (reviewed in (114)).  
Despite numerous reports on IL-1 and the obvious importance of IL-1 in the cytokine 
network, very little is known regarding the molecular details of IL-1 gene regulation. The structure of 
the IL-1a and IL-1b gene promoters differ. The IL-1a promoter, unlike that of IL-1b, does not have 
a typical TATA box(102;115), suggesting that both genes have distinct physiological modes of 
regulation. Both human promoters contain NF-kB regulatory elements, binding sites for NF-IL6, 
activator protein (AP)-1 proteins and cyclic adenosine 3’,5’-cyclic monophosphate (cAMP) response 
element binding protein (CREB). IL-1β mRNA is absent from cells until stimulated by extracellular 
signals. Constitutive activity of murine IL-1b promoter is controlled by a transcriptional 
 
 
Figure 2. Steps in the processing and secretion of IL-1b . A TLR ligands such as endotoxins trigger synthesis of the IL-1b precursor, which remains 
in the cytosol. In the same cell, inactive procaspase-1 is bound to components of the IL-1b inflammasome. The IL-1b inflammasome is kept in an 
inactive state by binding to a putative inhibitor. B After TLR signals, there is a transient uncoupling of the inhibitor from the procaspase-1, which 
then colocalizes with the IL-1b in secretory lysosomes. C Autocrine activation of the P2X7 receptor by ATP initiates the efflux of potassium from the 
cell via a potassium channel. The efflux of potassium activates the autocatalytic processing of procaspase-1. Active caspase-1 cleaves the IL-1b
precursor in an active cytokine. D The efflux of potassium ions results in the influx of calcium ions, which in turn activate phospholipases. 
Phosphatidylcholine-specific phospholipase C (PC-PLA-2) facilitates lysosomal exocytosis and secretion of IL-1b. (From (12)). 
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repressor(107). Actually, proIL-1b gene is under the control of both activators and repressors of 
transcription(116). 
Two receptors have been characterized. IL-1RI is an 80 kD transmembrane molecule with a 
signal transducing cytoplasmic domain, through which all IL-1-mediated responses are relayed 
(Figure 3)(117). Therefore, IL-1RI-deficient mice fail to respond to IL-1 and display reduced 
inflammatory responses(118). IL-1RI contains three immunoglobulin domains, which domains 1 and 
2 bind IL-1 agonists with low affinity but bind IL-1Ra (sIL-1Ra and icIL-1Ra1) with high 
affinity(119;120). Besides, the conformational changes induced in the ligand-receptor complex by 
tight binding of the IL-1 agonists to domain 3 of IL-1RI, that did not occur with IL-1Ra, may allow a 
secondary interaction of this complex with the IL-1 receptor accessory protein (IL-1RAcP) (Figure 
3). Thus, domain 3 of IL-1RI is necessary to achieve high-affinity binding with the two IL-1 
agonists, in addition to generation of agonist activity. Although the IL-1RAcP molecule itself does 
not bind the IL-1 agonists, association of IL-1RAcP with the ligand-receptor complex drives a 
fivefold increase in the affinity of binding of IL-1 agonists to the receptor(121). An excess of IL-
1Ra, commonly the soluble form, is necessary to block the biological effects of IL-1 agonists 
because the binding of only few molecules of IL-1 per cell suffices to stimulate a full biological 
response. In addition to IL-1RI, which mediates the effect of IL-1 binding, the type II receptor (IL-
1RII) is a smaller molecule (68 kD) with a truncated cytoplasmic domain, which functions as a 
nonsignaling decoy target for IL-1 receptor ligands (Figure 3)(45;122). IL-1 receptors play an 
additional role in the control of IL-1 activities through the proteolytic cleavage of their extracellular 
 
Figure 3. Natural mechanisms for reducing IL-1 activities. A IL-1 receptor type I (IL-1RI) binds IL-1b, which then recruits the IL-1 receptor 
accessory protein (IL-1RAcP) to transmit signalling. When secreted IL-1 receptor antagonist (sIL-1Ra) occupies the IL-1RI, the IL-1RAcP is not 
recruited, and there is no signal. The affinity of sIL-1Ra for the IL-1RI is greater than that for IL-1b. IL-1RII is termed “decoy” receptor since it has 
a greater binding affinity to IL-1b than the type I receptor, and lacks a significant intracellular segment and hence does not signal. IL-1b bound to 
the IL-1RII can also form a high-affinity complex with the IL-1RAcP. Soluble IL-1RAcP may form a complex with IL-1RI and IL-1b but without 
initiating a signal. B  The extracellular (soluble) domains of IL-1RI (sIL-1RI) bind IL-1Ra with a greater affinity than that for IL-1a or IL-1b. sIL-
1RI may act as a sink for sIL-1Ra. The sIL-1RII binds IL-1b and neutralizes its activities. The sIL-1RAcP does not bind IL-1b but rather forms a 
high-affinity complex with the sIL-1RII and neutralizes IL-1b activities. (Adapted from ref. (11)). 
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domains, although soluble-type IL-1RII receptor (sIL-1RII) is the predominant shed form in 
vivo(43). Soluble IL-1RI (sIL-1RI) is considered as a pro-inflammatory moiety, since it retains the 
ability of membrane-bound IL-1RI to bind sIL-1Ra and IL-1a with greater affinity than IL-1b, and 
therefore further enhanced the inflammatory effects of IL-1 on target cells (Figure 3)(119;123-125). 
These findings might explain the lack of efficacy of recombinant human IL-1RI in clinical trials in 
RA patients(126). In contrast, sIL-1RII binds to sIL-1Ra and IL-1a with much lower affinity than 
IL-1b and may thus increase the anti-inflammatory effects of sIL-1Ra(119;123;127-129). Thus, sIL-
1RII contributes to IL-1 antagonism through the preferential neutralization of IL-1b 
activity(123;128;130). The administration of sIL-1RII in experimental models resulted in a manifest 
inhibition of joint damage and joint swelling(131;132). Recently, an alternative splice transcript of 
the membrane IL-1RAcP, encoding a smaller and soluble protein (sIL-1RAcP) has been 
described(133;134). This sIL-1RAcP is mainly produced by the liver and circulates systemically. 
Overexpression of sIL-1RAcP ameliorates joint and systemic manifestations of collagen-induced 
arthritis (CIA) in mice(135). A possible explanation is that sIL-1RAcP can interact with sIL-1RII, 
thus forming a high-affinity IL-1 scavenger (Figure 3)(136). 
2.2.2. Interleukin-1 receptor antagonist (IL-1Ra) 
The activity of IL-1 is blocked by IL-1Ra, a naturally occurring receptor antagonist(137) 
(138) that binds to the type I IL-1R (IL-1RI), but does not initiate signal transduction (Figure 
3)(139). 
Actually, the term IL-1Ra refers to four different peptides derived from the same gene. The 
IL-1Ra gene, IL-1RN, generates a number of products that fall into two patterns: the secreted isoform 
(sIL-1Ra) and the intracellular isoforms (icIL-1Ra types 1, 2, and 3). sIL-1Ra possesses a leader 
peptide and is released from cells as a variably glycosylated protein of 22–25 kD(140;141) and 
appears to be as an inhibitor of IL-1. Athough, while it is generally considered that a 10–100-fold 
molar excess of sIL-1Ra over IL-1 is required to completely suppress the biological effects of IL-1, 
lower amounts of sIL-1Ra already decreased IL-1-induced responses(142). sIL-1Ra is produced 
primarily by monocytes and macrophages but may be synthesized by almost any cell that produces 
IL-1. In addition, sIL-1Ra is produced in large amounts by the liver as an acute phase protein and 
may also function as a systemic anti-inflammatory protein(143-145) (12, 13, 14). The icIL-1Ra1 
protein is produced by a transcriptional splice from an alternate upstream exon into the leader region 
for sIL-1Ra(146). At the genomic level, distinct promoters separated by nearly 10 kb of DNA control 
the expression of sIL-1Ra and icIL-1RaI(146). icIL-1Ra1 lacks a signal sequence and is synthesized 
in the cytoplasm as a nonglycosylated protein of 18 kD, being expressed in monocytes, 
keratinocytes, and endothelial cells. icIL-1Ra2 also results from another alternative first exon and 
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encodes for a predicted protein of 25 kD that has not been detected in human cells(147). Although 
icIL-1Ra2 mRNA has been localized in vivo, it may not be translated. Lastly, icIL-1Ra3 is a 
truncated variant of 16 kD that may be generated by alternative translation initiation primarily from 
the sIL-1Ra mRNA(148;149), or by an alternative transcriptional splice(150) and is found in 
monocyte/macrophages, neutrophils, and hepatocytes. The expression of the various IL-1Ra isoforms 
is cell type and stimulus specific(151). 
Because of their cytoplasmic localization, the biological functions of icIL-1Ra isoforms 
remain unclear. Recent studies indicate that icIL-1Ra1 and maybe others isoforms may be released 
by cells(152-155). Thus icIL-1Ra isoforms may function as intracellular stores of IL-1Ra, being 
released into the extracellular space upon necrotic cell death where it may then bind to cell surface 
receptors and block the stimulatory effects of IL-1. For instance, it has been observed that icIL-1Ra1 
could be released by LPS-primed macrophage-like cells and by human umbilical vein endothelial 
cells upon P2X7 receptor activation(156). In vitro, icIL-1Ra1 binds to IL-1RI with equal affinity 
than sIL-1Ra suggesting that both isoforms may function as extracellular receptor antagonist of IL-
1(157). In addition, icIL-1Ra isoforms may also possess important functions inside the cells 
independently from binding to IL-1 receptors. For example, icIL-1Ra1 is able to down-regulate the 
IL-1-induced production of the chemokines IL-8 and GRO by diminishing the stability of their 
transcripts(158). Furthermore, icIL-1Ra1 is capable to inhibit the production of IL-6 and IL-8 in 
response to IL-1 in epithelial cells and keratinocytes through inhibition of p38 mitogen activated 
protein (MAP) kinase and NF-kB pathways(159). The interaction of icIL-1Ra1 to the third 
component of the COP9 signalosome (CSN3) in the cytosol subsequently blocks the activities of 
necessary kinases in signal transduction pathways involved in IL-1-induced IL-6 and IL-8 
production(160). 
The regulation of sIL-1Ra gene expression is a complex event involving the interaction of 
different transcription factors, such as NF-kB, CCAAT/enhancer-binding protein (C/EBP), PU.1, 
GA-binding protein (GABP) and signal transducers and activators of transcription (STAT) 6(161). 
Of these PU.1 appears to be the most critical for the response of the sIL-1Ra gene to LPS in 
monocyte/macrophages. More specifically, two PU.1 binding sites control such expression. The 
proximal PU.1 site, located between positions -80 and -90 on the minus strand, binds all PU.1, GA-
binding protein (GABP) and NF-kB, and thus represents a composite NF-kB/PU.1/GABP binding 
site(162). Both NF-kB and PU.1-binding is approximately responsible for 50% of the response to 
LPS. GABP appears to have no effect on the LPS response but did play a role in the regulation of 
basal promoter activity, thus suggesting that PU.1 and NF-kB may be functionally redundant. The 
distal site, located between positions -230 and -220, controlled roughly 50% of the activation of the 
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sIL-1Ra expression in response to LPS. Interestingly, it is assumed that a major role for PU.1 is to 
recruit others factors into the transcriptional complex necessary to regulate sIL-1Ra gene expression 
induced by LPS(163). Finally, the full control of sIL-1Ra transcription is influenced by other cis-
acting elements in cell type- and stimulus-specific manners, as exemplified by STAT6 which is 
required for IL-4-induced transcriptional activation of the sIL-1Ra gene(164), and by STAT3 which 
controls LPS-induced-sIL-1Ra gene expression via an autocrine loop of IL-10(165).  
The diverse isoforms of IL-1Ra are differentially produced by LPS-stimulated peripheral 
blood mononuclear cells (PBMC)(149). sIL-1Ra is early transcribed and translated in PBMC in 
response to LPS, suggesting that sIL-1Ra plays an important role in regulating the cytokine effects of 
IL-1 in the extracellular environment. The late transcription and translation of icIL-1Ra1 in PBMC 
possibly plays an intracellular regulatory role when acute inflammation resolves or becomes chronic.  
2.2.3. IL-1/sIL-1Ra balance in pathology 
The cytokine network is self-regulating through the action of opposing cytokines, the release 
of soluble cytokine receptors, and the production of antagonists of cytokine binding to receptors. An 
important principle to emerge is that the net biologic response in a diseased organ or tissue reflects a 
balance between the local levels of pro-inflammatory and anti-inflammatory cytokines and factors. 
Thus, a chronic disease may result from the excessive production of pro-inflammatory cytokines or 
the inadequate production of anti-inflammatory cytokines(15). Particularly, endogenous sIL-1Ra is 
produced in numerous experimental animal models of disease as well as in human autoimmune and 
chronic inflammatory diseases. The balance between IL-1 and sIL-1Ra has been extensively studied 
in a variety of experimental animal models of disease including arthritis, central nervous system 
(CNS) diseases, and infectious diseases. In each of these diseases, either local overproduction of IL-1 
and/or underproduction of sIL-1Ra predisposes to the development of disease(35).  
The relative levels of sIL-1Ra and IL-1 at an inflammatory site are crucial factors 
determining whether a pro-inflammatory response will be initiated and persist or will be 
terminated(166). Typically, the concentration of sIL-1Ra increases late during the course of an 
inflammatory event so that an induced acute inflammation can terminate and does not become 
chronic and damage healthy cells(167). Consequently, the tight modulation of the IL-1/sIL-1Ra 
balance could be of therapeutic interest in chronic inflammatory diseases such as MS and RA. Of 
interest, IFNb acts as a negative modulator of IL-1 in human microglial cells by suppressing IL-1-
induced IL-1b, while inducing the production of sIL-1Ra, shifting the balance toward the expression 
of the latter cytokine(168). By analogy, IFNb displays similar regulatory capacity upon cell-contact-
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mechanisms between T lymphocytes and monocyte/macrophages, a pathogenic model supposed to 
take place in MS and RA(169). (See chapter 4) 
2.2.3.a. IL-1/sIL-1Ra balance in rheumatoid arthritis 
RA may be considered a disorder of “cytokine deregulation” in that the activity of pro-
inflammatory cytokines such as TNF and IL-1 is enhanced, and overwhelms the effects of anti-
inflammatory cytokines such as TNFsRs and sIL-1Ra(170). This suggests that an imbalance between 
pro-inflammatory cytokines and cytokine antagonists or inhibitors may be one factor predisposing to 
initiation or perpetuation of RA. For instance, while sIL-1Ra is produced locally in tissues during 
active disease, the local balance of net biologic function remains in favor of the agonists IL-1a and 
IL-1b. As a result, although sIL-1Ra is found in large amounts in rheumatoid synovial fluids and is 
produced by synovial tissue from RA patients, the relative levels of production of sIL-1Ra are not 
adequate to effectively block the pro-inflammatory effects of IL-1. The importance of the balance 
between IL-1 and sIL-1Ra is further supported by the development of more aggressive collagen-
induced arthritis (CIA) in IL-1Ra-knockout mice with much less severe disease in IL-1Ra transgenic 
mice(171). Moreover mice that lacked the ability to produce IL-1Ra, developed spontaneously 
inflammatory diseases that were similar to RA and arteritis in humans(172;173). These observations 
emphasize the importance of maintaining adequate tissue levels of both IL-1 and sIL-1Ra in ratio to 
prevent inflammatory disease.  
These different findings have resulted in a course of interest for the development of ways of 
blocking cytokines and their actions in a specific and safe manner. A restoration of the balance 
between sIL-1Ra and IL-1 in RA or more generally in human diseases can theoretically be achieved 
through the administration of recombinant sIL-1Ra protein, gene therapy with the sIL-1Ra 
complementary DNA, or stimulation of production of endogenous sIL-1Ra. Therapeutic modalities 
that may enhance endogenous sIL-1Ra production, such as the administration of recombinant 
IFNb(7), are currently being evaluated in patients with RA. Utilization of exogenous sIL-1Ra to 
counteract the extensive pro-inflammatory immune response that occurs in RA has been 
beneficial(151); administration of recombinant sIL-1Ra significantly reduced local inflammation of 
joints and bone erosion in patients with moderately severe RA(174-176). 
2.2.3.b. IL-1/sIL-1Ra balance in multiple sclerosis 
Both IL-1 and sIL-1Ra are produced in the CNS and the ratio between these two cytokines 
may influence the development of MS(177). Studies support that IL-1b is implicated in 
inflammatory reactions of the CNS(178;179), being released by infiltrating monocyte/macrophages, 
microglial cells, astrocytes and brain endothelial cells(180). In normal CNS tissue, while there is 
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almost no expression of IL-1b, MS lesions are characterized by increased levels of this cytokine 
(178). Because IL-1b is assumed to influence the severity of MS, sIL-1Ra is also currently being 
evaluated in clinical trials. Indeed, sIL-1Ra might play an important role in regulating MS 
inflammatory process(86;181), since circulating levels of sIL-1Ra correlate with disease 
activity(182;183). This hypothesis is strengthened by the premise that in experimental allergic 
encephalomyelitis (EAE), a rodent model of MS, treatment with recombinant sIL-1Ra results in 
delayed and milder disease(184;185). Animal model studies emphasize the natural balance between 
the pro-inflammatory activities of IL-1 and their control by sIL-1Ra. Besides the production of sIL-
1Ra by infiltrating monocyte/macrophages, microglial cells and astroglial cells, blood sIL-1Ra can 
crossed the BBB(186). Accordingly, the long-lasting and quantitatively important induction of sIL-
1Ra by IFNb may contribute to the anti-inflammatory effect of this drug and partially account for the 
reduction of exacerbation rate shown in most IFNb-treated MS patients(187). Together, these studies 
indicate that the balance between IL-1b and sIL-1Ra production might be of importance for MS, 
rather than the absolute level of each cytokine alone, and suggest that the relative levels of IL-1 and 
sIL-1Ra may determine the extent of tissue injury in the CNS.  
2.2.3.c. IL-1/sIL-1Ra balance in infection and physiology 
It was hypothesized that the physiological consequences of overwhelming infection and 
shock might be ameliorated by inhibition of IL-1. However, utilization of exogenous sIL-1Ra to 
combat the extensive pro-inflammatory immune response that occurs in sepsis has been unsuccessful 
or very moderate(151;188). Alternatively, one could keep in mind that in addition to a pro-
inflammatory role in various diseases, IL-1 may be important in host defenses, particularly to 
infections with intracellular organisms(189). Thus, patients treated systemically with sIL-1Ra need to 
be followed closely over long periods of time to carefully assess the risk of increased infection. 
It is important to pinpoint that the balance between IL-1 and sIL-1Ra may as well play an 
important role in the normal physiology of various organs and tissues(35). 
2.3. IL-1Ra gene polymorphism in rheumatoid arthritis and multiple sclerosis?  
Different studies attempt to reveal a theoretical justification of cytokine production 
abnormalities in chronic inflammatory diseases that could come from the polymorphic nature of the 
foremost genes implicated in their pathogenesis. Indeed, many genes are polymorphic; in coding or 
noncoding regions of a specific gene, there may be either a single base pair substitution of one 
nucleotide for another or a variable number of repeats of a short, repetitive DNA sequence. These 
variations may influence the rate of gene transcription, the stability of the messenger RNA, or the 
quantity and activity of the resulting protein. Thus, the susceptibility or severity of a number of 
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disorders will be influenced by possession of specific alleles of polymorphic genes. A polymorphism 
is present in intron 2 of the human IL-1Ra gene, due to the presence of variable numbers of an 86-bp 
tandem repeat(190). Five alleles were described, and this allelic region contained three potential 
protein binding sites, suggesting possible functional significance. IL1RN*2, an allelic polymorphism 
in intron 2 of the IL-1Ra gene, found in 21.4% of the normal population, has been associated with a 
variety of human diseases(138), including MS(177). In many of these diseases, IL1RN*2 is 
associated with severity rather than with a predisposition to acquire the disease. Indeed, persons 
homozygous for allele 2 of the IL-1Ra gene (IL1RN*2) have a more prolonged and more severe pro-
inflammatory immune response than persons with other IL-1Ra genotypes. Thus, being IL1RN*2 
homozygous might be beneficial when combating infectious agents, but it might be detrimental for 
those with chronic inflammatory conditions(191). In such context it has been observed that persons 
who express an innate pro-inflammatory cytokine profile, as determined by endotoxins (LPS)-
induced IL-1b over sIL-1Ra ratio, are far more susceptible to develop relapse-onset MS, but not 
primary progressive MS, as compared to persons with an anti-inflammatory cytokine profile(177). 
This suggest that an innate imbalance of IL-1b and sIL-1Ra may contribute to an increased disease 
progression in relapse-onset MS. An association between IL1RN*2 with RA has also been 
demonstrated(192;193). However, not all studies have been able to confirm this association. 
3. Non-septic T cell-mediated chronic inflammatory diseases 
In so-called non-septic T cell-mediated chronic inflammatory diseases, inflammation is 
characterized by the infiltration into the target tissue of immune cells such as T and B lymphocytes, 
granulocytes and mononuclear phagocytes. This influx of inflammatory cells is associated with the 
proliferation of invading and resident cells and commonly with the destruction and remodeling of the 
extracellular matrix. Tissue destruction is mainly accomplished by proteases including matrix 
metalloproteinases. The expression of these proteases and their inhibitors, in particular the tissue 
inhibitors of metalloproteinases, is controlled by soluble factors such as cytokines, contact with 
extracellular matrix components, and direct cell-cell contact(194-196). RA and MS will illustrate this 
type of disease in this thesis. 
The autoimmune diseases are supposed to result from inappropriate responses of the immune 
system to self-antigens. The etiology of autoimmune diseases remains largely unknown but it 
appears that infections, genetic, environmental, and hormonal factors are all involved in complex, 
interrelated ways. Infectious agents can cause autoimmune diseases by different mechanisms, which 
fall into two categories: antigen specific in which pathogen products or elements have a central role 
e.g. superantigens or epitope (molecular) mimicry, and antigen non-specific in which the pathogen 
provides the appropriate inflammatory setting for “bystander activation”. Thus, TLRs, which are 
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considered as innate sensors of microbial components, may have the potential to recognize self-
antigens and trigger autoimmune diseases(197). In addition, an uncontrolled polyclonal activation of 
the immune system may as well contribute to the autoimmune pathogenesis(198).  
RA is an autoimmune, chronic inflammatory disease affecting joints (synovium, bone, and 
cartilage), that concerns 0.5-1% of the population in the industrialized world (199;200). It has long 
been speculated that RA could be triggered by infectious agents(201;202), but proof of this is still 
lacking. To date, neither the initiating events, nor the perpetuating factors in the pathogenesis of RA 
are well understood(203;204). RA is characterized by the infiltration of the synovial membrane by 
blood-borne cells, primarily T lymphocytes and monocyte/macrophages. 
MS is considered a prototype chronic inflammatory autoimmune disorder of the CNS(205). 
The prevalence of MS is estimated to be two million peoples worldwide(206). The etiology of this 
disease remains unknown, but an interplay between as-yet unidentified environmental factors and 
susceptibility genes appears most likely(207). MS involves inflammatory responses within the CNS 
that result in demyelination, oligodendrocyte death, axonal damage, gliosis, and 
neurodegeneration(208). Alike RA, a fundamental event in MS is the considerable CNS infiltration 
of peripheral blood born T lymphocytes and monocyte/macrophages.  
In both RA and MS, tissue destruction takes place in the proximity of areas where T 
lymphocytes are in close contact with monocyte/macrophages, suggesting the importance of contact-
mediated interactions potentiating inflammation. Indeed, besides the numerous roles of T cell-
derived cytokines in modulating the diverse monocyte/macrophage activities, research over the past 
few years has demonstrated that contact-dependent signaling occurring during T cell-
monocyte/macrophage interactions is a critical triggering event in the activation of 
monocyte/macrophage functions(209). 
3.1. T lymphocytes in chronic/sterile inflammation 
Committed lymphoid progenitors arise in the bone marrow and migrate via the blood to the 
thymus, where they are subjected to a severe dual selection process (Figure 4): a) A positive 
selection for thymocytes, which are able to bind self-major histocompatibility complex (MHC) 
molecules, the latter presenting small peptide fragments that have been generated from protein 
antigens; and b) a negative selection against thymocytes that posses excessive affinity for self-
antigens(210). Consequently, only few thymocytes that enter the thymus are released to the systemic 
circulation and form the peripheral T-cell repertoire. However, many naive lymphocytes exiting the 
thymus remain able to recognize self-antigens, although with low affinity(211). Autoreactive T cells 
to CNS antigens, for example, are consistently found in healthy individuals(212).  
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The great majority of human peripheral blood T lymphocytes bear T-cell receptors (TCRs) 
composed of a and b chains (ab T lymphocytes) that mediate the classical helper (CD4+ T cells) or 
cytotoxic T cell responses (CD8+ T cells). TCR that confers antigen specificity to the T lymphocyte 
does not bind antigen directly, but in contrast an interaction of the TCR with MHC molecules is a 
required process for T-cell specific activation. MHC class I molecules, which expression takes place 
on almost all nucleated cells, present to CD8+ T cells antigens that are produced by the particular 
cells themselves or come from intracellular pathogens that reside in the their cytoplasm. Such cells 
are programmed to turn into cytotoxic effector cells that kill cells that are infected. On the other 
hand, MHC class II molecules, which expression is limited to professional antigen-presenting cells 
(APCs), such as dendritic cells (DCs) and macrophages, present to CD4+ T cells antigens derived 
from ingested proteins, such as extracellular bacteria or damaged self-tissue. Helper T (TH) cells are 
special subpopulations of CD4+ T cells that provide help to other cells of the immune system in 
mounting immune responses by cell activation or the secretion of cytokines.  
CD4+ and CD8+ T lymphocytes that are released from the thymus are considered as naïve T 
cells since they do not have yet encountered their specific antigen. As a result, such cells 
continuously travel throughout the body from the peripheral blood to secondary lymphoid organs for 
the search of their particular antigen. Upon activation, naïve T cells are subjected to proliferation and 
differentiation into specialized effector T cells, a process associated with the acquisition of functional 
changes in their capacities of migration and of secretion of effector cytokines.  
 
Figure 4. Schematic representation of T cell development. T cells that originate from the common lymphoid progenitor cells in the bone marrow 
migrate as immature precursor T cells via the bloodstream into the thymus, which they populate as thymocytes. The thymocytes go through a series 
of maturation steps. More than 98% of the thymocytes die during maturation by apoptosis (†), as they undergo positive selection for their T cell 
receptor’s (TCR) compatibility with self-major histocompatibility molecules, and negative selection against those T cells that express TCRs 
reactive to autoantigenic peptides. αβ and γδ T cells diverge early in T cell development. αβ T cells that survive thymic selection lose expression of 
either CD4 or CD8, increase the level of expression of the TCR, and leave the thymus to form the peripheral T cell repertoire. (From (10)). 
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The mechanisms resulting in tissue destruction and loss of organ function throughout the 
course of an autoimmune disease are basically identical as in protective immunity against invading 
microorganisms. The accomplishment of protective immunity depends on the capacity to elicit the 
type of immune response that is appropriate to fight a particular pathogen. Once activated, CD4+ T 
cells differentiate into specialized effector cells and become the central regulators of specific immune 
response. On the basis of distinctive cytokine secretion profiles and concomitant effector functions, 
CD4+ T cells might be divided into at least two major subsets (Figure 5). Protection from 
intracellular microorganisms, such as viruses and bacteria, depends on cell-mediated immunity, 
which is supported by TH1 cells. These cells produce a number of cytokines known as TH1 cytokines 
such as IL-2, IFNg and IL-12. TH1 cells activate macrophages to produce inflammatory metabolites 
such as reactive oxygen intermediates and nitric oxide, stimulate their phagocytic functions, and 
enhance their antigen presenting function by up-regulating MHC class II molecules. While TH1-
dominated responses are effective in protection against several microbes and usually drive their 
clearance, inflammatory tissue damage could result from chronically ongoing TH1 responses when 
the pathogen persists. TH2 cells promote humoral responses that are more efficient against 
extracellular pathogens, such as multicellular parasites (gastrointestinal nematodes and helminths). 
TH2 cells produce cytokines referred to TH2 cytokines such as IL-4, IL-10 and IL-13(213) and 
mediate allergic immune responses and down-modulate macrophage activation. In addition, TH2 
cells depress TH1 cells and vice versa. Besides TH1 and TH2 cells, TH3 cells are regulatory cells 
associated with immune mechanisms involving oral tolerance towards antigens(214). These cells are 
characterized, among other things, by the secretion of TGF-b and they have suppressive properties 
for TH1 and TH2 cells(215). Moreover, TH3 cells exert a paracrine suppressor effect on APCs that 
come into contact with effector T cells through the secretion of TGF-b(212). By analogy, CD25+ 
 
 
Figure 5. Differentiation of CD4 T cells into specialized T-helper 1 (TH1) or TH2 effector cells. Upon activation with specific antigen, CD4 
T cells proliferate and differentiate into either the TH1 or TH2 subset. TH1 cells promote cellular immunity and are involved in the development 
of autoimmune diseases; TH2 cells mediate humoral immunity and are involved in allergic immune responses. (From (2)). 
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regulatory CD4+ T cells (Treg cells) are able to regulate actively the responsiveness of autoreactive T 
cells and may prevent the evolution of autoimmune inflammation(216;217). 
T cell subsets originate from naïve T cells, a non-committed population of precursor T cells. 
The process, by which commitment develops, called polarization, is mainly driven by 
cytokines(218;219) that are rapidly produced by APCs, such as DCs and macrophages, after 
exposure to microbial products. In order to develop the proper immune response, the specific nature 
of the pathogen has to be translated into differences in the pattern of cytokines that are produced by 
APCs(219). Several lines of evidence indicate that TLRs, mediators of pathogen recognition by the 
innate immune system, play a central role in this translation process(220). Such recognition results in 
the initiation of an inflammatory immune response and consecutive instruction of the adaptive 
immune system, both of which are designed to clear the host of the invading pathogen. Modulation 
of T cell polarization incriminates cytokines, antigen dose or avidity(221), co-stimulatory 
molecules(222), chemokines(223), and APC(224-226). All of these factors may be different in 
specific tissues or microenvironments.  
Although differentiation of the appropriate T cell subset is of crucial importance to the host 
for developing protective immunity against exogenous microorganisms, it might be implicated in the 
development of pathologic immune diseases. Indeed, it is currently suggested that the overactivation 
of the TH1 pathway, which is often portrayed as being more aggressive than the TH2 pathway, 
generates chronic inflammatory and organ-specific autoimmune diseases such as MS and 
RA(227;228) and their counterpart experimental animal model, EAE and CIA(213). To date 
however, none of these two diseases has been proven to be TH1 dominant(229).  
3.1.1. T lymphocytes in rheumatoid arthritis 
In RA, T lymphocytes are the main infiltrating cells in the pannus, at percentage ranging from 
16% of total cells in “transitional areas” and 75% in “lymphocyte-rich perivascular 
areas”(230;231;231). Evidence coming from different experimental approaches supports that RA is 
T-cell driven at all stages of the disease(232). CD4+ T cells are assumed to play a central role in the 
immuno-pathogenesis of RA since activated CD4+ T lymphocytes cells are found in the 
inflammatory infiltrates of the rheumatoid synovium(233). Furthermore, adoptive transfer of CD4+ T 
cells from arthritic animals into healthy syngeneic recipients lead to the development of the 
disease(234;235). T-cell directed therapies have noticeably conferred clinical benefit in RA(236). 
The most convincing discovery that imply a fundamental role for CD4+ T lymphocytes in RA 
pathogenesis is the association of severe forms of the disease with particular MHC class II 
alleles(237;238). However, to date the specific antigen (s) recognized by the autoreactive CD4+ T 
lymphocytes in RA remained unidentified.  
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Numerous clinical and experimental observations suggest that RA might be driven by 
activated TH1 effector cells without sufficient TH2 cell development to down-regulate 
inflammation(239). While there is ample evidence that TH1 cells and their cytokines substantially 
promote many aspects of synovial inflammation, no data yet allow to conclude whether TH1 cells are 
the initiators of rheumatoid inflammation or rather appear as a consequence of it(240). Moreover, 
reducing the complexity of RA in terms of TH1/TH2 balance may be an over-simplification because 
TH1/TH2 dichotomy is not sufficient to explain why autoreactive T cells are only rarely activated by 
cells that present self-antigens(241). Therefore, the absence of autoimmunity cannot be attributed 
solely to deletion in the thymus of autoreactive T cells: an active mechanism capable of inhibiting 
potentially autoreactive T cells released by the thymus must as well be implicated(212). In this 
context, it becomes evident that CD4+ T cells, besides their effector functions in propagating specific 
immune responses, might as well restrain the initiation of immune reactions and even down-regulate 
established immune responses. CD4+ CD25+ regulatory T cells that are present and functional in 
patients with RA, display a higher suppressive activity in synovial fluids as compared with peripheral 
blood(242). Actually, human CD4+ CD25+ regulatory T cells can inhibit the pro-inflammatory 
properties of monocyte/macrophages. 
A role for reactive CD8+ T lymphocytes in rheumatoid inflammation is supported by the fact 
that such cells have the ability to produce very high levels of TNF and IFNγ, which may contribute 
directly and/or indirectly to target cell destruction. The nature of these CD8+ T lymphocytes could be 
T cell specific for foreign antigens(243) or autoreactive T cell specific for self-antigen(244). 
However, the accurate role played by these cells in rheumatoid inflammation remains to be clarified, 
since in addition to effector functions, they may display a regulatory/protective effect on auto-
immune inflammation(245).  
Besides ab T lymphocytes, a small subpopulation of peripheral T lymphocytes, whose 
function in the immune system is poorly documented, express an alternative TCR composed of γ and 
δ chains (γδ T cells). Such γδ TCRs seem to recognize antigen directly without the requirement of 
presentation by MHC molecules or other proteins and do not depend on antigen processing. γδ T 
cells might be implicated in the pathogenesis of RA because their frequencies are significant in the 
synovial infiltrates, and tissue inflammation is greater in rheumatoid synovium with augmented 
levels of γδ T cells as compared with RA synovium with few γδ T cells(246;247).  
3.1.2. T lymphocytes in multiple sclerosis 
Based on animals models, MS has long been claimed to be a TH1-mediated disease, however, 
the potential role of CD8+ T lymphocytes as effector cells mediating CNS damage is getting growing 
attention. In active MS plaques these cells outnumber CD4+ T lymphocytes. Activated MHC class I 
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restricted CD8+ T cells (248;249) predominate in areas of active tissue damage, closely attached to 
degenerating myelin sheaths(249) and axons(250;251), suggesting that CD8+ cytotoxic T 
lymphocytes have the ability to initiate brain inflammation and tissue injury in MS 
plaques(252;253). In addition, clonally expanded CD8+ T cells have been found within lesions(248) 
as well as in the cerebrospinal fluid(254) and blood of MS patients(255). Interestingly, some of the 
brain-infiltrating CD8+ T cell clones persisted for more than five years in the cerebrospinal fluid and 
blood, emphasizing the putative role of this cell population in the persistence/progression of MS. Up 
till now, the antigen(s) recognized by these CD8+ T lymphocytes in MS are not determined. Viral 
antigens would stand for evident candidates; on the other hand, CD8+ T cells might recognize CNS 
auto-antigens, such as myelin constituents. The most attractive feature of CD8+ T lymphocytes is 
their capability to recognize human leukocyte antigen (HLA) class I-associated antigens. This may 
allow them to assault directly all CNS cell subtypes, including neurons, astrocytes, microglial cells, 
and oligodendrocytes which can only secondarily be targeted by CD4+ T cells(251).  
These findings, however, do not rule out that CD4+ T lymphocytes have an equally important 
role in MS pathogenesis. The adoptive transfer of encephalitogenic CD4+ T cells induces EAE in 
naive syngeneic recipient mice(256). In the CNS, naive CD4+ T cells differentiate into TH1 and TH2 
cells, which have different functions. The inflammation seen in MS appears to be due in part to a 
misguided and overactive TH1 response, as there appears to be an elevation of TH1 cytokines (IL-2, 
TNF, and IFNg), and a diminution of TH2 cytokines (IL-4, IL-5, IL-6, IL-10, and IL-13). Such 
“immune deviation” could activate and/or damage the endothelium of the blood-brain barrier (BBB) 
allowing the extrvasation of other cell types. The CD4–TH1 hypothesis of MS pathogenesis is over 
decades less and less assumed(252) because the existing data from MS patients do not reasonably 
further support MS as a pure TH1-mediated inflammatory disease(229;252). Indeed, while a large 
body of evidence suggests that there is a TH1-type bias in MS and that factors associated with TH2- 
or TH3-type responses are, in principle, beneficial in MS(252;257), other T-cell populations can be 
implicated in the induction, propagation and modulation of the disease. The role of CD4+ CD25+ 
regulatory T cells has received growing attention since they contribute to the maintenance of 
peripheral tolerance. Indeed, breakdown of peripheral tolerance to CNS self-antigens is considered 
central in the development of the auto-aggressive immune response. Of note, the deletion of this 
regulatory T cell population led to spontaneous autoimmune disease in mice(258). It has been 
observed that the effector functions of CD4+ CD25+ regulatory T cells was considerably reduced in 
the peripheral blood of patients with MS, in comparison with healthy donors, suggesting functional 
alterations of suppressor cells in MS(259). However, this finding has not been confirmed by 
others(260). 
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3.2. Inflammatory and effector activities of cells of the monocyte/macrophage lineage 
Monocyte/macrophages play various roles in T cell-mediated inflammatory diseases because 
they function as accessory cells for T cell activation, as pro-inflammatory cells, as effector cells that 
mediate tissue damage, and as anti-inflammatory cells that promote wound healing/tissue repair 
(Figure 6). There is strong evidence that 
deregulation of monocyte/macrophage 
functions could be responsible for 
disease development. For instance, pro-
inflammatory activated 
monocyte/macrophages are cardinal 
inflammatory cells implicated into the 
pathogenesis of RA and MS.  
Human monocytes constitute 
between 3% and 7% of peripheral blood 
leukocytes. Monocytes are members of 
the human mononuclear phagocyte 
system, which is important for non-specific defence against pathogenic organisms and tumor 
surveillance, and which exerts immunoregulatory functions like accessory activities and cytokine 
production. Monocytes derive from progenitor cells in the bone marrow, circulate in the blood as 
monocytes for 1-3 days before entering tissue to differentiate into locoregional-specific and 
heterogeneous cells, such as alveolar macrophage of the lung, as macrophages or DCs in connective 
tissue (261), and as microglial cells in the CNS(262). In inflammatory conditions, monocyte 
production is increased in the bone marrow and after release into circulation monocytes are rapidly 
recruited to sites of injury and infection where they differentiate into inflammatory 
macrophages(263). The term monocyte/macrophages broadly used in this thesis refers to cells that 
undergo a transition from a quiescent to an inflammatory phenotype and consequently represents 
somewhat a heterogeneous cell population. The classical immunophenotypic marker for monocytes 
is CD14, the receptor for complexes of lipopolysaccharides (LPS) and LPS-binding protein(264). 
Human peripheral blood monocytes are not a homogeneous population, but differ in their phenotypes 
and functions. Human monocytes could be divided into two major populations by the presence or 
absence of CD16, the low affinity Fc-gamma receptor III(63). The CD14+/CD16+ subpopulation of 
monocytes represents approximately 10% of total blood monocytes. In comparison to main 
subpopulation of CD14++ (so-called “classical”) monocytes, this subpopulation is characterized by 
enhanced expression of MHC class II determinants, and increased ability to produce pro-
 
Figure 6. The diverse functions of monocyte/macrophages (Mf).
Monocyte/macrophages are capable of many functional activities and contribute 
both to the initiation of cell-mediated immune response and to the effector limb 
of those responses. During the course of the response, monocyte/macrophages
can display, at different times, both inflammatory and anti-inflammatory 
activities. (From (3)). 
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inflammatory cytokines (TNF, IL-1b, IL-6) following stimulation by TLRs agonists(265;266). The 
CD14+/CD16+ subset of peripheral blood monocytes is also thought to be a transitional stage in the 
development of monocytes to either macrophages or DCs(267-269). Consistent with this notion, an 
expansion of the CD14+/CD16+ population has been found in septicemia(270) and other infectious or 
inflammatory disorders(267). However, the latter phenotypic switch is still controversial in 
RA(271;272) while it has been so far not identified in MS(273;274).  
Monocytes selectively home to different tissues, presumably under the influence of 
chemokines or other tissue-specific homing factors(275). Upon entry into a tissue, maturing 
monocyte/macrophages migrate into the parenchyma, the environment of which significantly 
influences the function of macrophages such that macrophages localized in different tissues display 
different patterns of function(276;277). Upon inflammatory insult to the tissue, resident tissue 
macrophages can contribute to the innate immune response by expression of a wide variety of 
inflammatory and effector activities, the pattern of which is differentially regulated by the 
microenvironment of the different tissues. Moreover, macrophages priming is a very effective first 
step towards full-scale activation. Upon priming, cells are educated by an initial insult(278), and thus 
prepared for subsequent second insults, in such a manner that the priming alters or modulates cell 
response to the secondary stimulation.  
As stated above, cells belonging to the monocyte/macrophage lineage are heterogeneous and 
as such are engaged in a variety of activities that may appear opposing in nature: pro-inflammatory 
versus anti-inflammatory activities, immunogenic versus tolerogenic activities, and tissue-destructive 
versus tissue-restorative activities(13;279-281). To date, monocyte/macrophage heterogeneity is 
likely to reflect the plasticity and versatility of these cells in response to exposure to 
microenvironmental signals. In this respect, it is assumed that five types of monocyte/macrophage 
activation occurs(13) as depicted in Figure 7. Besides these different mechanisms, the process that 
control monocyte/macrophage activation in chronic/sterile inflammation, while not completely well 
understood, might be elicited by direct cellular contact with activated T lymphocytes. 
3.2.1. Cells of the monocyte/macrophage lineage in rheumatoid arthritis 
Monocyte/macrophages play a pivotal role in RA(230;282;283). Indeed, they are numerous 
in the inflamed synovial lining membrane and at the cartilage-pannus junction. Extensive 
investigations have identified the monocyte/macrophage as the only cell type in the synovium whose 
number correlates with disease severity(282). This is in accordance with the premise that 
monocyte/macrophages are the main producers of TNF and IL-1b, which levels strongly correlate 
with disease symptoms and with joint damage(58;230;282). It has been hypothesized that in addition  
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Figure 7. Innate and acquired immune activation of monocyte/macrophages. a) The innate immune activation (antigen non-specific, T cell-
independent) of monocyte/macrophages is triggered by microbial stimul and results in the production of pro- and anti-inflammatory mediators 
including cytokines, upregulation of antigen presentation capacity and promotion of the phagocytosis and endocytosis of host and exogenous 
ligands. b) The humoral activation and phagocytosis of monocyte/macrophages that are mediated by the occupancy of Fc and complement 
receptors trigger a cytolytic activity and production of pro-and anti-inflammatory cytokines. c) The classical activation which is mediated by the 
priming stimulus IFNg, followed by exposure to TH1 cytokines such as IFNg or other activators, including TNF and LPS (e,g. in intracellular 
killing of phagocytosed pathogens), gives rise to the production of pro-inflammatory cytokines and mediators that subsequently direct microbicidal 
activity, tissue damage and cellular immunity. d) The alternative immunologic activation that is promoted by IL-4 and IL-13 enhances endocytotic 
antigen uptake and presentation, in response to parasitic and extracellular pathogens and has been proposed to be a way to attenuate excessive 
inflammation. e) The deactivation (switch-off) of already activated monocyte/macrophages is triggered by the uptake of apoptotic cells or 
lysosomal storage of host molecules. This active process that could be of innate or acquired origin generates anti-inflammatory responses in which 
cytokines and glucocorticosteroids are potent modulators of activation. Pathogens can deactivate monocyte/macrophages by various mechanisms. 
(Adapted from (13)).  
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to the infiltration from the circulation, the subsequent possible local proliferation of 
monocyte/macrophages may contribute to the local hyperplasia exhibited in inflamed joints(284). 
However, it is unlikely that monocyte/macrophages occupy a causal position in the pathogenesis of 
RA, except for their function as APCs in the hypothesis of a primary autoimmune disorder(285). At 
the inflammatory site, monocyte/macrophages show clear signs of activation, such as over 
expression of MHC class II, and possess broad pro-inflammatory, destructive, and remodeling 
capacities. Monocyte/macrophages act as amplifiers of local and systemic inflammation in both the 
acute and the chronic phases of RA(283;286-288). Locally, monocyte/macrophages are implicated in 
recruitment and activation/differentiation of neighboring/inflammatory cells, secretion of matrix-
degrading enzymes, and neovascularization. While monocyte/macrophage activation is most obvious 
within the rheumatoid joint, “presynovial” activation, has been evidenced, although unclear in its 
extent(286;289). One hypothesis imply that initiation of the autoimmune response is non-specific 
and depends solely on the presence of misplaced peripherally activated pro-inflammatory 
monocyte/macrophages, which come into the target organ as a result of their activation status. 
Peripheral monocyte/macrophage activation is characterized overall by gene activation with a pattern 
closely resembling the synovial activation pattern, including the spontaneous production of 
inflammatory mediators, such as TNF, IL-1, and IL-6(290;291), enhanced levels of adhesion 
molecules(292;293) and increased phagocytic activity(294). In addition to local effects, the 
observation of a peripheral blood monocytosis(295;296), and both quantitative and qualitative 
alterations of myelomonocytic cells in the bone marrow in RA patients(297) emphasize the 
importance of monocyte/macrophages in this disease. Thus at the systemic level, 
monocyte/macrophages might amplify disease via the development of bone marrow differentiation 
abnormalities, and chronic activation of circulating monocytes.  
Monocyte/macrophage sensitization can be detrimental in RA synovitis, which is 
characterized by only low production of IFNg by T lymphocyte(66;298;299), but ample production 
of various monocyte-derived cytokines(300). Indeed, it is well supported that subthreshold 
concentrations of IFNg are capable to up-regulate the sensitivity (i.e. priming) of 
monocyte/macrophages to a subsequent second stimulus. Therefore the low concentration of locally 
produced IFNg, may prime the synovial monocyte/macrophages to a subsequent non-IFN-type 
stimulus (for example TNF or cell-cell contact), explaining the over activity of such cells in RA 
synovitis. 
3.2.2. Cells of the monocyte/macrophage lineage in multiple sclerosis 
Infiltrates of inflammatory cells in the CNS, as well as the production of pro- and anti-
inflammatory cytokines and chemokines, all have proposed roles in MS disease pathogenesis and 
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severity(301;302). In this regard, inflammation is believed to be an initial feature of MS followed by 
demyelination(303). The early MS lesion is characterized by the presence of large numbers of 
activated T lymphocytes and monocyte/macrophages, implicating these cells as possible mediators in 
the formation of inflammatory lesions(304-311). In MS, monocyte/macrophages are thought to be 
responsible for cellular pathology and tissue damage, while T lymphocytes are thought to orchestrate 
the process(208;312-315). The key role for monocyte/macrophages was illustrated in EAE. In EAE, 
a systemic depletion of monocyte/macrophages or a treatment by CNI-1493, a macrophage inhibiting 
agent, protects animals from EAE(316-319). These studies suggest that the infiltration of 
monocyte/macrophages into the brain parenchyma is essential for the development of new lesions in 
EAE and MS. In this context, during MS, recruitment of T lymphocytes across the BBB is facilitated 
by monocyte/macrophages(320-322). 
Monocyte/macrophages together with microglial cells, a brain resident monocytic cell type, 
are competent presenters of antigen and can effectively activate or reactivate infiltrating T cells 
recruited to the inflamed CNS to promote myelin-specific T cell responses. Alternatively, 
monocyte/macrophages can digest CNS myelin in response to signals produced by the infiltrating 
myelin-specific T cells. Otherwise, in the aberrant response to infection paradigm, an essential signal 
for autoimmunity may originate from the presence of pro-inflammatory molecules by activated 
monocyte/macrophages that initiate locally tissue damage directly and so generate 
autoantigens(323;324). The sequence initiating autoimmunity would begin with 
monocyte/macrophages, putatively derived from acute or chronic peripheral infections, penetrating 
the BBB(323). 
Monocyte/macrophages are an important sources of cytokines(306;325-327) and secrete 
inflammatory and potentially cytopathic mediators toxic to myelin and oligodendrocytes in the 
inflammatory milieu, such as TNF(328). Importantly, IL-12, that shifts the immune response towards 
a TH1 profile and facilitates TNF and IL-6 secretion, is another cytokine predominantly secreted by 
monocyte/macrophages(329;330). Monocyte/macrophages secrete as well IL-10, a TH2-related 
cytokine that counteracts many of the TH1 cytokines and could be therefore beneficial in MS(331). 
Because monocyte/macrophages secrete several cytokines implicated in the pathogenesis of MS (as 
reviewed in ref. (332)) this argue for their importance in the pathogenesis of MS. On the other hand, 
monocyte/macrophages can damage the myelin sheath by mediating antibody-dependent cytotoxicity 
against oligodendrocytes after the binding of pathogenic autoantibodies directed against myelin- or 
oligodendrocyte-specific antigens. In consequence monocyte/macrophages may contribute to the 
induction, perpetuation and resolution of inflammatory observed in patients with MS. Noticeably, the 
CD14+/CCR2+ subset of peripheral blood monocytes might correct the presumed TH1/TH2 balance 
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and may therefore possibly play an important role in the shift from the active disease state to a state 
of remission(333). 
3.3. Etiology of rheumatoid arthritis and multiple sclerosis 
3.3.1. Rheumatoid arthritis  
The preponderance of CD4+ T cells over CD8+ T cells(334) in rheumatoid synovitis supports 
a model of disease-associated HLA class II molecules presenting arthritogenic antigen(s) and 
promoting the chronic inflammation(335). This is correlated by the observation that synovial fluid 
and synovial tissue CD4+ T cells clearly have a TH1 bias(240;336;337). Therefore, it is supposed 
that, in a genetically predisposed individual, these CD4+ T cells are either already pre-activated or 
become (further) activated by APCs in conjunction with arthritogenic autoantigen (s) and appropriate 
major MHC class II in conjunction with co-stimulatory molecules and an appropriate cytokine 
environment. The earliest event (s) might involve activation of the innate immune response(338), 
such as the triggering of DCs, through TLRs expressed on synovial cells(339), by foreign agents or 
by a combination of such exogenous stimuli together with autologous antigens, before or in parallel 
to T-cell involvement.  
It is proposed that antigen drive may predominate during the early phase of inflammatory 
responses. Several studies have shown that only a minority of T cells in an antigen-driven 
inflammatory process are antigen-specific(340;341). Although autoantigen specific T cells are 
probably the primary inducers of the autoimmune inflammation, other non-autoantigen specific T 
cells may play an important pathogenic role at later phases in the inflammatory process(340). The 
accumulation of large numbers of activated T cells at an inflammatory site is possibly due to their 
activated state in the blood, and their increased ability to bind to endothelial cells and to migrate into 
the target organ. Since IFNg is produced at high levels in the blood of patients with RA(291;342), it 
is possible that IFNg-induced activation mechanism may play an important role in the stimulation 
and recruitment of non-autoantigen specific activated T cells. Alternatively, additional T cells could 
be recruited by bystander activation (cytokines), or by stimulation with self-antigens released from 
inflamed tissues. When the inflammatory process progresses, chronic cytokine production induces a 
profound non-deletional–T cell hyporesponsiveness(343), coupled with low levels of IFNg and IL-
2(66). This T cell hyporesponsiveness is reflected by low proliferative responses both in vitro and in 
vivo(344;345). Such T cells then function as effector cells and sustain the chronic inflammatory 
process through mechanisms less dependent on antigen signals. Accordingly, depletion of 
hyporesponsive T cells from RA synovial mononuclear cell cultures significantly reduces the 
expression of pro-inflammatory cytokines(346). Evidence suggests that this process of activation 
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may be mediated by cell-cell contact between these T cells(347;348) and monocyte/macrophages(71-
74). The target cells then overproduce pro-inflammatory mediators, including chemokines and 
cytokines, mainly TNF, IL-1b and IL-6, which may constitute the pivotal event leading to chronic 
inflammation(63-70). In addition, failure of synovial joint T cells from RA patients to undergo 
apoptosis could further facilitate cell-cell contact and perpetuate the inflammatory response(349). 
3.3.2. Multiple sclerosis 
A prevailing hypothesis of MS pathogenesis(314;350) is that pre-existing autoreactive T cells 
are activated in the periphery by unknown factor (foreign microbes, self proteins, or microbial 
superantigens, or yet undefined mechanisms). These T cells then cross the BBB into the CNS 
parenchyma, where they are reactivated in response to myelin antigen restimulation(351-353), 
resulting in the secretion of pro-inflammatory cytokines(354) that induce a chain reaction with the 
activation of resident microglial cells, infiltrating monocyte/macrophages and B cells. It is assumed 
that the presence of autoreactive T cells is clearly not the single decisive factor for the development 
of MS, because myelin-reactive T cells are also found in healthy individuals(207;355). This implies 
that other factors play an important role in the initiation and perpetuation of pathological 
autoantigen-specific immune processes.  
The complexity about the sequence and the directionality of in vivo immune responses may 
enlarge from reciprocal activation, through bi-directional interactions of co-stimulatory molecules 
(e.g. CD40-CD40L). Following their extravasations, activated (antigen specific or non-specific) T 
cells localize in proximity to macrophage/microglia or infiltrating 
monocyte/macrophages(311;356;357) and can also interact directly with the latter cells through cell-
cell contact mechanisms to up-regulate the production of numerous pro- and anti-inflammatory 
cytokines, at least as demonstrated in vitro(16;358). The latter inflammatory cytokines apparently 
might be instrumental in initiation and propagation of the MS process(178;359), as well as in the 
recovery phase of MS(358;360).  
4. T cell contact-mediated activation of monocyte/macrophages 
As previously stated, the production of IL-1 and TNF, the main pro-inflammatory cytokines 
contributing to the pathogenesis of chronic inflammatory diseases such as RA and MS(361;362), is 
mainly supported by both resident and infiltrating cells from the monocyte/macrophage lineage. 
While the production of both cytokines in acute/infectious inflammation is primarily triggered upon a 
microbial challenge as exemplified by LPS, the mechanisms leading to their production in diseases 
characterized by the absence of an infectious agent has long been elusive. Based on observations in 
animal models of RA and MS, it has been first suggested a predominant role of T cell products since 
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the typical infiltration of T lymphocytes into the target tissue precedes tissue damage. However, in 
RA, the concentrations of T cell cytokines, such as IFNg(363), in the rheumatoid joint, are lower than 
expected for a chronic T cell-mediated disease(364). As a result it has been envisioned that, in 
alternative to a direct contribution by soluble T cell products, IL-1 and TNF production might result 
from the potential contribution of T lymphocyte-monocyte/macrophage interactions. Studies carried 
out in our laboratory during the last decade have proved this assertion, which was further confirmed 
by others(196;279;346;348;365-368). Of importance, contact-mediated activation by stimulated T 
cells is as potent as optimal doses of LPS in inducing IL-1b and TNF production in 
monocyte/macrophages and cells of the monocytic 
lineage such as THP-1 cells(195). Similarly, 
activated human T lymphocytes induce TNF 
production in microglial cells(16). The relevance of 
T lymphocyte-monocyte/macrophage interactions is 
well illustrated in both MS and RA. In RA, 
monocyte/macrophages are present at an early stage 
in the lesion, and interactions are likely to take 
place between such cells and T lymphocytes 
(Figure 8)(369;370). In MS, demyelination and 
axonal damage occur in areas where T lymphocytes 
are in close contact with monocyte/macrophages and microglial cells, suggesting the importance of 
such mechanisms to potentiate inflammation(253;371-373). It is proposed that this mechanism might 
be of importance in the inflammatory and destructive phases of RA and MS, because once activated 
by stimulated T cells, monocyte/macrophages, and migroglial cells can increase the production of IL-
1, TNF, IL-6, IL-8, metalloproteinases, and prostanoids(71;347;374-376). Therefore, while both RA 
and MS are presumably initiated by antigen-specific T cells, they may be amplified and perhaps also 
perpetuated by bystander T cells of unrelated antigen specificity that constitute the majority of the 
lesional T lymphocyte infiltrate.  
The importance of gender on contact-mediated activation of monocytic cells has been 
recently highlighted by a study showing that myelin basic protein -primed T cells isolated from 
female and castrated male but not male mice induced the expression of pro-inflammatory cytokines 
(IL-1, TNF and IL-6) and nitric-oxide synthase in male and female microglia by cell-cell contact. 
This gender-sensitive activation of microglia by neuroantigen-primed T cell contact could 
emphasizes the mechanisms behind the female-loving nature of MS(377) and RA, which both 
diseases display a gender bias, about 66% of all patients being female. 
 
 
Figure 8. Electron photomicrograph of cells in rheumatoid 
synovium. T lymphocytes (T-blast) communicate by direct 
cellular contact with monocyte/macrophages (Mp) in RA 
inflammatory site. (From Harris E.D., Rheumatoid Arthritis. 
W:B: Saunders, Philadelphia, 1997)  
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4.1. T-cell signaling of monocyte/macrophages by direct cell-cell contact 
Most T cell types including freshly isolated T lymphocytes, T cell clones and T cell lines 
such as HUT-78 cells induce IL-1 and TNF in monocyte/macrophages(347;375;378;379). In 
addition, numerous stimuli induce T lymphocytes to activate monocyte/macrophages by direct 
interaction. Indeed, monocyte/macrophage activation could be triggered by direct contact with T 
cells stimulated by a combination of mitogens such as phytohaemagglutinin (PHA)/phorbol 12-
myristate 13-acetate (PMA), by cross-linking of CD3 by immobilized anti-CD3 monoclonal 
antibodies with or without cross-linking of the co-stimulatory molecule CD28(16;360;365;368;380-
383), by cytokines(346;348;384) and by specific antigens(381). Noticeably, synovial T lymphocytes 
isolated from RA joints induce IL-1b and TNF production upon contact with syngeneic 
monocyte/macrophages(382;385). Importantly, the manner in which T cells are activated influences 
the pattern of cytokines induced in monocyte/macrophages. For instance, while T lymphocytes 
activated by cross-linking of CD3 triggered the production of TNF and IL-10 in 
monocyte/macrophages(365), bystander activation of T cells with a cocktail of cytokines (TNF, IL-2 
and IL-6) elicited TNF but not IL-10 production(346). Furthermore, depending on T-cell phenotype, 
direct cellular interactions with stimulated T cells can induce different patterns of product in 
monocyte/macrophages(196). Of note, CD4+ TH1 clones induced high levels of IL-1b production by 
monocyte-like cells, while TH2 clones induced higher levels of sIL-1Ra(381). These different 
considerations imply that depending on the T cell type and stimulus, various ligands/counter-ligands 
pairs are implicated in the contact-mediated activation of monocyte/macrophages. Alternatively, 
besides the stimulus encountered by the T lymphocytes, the cytokine production patterns depend on 
the differentiation status of the monocyte/macrophages in response to stimulated T cells(386). 
4.2. Cell surface factors implicated in contact mediated monocyte/macrophage activation 
Monocyte/macrophage accessory, inflammatory, effector, and inhibitory functions have all 
been shown to be stimulated by activated T cells(279;376;378;387-395). Pre-activation of the T 
lymphocytes is a requirement for cell contact-dependent signaling, suggesting the involvement of 
activation-induced membrane-anchored ligands on the T cells. Consequently, much attention was 
focused on the probable candidate molecules on T cell surface that mediate these functions. 
Numerous T cell surface molecules have proved to be implicated in the contact-mediated activation 
of monocyte/macrophages(195), including CD69 and lymphocyte function-associated antigen- 
(LFA-) 1(347;375;396). Soluble CD23 as well is capable to induce cytokine production on 
monocyte/macrophages(397-399) through the binding(398;399) of the counter-ligands CD11b/CD18 
and CD11c/CD18(399;400). By analogy, CD23, CD40 and B7 take part in IL-10 production elicited 
in human microglia-T cell interaction and B7 as well as very late antigen- (VLA-) 4/vascular 
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adhesion molecule- (VCAM-) 1 in that of TNF(16;360;360). These results were substantiated on 
U937 human monocyte-like cells, which when treated with PMA and IFNg displays some similarities 
to human microglial cells(368). Besides, T-cell membrane-associated activating factors, membrane-
associated cytokines was the subject of a specific attention. Indeed, while numerous studies 
established a role of membrane-associated TNF in monocyte/macrophage juxtacrine 
activation(365;391;401;402), a controversial study demonstrated that stimulated T lymphocytes 
from a T cell line that did not express membrane-associated TNF induced both TNF and IL-1 
production in monocyte/macrophages(390). This suggests that TNF might play a part but not a 
primary one. Besides, neutralizing antibodies to TNF, IL-1, IL-2, IFNg and granulocyte/macrophage 
colony-stimulating factor (GM-CSF) all failed to affect monocyte/macrophage activation by 
stimulated T cells(347;347;375;376;376). Similarly, while lymphotoxin (LT) receptor is expressed 
in monocyte/macrophages(403), T-cell membrane-associated LT is not likely to be implicated in 
monocyte/macrophage activation(404). Overall, to date, attempts at identifying the surface factor 
primarily involved in the induction of cytokine production in monocyte/macrophages failed to reach 
a clear-cut answer, because inhibitors (e.g. antibodies) of surface molecules that display some 
inhibitory effects failed to abolish monocyte/macrophage activation. This suggests that the factor(s) 
required for T cell signaling of human monocyte/macrophages by direct contact remain(s) to be 
identified. Of importance, numerous studies have investigated the putative implication of the CD40-
CD40L interaction in this process. Indeed, in patients with RA and MS, CD40L expression is up-
regulated in T lymphocytes of both peripheral blood and the inflammatory site(405-408). Moreover, 
monocyte/macrophages in RA synovium(409) and macrophage/microglia in MS brains(408) have 
been shown to express CD40. These CD40-positive monocyte/macrophages and 
macrophage/microglia co-localize with CD40L-positive T cells within RA joints and MS brain, 
raising the possibility of functional interactions between these two cell types that might play a part in 
the pathogenesis of these diseases. While such interaction may play a part but not a primary one, to 
date controversial results have been published about this interaction in monocyte/macrophage 
activation by stimulated T cells(384;410;411). This specific purpose is one of the subjects of my 
thesis, which results are presented and discussed in Results, section 1. 
4.3. Modulation of T-cell monocyte/macrophage interactions 
Contact-dependent interactions between T cells and monocyte/macrophages may be the 
object of modulation by various factors, therefore giving rise to impaired or alternatively amplified 
pathologic mechanism (Figure 9). Such a property may participate to a better understanding of the T 
cell contact-mediated activation of monocyte/macrophages. This includes the determination of 
ligand/counter-ligand pairs that were found to be potentially implicated in this mechanism.  
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Leflunomide and, in a lesser extent, dexamethasone have the potential to affect the capacity 
of stimulated T lymphocytes to activate monocytic cells(412). Leflunomide (LF), a therapeutic 
agents administered to 
RA(413-415) patients, restrain 
the capacity of stimulated T 
lymphocytes to trigger IL-1b 
production in 
monocyte/macrophages, 
resulting in an enhancement 
of the sIL-1Ra/IL-1b molar 
ratio(412). By analogy IFNb, 
a MS medication(416-418), 
down-regulates IL-1b and 
TNF production(419) by interfering with the activation of both T lymphocytes and 
monocyte/macrophages(169). Alternatively, IFNb directly up-regulates sIL-1Ra production by 
monocyte/macrophages, thus enhancing the molar ratio of sIL-1Ra/IL-1b (Figure 9)(419). The 
interaction of IFNb-treated T cells with microglial cells lead to the up-regulation of IL-10 while 
diminishing TNF, IL-1b, IL-12, but also IL-4 and IL-13(16;420). In addition, minocycline, a 
tetracycline with anti-inflammatory properties that attenuates the clinical and histological severity of 
EAE, impairs both stimulated T lymphocytes and microglial cell activity thus diminishing TNF 
production, and simultaneously upregulating IL-10 production(421). Glatiramer acetate (GA), an 
efficient MS therapeutic agent, impairs stimulated T cells to effectively interact with microglial cells 
to produce pro- (TNF, IL-1b, IL-12) and anti-inflammatory cytokines (IL-10, IL-4 and IL-13)(422). 
These different drugs or cytokine therefore act as potent negative regulators of cytotoxic activity of 
cells of the monocyte/macrophage lineage. The net outcome of a non-inflammatory milieu within the 
specific organ, despite T cell infiltration, could account for part of the anti-inflammatory effects of 
such therapies. The effects of these therapeutic agents are similar to those observed in patients in 
vivo, suggesting, in analogy, the occurrence of contact-mediated activation of monocytic cells in 
vivo.  
On the other hand, IL-18, a cytokine related to IL-1b, up-regulates IL-1b and TNF production 
by monocyte/macrophages following contact with stimulated T lymphocytes by enhancing 
monocyte/macrophage activity(385). Moreover, T lymphocytes activated by IL-15, a pleiotropic 
cytokine thought to play a critical role in T-cell recruitment and activation in RA, markedly induces 
TNF production by monocyte/macrophages upon contact (Figure 9)(348). Both IL-18 and IL-15 may 
 
Figure 9. Cytokines network in contact-mediated induction of cytokines in 
monocyte/macrophages in RA. T lymphocytes and monocyte/macrophages are adjacent to one 
another at the inflammatory site and produce cytokines that can activate either themselves or their 
neighbouring cells, including fibroblasts. The latter then produce matrix-destructive 
metalloproteinases (MMPs) and prostaglandin E2 (PGE2), foremost products involved in cartilage 
destruction and bone resorption. Pro-inflammatory cytokines (IL-15, IL-18) and anti-
inflammatory proteins (IFNb) are indicated. This scenario involving interactions between both T 
lymphocytes and monocyte/macrophages can participate in many inflammatory reactions and is 
not necessarily specific to RA. (Adapted from (4)).  
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generate a positive feedback loop because, they are produced by activated 
macrophages(385;423;424). As a result, both cytokines may further activate either newly infiltrating 
monocyte/macrophages or T lymphocytes to maintain cytokine production and subsequent chronic 
inflammation. 
In accordance with the effects described above, minocycline decreases the expression of 
CD40L on T cells, underlining a key role of this molecule in the regulation of the contact-mediated 
interaction of T cells with microglial cells(421). In agreement with this, IL-15 up-regulates the 
expression of CD40L on T cells(425). In contrast, CD40LT expression on surface of stimulated T 
lymphocytes was not down-regulated by IFNb or GA(16;169;412;422), suggesting that this ligand 
might be implicated as co-activator but not as the primary signal. This hypothesis is strengthened by 
the fact that IL-18 had any effect on CD40 expression on the surface of 
monocyte/macrophages(385). Therefore, taking into account cell specificities, it might be envision 
that the CD40L-CD40 interaction depends on the differentiation stage of monocyte/macrophages. 
This is part of the subjects of my thesis, which results are presented and discussed in Results, section 
1. 
4.4. Intracellular signaling pathways implicated in cytokine production by 
monocyte/macrophages upon cellular contact 
The characterization of intracellular signaling cascades distal to cognate signals is of great 
importance as potential targets in the treatment of diseases whose pathogenesis is elicited by T-cell 
contact-dependent interactions. Upon cellular contact with CD40L-transfected cells, macrophage 
colony-stimulating factor (M-CSF)-primed monocytes/macrophages produced IL-10 and TNF(426). 
IL-10 production requires the activity of PI3Ks and of its downstream substrates, Akt and p70 S6 
kinase K (p70S6K), whereas the production of TNF was repressed by PI3Ks but was dependent on 
p70S6K activity, bifurcating from the IL-10 pathway by utilizing p42/44 MAPK(426). Thus, 
activation of macrophages by CD40L triggers two different pathways for the induction of IL-10 and 
TNF. The production of IL-10 by M-CSF-primed monocytes/macrophages activated by cellular 
contact with either cytokine-stimulated T cells or T cells isolated from RA synovial tissue was as 
well triggered through a PI3K/p70S6K-dependent pathway(427). However, the production of TNF 
by monocyte/macrophages upon direct cellular contact with cytokine- but not anti-CD3-activated T 
lymphocytes was repressed by PI3Ks(382). Thus the production of pro- and anti-inflammatory 
cytokines upon monocytes/macrophages activation by cellular contact with T cells is utilizing 
different pathways, PI3Ks being mainly involved in IL-10 induction, whereas NFkB is involved in 
TNF production(427;428). This strongly suggests that PI3Ks are preferentially involved in pathways 
controlling the production of anti-inflammatory factors whereas NF-kB activity rather controls the 
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production of pro-inflammatory mediators(427;428). Moreover, upon contact with stimulated T cells 
the balance between IL-1b and sIL-1Ra production in monocyte/macrophages is ruled by 
serine/threonine phosphatase(s)(358). Thus the triggering of these intracellular processes by direct 
contact with stimulated T lymphocytes may regulate the production of pro-inflammatory cytokines 
and their inhibitors, and the resulting ratio of their production in monocyte/macrophages influences 
in part the outcome of the inflammatory process(429). 
5. Immuno-modulatory cytokines: members of the interferon family 
In 1957, Isaacs and Lindenmann discovered a substance that protected cells from viral infection -they 
called it interferon (IFN)(430). The IFNs represent proteins with antiviral activity that are secreted 
from cells in response to a variety of stimuli(431). There are two types of IFNs, type I and type II, 
and IFN-like cytokines. To date, type I IFNs consist of eight classes: IFNa, IFNb, IFNe, IFNk, 
IFNw, IFNd, IFNl (limitin, IL-28A, IL-28B, and IL-29) and IFNt(432). Type II IFN consists of 
IFNg only. IFNa, IFNb, IFNe, IFNk, IFNw, IL-28A, IL-28B, and IL-29 are found in humans, 
whereas IFNd(433), IFNt(434), and limitin(435) are not. IFNs (Type I and Type II) were the first 
cytokines discovered and the first to be used therapeutically(431). Type I IFNs (mainly IFNa and 
Figure 10. Multiple biological activities of IFNβ. IFNβ produced by several types of cells exerts multiple functions, including those on the innate 
and adaptive immune systems by acting directly to activate major figures of the immune system such as dendritic cells, T cells and 
monocyte/macrophages. IFNβ down-regulates the pro-inflammatory cytokines IL-1β and TNF in vitro, and it enhances sIL-1Ra and IL-10 
production. In addition, other possible effects of IFNβ in MS or RA treatment include the following: inhibition of T-cell proliferation and migration, 
down-regulation of major histocompatibility complex class II expression, down-regulation of several adhesion molecules and enhancement of 
soluble adhesion molecules in serum, upregulation of transforming growth factor (TGF)-b1 and TGF-b receptor 2 expression on peripheral blood 
mononuclear cells. (Adapted from(7)). 
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IFNb) are pleiotropic, displaying pro- and anti-proliferative, pro- and anti-apoptotic, and immuno-
regulatory activities(436-440). The pleiotropic activities of IFNb have been broadly exploited for 
therapeutic purposes (Figure 10) and various preparations of IFNb have been approved for the 
treatment of MS(441;442). They are all effective, thought no treatment can eliminate the disease. 
Similarly, IFNb treatment is supposed to be beneficial in RA(7).  
Nevertheless, taking into account the immuno-modulatory activities of IFNb, IFNb treatment 
of MS patients may lead to an adapted state of immuno-suppression that may increase the mortality 
risk from coincident opportunistic infection(443). There are however rare post-approval reports of 
opportunistic infections with IFNb treatment. This might due to the contribution of IFNb to the host 
defence against pathogens(444), including those of bacterial origin. As such, IFNb has been reported 
to represent an autocrine/paracrine signal critical for robust innate immune responses elicited by 
LPS(445;446). This is one subject of my thesis, which results are presented and discussed in Results, 
section 2. 
5.1. IFNb in multiple sclerosis 
Because IFNs possess antiviral properties, the rationale for the use of IFNb in MS in the past 
was based on the belief that viruses may play a role in the pathogenesis of MS. At present, the 
current model in the pathogenesis of MS suggests that this disease has its origin in disruption of self-
tolerance for CNS antigens.  
While several reports have demonstrated the efficacy of IFNb in MS(441;442), the 
mechanisms by which IFNb therapy works remain unclear. As stated above, cytokine production is 
generally considered an important factor in determining disease activity in chronic autoimmune and 
inflammatory diseases. Since disease progression in MS correlates with increased levels of pro-
inflammatory cytokines such as, IFNg, IL-12, IL-1b, and TNF, and decreased levels of anti-
inflammatory cytokines such as IL-10 and IL-4(179;447-450) it has been suggested that a potential 
way in which IFNb might exert its beneficial effect in patients with MS was the restoration of 
physiologic balance between pro-inflammatory and anti/immuno-regulatory cytokines (Figure 10). 
Self-tolerance disruption results in manifestation of cell-mediated autoreactivity that is mostly 
administrated by activated TH1 cells related with relatively high-level production of IFNγ and 
moderately low-level production of TH2 cytokines such as IL-4. Generally, while most studies point 
out a repression of the generation of TH1 cytokines following treatment with IFNb; a distinct shift of 
the cytokine pattern toward a TH2-dominated profile has not been demonstrate so far(451). 
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IFNb is considered as an anti-proliferative agent since its ability to inhibit the clonal 
expansion of pathogenic T cell(452). IFNb might also affect the infiltration of activated T 
lymphocytes into the CNS of patients with MS that represents a significant event in MS outcome. It 
may as well affect the antigen presentation by preventing the IFNg-induced up-regulation of MHC 
class II molecule expression on APCs(453). In addition, IFNb might down-regulate the expression of 
various co-stimulatory molecules and thus possibly affects other aspects of antigen presentation.  
Following their extravasations, activated CNS-antigen-primed T cells localize in proximity to 
microglial cells, and in such a case could potently induce the expression of IL-1b, IL-1a, TNF, and 
IL-6 through cell-cell contact with such CNS-adapted macrophages(377). Moreover, the great influx 
of non CNS–antigen specific T cells might potentiate CNS immune responses(356;357). Pre-
treatment of antigen-nonspecific T lymphocytes with IFNb prior their contact with microglial cells 
represses TNF production while simultaneously enhance that of IL-10(16;420). By analogy, pre-
treatment of non-antigen specific-T cells with IFNb before their encounter with 
monocyte/macrophages, a primary source of pro-inflammatory cytokines in CNS inflammation, 
repress IL-1b and TNF production(169;454). However such pre-treatment also decreases the ability 
of stimulated T cells to induce sIL-1Ra production in monocyte/macrophages. In contrast, IFNb 
directly enhances sIL-1Ra production in the latter cells(169). Because it is unclear whether IFNb can 
penetrate the BBB, it is also conceivable that comparable interactions occur as well in the systemic 
circulation between IFNb-treated cells and monocytes, to result in the increased sIL-1Ra and IL-10 
levels observed in the serum of patients with MS upon IFNb therapy(182;331;455;456). Besides, 
IFNb could display CNS-anti-inflammatory effect through exposure of T cells to in the systemic 
circulation and the subsequent entry of these cells into the CNS parenchyma where they encounter 
monocyte/macrophages or microglial cells. 
Although the effects of IFNb mentioned above fit well with the hypothesis that IFNb works 
by induction of solely anti-inflammatory cytokines, there are conflicting reports showing that IFNb 
could also up-regulate pro-inflammatory genes(457-459). This suggests that in addition to their 
pathological potential, pro-inflammatory mediators may have beneficial effects(460). In this context 
it has been observed that both TNF and IL-1 could be factors necessary for CNS repair(461;462). 
Alternatively, the balance of pro- and anti-inflammatory pathways influenced by IFNb results in an 
anti-inflammatory response overall. Up-regulation of inflammatory cytokines may also be related to 
the development of the so-called, flu-like syndrome, a common side effect of IFNb(463).  
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5.2. IFNb in rheumatoid arthritis 
To date various antirheumatic drugs are only modestly and inconsistently effective. Actually 
whilst novel therapeutic agents that aim to neutralize the important mediators of inflammation have 
proven some efficiency in a subset of RA patients, these drugs are not tolerated by all patients, and 
only a subgroup of patients respond to them(464;465). Such limitations stimulated the search for 
additional effective treatments that can reduce the outcome of the disease. Subsequently, since 
numerous studies have demonstrated that IFNb treatment is beneficial in MS(441;442), this has 
prompted studies on its therapeutic potential in RA, which is also considered to be an immune 
mediated disease.  
In contrast to the normal physiology, where pro- and anti/immuno-inflammatory cytokines 
are maintained in balance, in RA this balance shifts in favor of the pro-inflammatory cytokines. The 
most important pro-inflammatory cytokines in RA are IL-1b and TNF(89;466). Because blockade of 
the effect of TNF(467) and IL-1b(468) is effective in RA, IFNb treatment could be an interesting 
therapeutic strategy based on the inhibitory effects of IFNb on the production of TNF, IL-1b, 
combined with the stimulatory effect on IL-10 and sIL-1Ra secretion(419;455;469). Consistent with 
these studies, IFNb inhibits the production of pro-inflammatory cytokines in human monocytes 
activated by cell contact with stimulated T cells(169;383;419). In light of the literature showing the 
importance of T-cell contact-activated monocyte/macrophages in RA(4;470), IFNb might 
predominantly act as an inhibitor of TNF and IL-1b production by monocyte/macrophages in the 
inflamed synovium. In addition, IFNb decreases the production of IL-6, IL-8, and GM-CSF by 
stimulated fibroblast-like synoviocytes from osteoarthritic patients(471). Together these data suggest 
an anti-inflammatory effect of IFNb on the major effector, inflammatory cell populations in 
rheumatoid synovial tissue, T lymphocytes, monocyte/macrophages and the fibroblast-like 
synoviocytes (Figure 10). 
Several studies in animal models of RA (i.e. CIA) have shown noticeably beneficial effects of 
IFNb treatment(471). IFNb treatment reduced inflammation by markedly decreasing the number of 
inflammatory cells into the synovial tissue, and by significantly decreasing the expression of IL-6 
and TNF, and to a lower extent that of IL-18 and IL-1b, while strongly upregulating that of IL-10. 
IFNb might also inhibit osteoclastogenesis, since IFNb-treated animals display a reduced number of 
osteoclasts that correlates with a reduced cartilage and bone destruction. An interesting study done in 
rhesus monkeys with CIA demonstrated clinical improvement and decreased serum levels of C 
reactive protein, a well-known marker of inflammation, after IFNb treatment, confirming the work in 
the mouse model showing the therapeutic potential of IFNb for the treatment of RA(472). However, 
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treatment of RA patients with IFNb has been unsuccessful so far, probably due to pharmacokinetics 
issues(7). 
6. Bridging innate to adaptive immunity: Toll-like receptors (TLRs)  
The ability of the innate immune system to recognize microbial pathogens(473;474) is 
mediated by highly conserved families of pattern recognition receptors that activate host defence 
pathways. One such family comprises the phylogenetically conserved TLRs, which are expressed by 
a variety of cells of the innate and adaptive immune system as well as several other types of cells that 
contribute to inflammatory responses, such as epithelial and endothelial cells(475;476). In humans 
10 TLRs have been identified, and each of these seems to recognize distinct classes of conserved 
molecular microbial patterns (Figure 11)(477-479). The expression and activation of TLRs 
contributes to host defence against infection in Drosophila(480;481), mice(481;482) and 
humans(482;483). There are two different mechanisms by which activation of TLRs can contribute 
to host defence: 1) activation of TLRs can directly mediate innate responses by activating 
phagocytosis and triggering anti-microbial activity(484-486); and 2) activation of TLRs can trigger 
the release of cytokines (such as TNF, IFNg and IL-12)(487), the up-regulation of co-stimulatory 
molecules, and the differentiation of monocytes into either macrophages or DCs(488), which 
 
Figure 11. Human Toll-like receptors (TLRs) and their ligands. TLRs recognize a variety of pathogen-associated molecular patterns (PAMPs). 
The physiological ligands for TLR10 are not known. The majority of ligands for TLRs include cell wall components as well as unmethylated DNA 
of pathogens. Putative host-derived TLR ligands may aid in amplifying antibacterial response and alternatively to promote sterile inflammation. 
TLR-ligand interactions lead to a number of outcomes aimed at destroying the invading pathogen and tissue repair. (Adapted from(5)). 
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mechanisms seem to crucially control effective host defenses in human infectious disease by 
allowing the innate immune system to influence the adaptive immune response(489-491). In the area 
of adaptive immune responses, it has been proposed that TLRs initiate responses involving helper T 
cells of the TH1 subset(492). Beyond the field of infectious diseases per se, the question whether 
TLRs and their signaling pathways could contribute to autoimmunity and/or to sterile inflammation 
has been addressed(493). Accordingly, one hypothesis assumed that sterile inflammation is not 
driven by the response to infection with microorganisms but by ligands derived from damaged cells, 
which are not usually present in the extracellular environment: for example b-defensins and oxidized 
lipids(494). It can also be speculated that proteins modified by oxidation or nitration might be TLRs 
ligands thereby promoting sterile inflammation(495). 
6.1. TLR4 and lipopolysaccharides (LPS): a model for infection 
One of the first mammalian TLRs to be identified was TLR4. TLR4 was shown to be capable 
of sensing LPS (also known as endotoxins) and to initiate responses in both CD14-positive and 
CD14-negative cells in mice(496;497). This response also occurs in humans, since individuals 
carrying a missense mutation affecting the extracellular domain of the TLR4 receptor are 
hyporesponsive to inhaled LPS(498) and have an increased risk of Gram-negative bacterial 
infections and bacteremia(499;500). This suggests that humans have evolved to detect LPS to 
combat infection. Monocyte/macrophages orchestrate the innate immunity response to LPS by 
expressing a variety of inflammatory cytokines that include TNF and IL-1b. However, over-reaction 
to the presence of LPS can lead to sepsis, septic shock, or systemic inflammatory response 
syndrome(501). 
In addition to LPS, TLR4 recognizes several other ligands (Figure 11), including the fusion 
protein of respiratory syncytical virus(502) and the envelope proteins of mouse mammary tumor 
virus and Moloney murine leukaemia virus(503), suggesting that TLR4 is also apparently implicated 
in the recognition of a certain group of viruses. Furthermore, TLR4 seems to recognize some 
endogenous ligands as well, including extracellular matrix components such as fibronectin(504), 
hyaluronic acid(505), biglycan(506) and heparan sulfate(507). Such compounds are produced in 
response to tissue injury and play important roles in tissue remodeling, e.g. by containing the agent 
of injury, closing the wound, and completing healing. These compounds may be representative of a 
type of endogenous “danger signal”, i.e. molecules or molecular structures that are released or 
produced from host cells during processes such as abnormal cell death (necrosis), apoptosis, and 
inflammation. These signals are recognized by monocyte/macrophages and DCs and thereby initiate 
immune responses(508). Thus TLR4 is presumably involved in several aspects of the inflammatory 
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response by recognizing exogenous ligands as well as endogenous ligands produced during 
inflammation even in the absence of infection(494;495;509). 
Alternatively, it has been proposed that APCs are activated by “danger/alarm” signals from 
injured cells, such as those exposed to pathogens, toxins, mechanical damage, and so forth(510). Of 
note, it has been recently demonstrated that expression of TLR4 in monocyte/macrophages increased 
quickly in response to heat shock(511), suggesting that heat shock or other “danger/alarm” signals 
might directly up-regulate TLRs expression and thus influence the overall response of immune cells 
to pathogen-associated molecular patterns (PAMPs) or endogenous ligands.  
7. Signal transduction leading to cytokine production in sterile or infectious 
systems 
7.1. Lipopolysaccharides and intracellular signaling pathways 
The principal components of the outer membrane of Gram-negative bacteria, LPS, are 
recognized by a complex of cell surface receptors composed of CD14, MD-2, and TLR4 (Figure 
12)(487;512;513). The TLR4 signaling is mediated via four different adaptor molecules, part of two 
different signaling pathways. A group of Toll/IL-1R (TIR) domain-containing adaptor protein 
(TIRAP) and myeloid differentiation primary-response protein 88 (MyD88), and a group of TIR 
 
Figure 12. Simplified model of lipopolysaccharide (LPS) signalling. Circulating LPS-binding protein (LBP) recognizes LPS in the plasma and 
brings it to CD14. This aids the loading of LPS onto the LPS receptor complex, which is composed of dimerized TLR4 receptors and two 
molecules of the extracellular adapter MD-2. Subsequent signals activated by TLR4 can be subdivided into those dependent on MyD88 and 
MyD88 adapter like (Mal), which occur early, and those independent of MyD88, which occur later and use the adapters TIR-containing adapter 
molecule (TRIF) and TRIF-related adapter molecule (TRAM). LPS signalling leads to the early activation of nuclear factor (NF)-kB, interferon 
response factor 3 (IRF3) and mitogen-activated protein kinase (MAPK) kinase pathways, which is mediated by the adapters MyD88 and Mal. 
(Adapted from(8)). 
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domain-containing adaptor inducing IFNb (TRIF) and TRIF-related adaptor molecule (TRAM) 
mediate activation of distinct signaling pathways. The MyD88-dependent pathway involves the early 
phase activation of NF-kB and MAP kinases including the extracellular signal-regulated protein 
kinase (ERK), c-jun N-terminal kinase (JNK), and p38 kinases(514-517), which lead to the 
production of inflammatory cytokines. The MyD88-independent pathway activates IFN-regulatory 
factor 3 (IRF3) and involves the late phase activation of NF-kB, both of which lead to the production 
of IFNb and the expression of IFN-inducible genes, which are required for the production of pro-
inflammatory cytokines, as well as the maturation of DCs in response to LPS (Figure 12)(518-520) 
(521-523). In this context, signaling by TLR4 results in activation of the STAT1 signaling pathway, 
which was secondary to the action of IFNb(524). In contrast, MyD88-dependent signaling pathway 
is dispensable for the expression of IFN-inducible genes(515;525). LPS activates a number of 
intracellular signaling pathways that lead to the production of TNF, IL-6, IL-1b, and NO. PI3K 
pathway is one of these pathways and seems to be activated either by a direct interaction with 
MyD88(526) or downstream of IL-1-receptor-associated kinase (IRAK)(527). 
Negative regulation of the TLR4 pathway occurs at a number of levels. First, prolonged 
exposure with LPS results in tolerance to the agonist. Some aspects of tolerance can be attributed to 
the down modulation of TLR4, but evidence also indicates that TLR4 stimulation results in the 
modulation of signaling components(528). Several signaling components that inhibit TLR4 signaling 
are up-regulated after exposure to agonists. Negative feedback regulation of the TLR4 signaling 
pathway involves IRAK-M(529), suppressor of cytokine signaling 1 (SOCS1) (530;531), Src 
homology 2 (SH2)-domain-containing inositol 5-phosphatase 1 (SHIP1)(6) and PI3Ks(532), as well 
as others(533). Signal transduction pathways for cytokines can be targeted by therapy to cure 
inflammation. This is the subject of our recent review (Introduction, section 7.5). 
7.2. Interferon-beta (IFNb) intracellular signaling pathways 
Type I IFNs and type II IFN signal through distinct but related pathways. A foremost 
signaling pathway involves tyrosine phosphorylation and activation of signal transducers and 
activators of transcription (STATs) by JAnus tyrosine kinases (JAks) at the cell membrane, followed 
by migration of STATs to the nucleus, where they induce the expression of many gene products. 
More specifically, IFNb binds to a class II cytokine receptor composed of IFNa receptor 1 
(IFNAR1) and IFNAR2 chains, which are associated with the JAks Tyk2 and JAk1, 
respectively(534;535). Upon IFNb binding, the cascade starts with the phosphorylation of Tyk2. 
JAk1 can phosphorylate and activate Tyk2, which can then cross-phosphorylate JAk1 to further 
activate it(536). Genetic deletion of JAk1 results in the cell inability to respond to IFNb(537). In 
46 
contrast, IFNb can still elicit a limited signaling response in the absence of Tyk2(538). Both STAT1 
and STAT2 pre-associate with IFNAR2 in untreated cells(539). STAT2 binds IFNAR2 in the 
absence of STAT1, but STAT1 binds well only to the IFNAR2-STAT2 complex(539). Activated 
JAk1 and Tyk2 sequentially phosphorylate STAT2 and STAT1, and then the phosphorylated dimers 
dissociate from the receptor (Figure 13)(436).  
Interactions of STATs through reciprocal SH2 domain-phosphotyrosine binding results in the 
formation of two main distinct transcription factor complexes(9;540). IFN-stimulated gene factor 3 
(ISGF3), a heterodimeric complex consisting of 
STAT1 and STAT2 in association with a third 
protein, p48 or interferon regulatory factor 9 
(IRF9), that associates specifically with and 
transactivates genes with interferon-stimulated 
response element (ISRE) in their promoter or 
enhancer regions. A simpler complex, termed 
AAF, consisting of STAT1 homodimer, is also 
active as a transcription factor and binds to 
different DNA sequences, termed IFNg-
activated site (GAS) elements (Figure 13). 
Although, the canonical signaling by IFNb is 
through STAT1 and STAT2, this pathway can 
recruit STAT3(541), STAT4(542), STAT5(543) 
and CrkL(544) in various cell lines under 
diverse conditions. The STATs can all form 
homodimers, and in addition, STAT1:STAT3, 
STAT3:STAT5, STAT5A:STAT5B and 
CrkL:STAT5 heterodimers have all been 
described. Distinct GAS elements display 
different binding affinity for diverse STAT dimers, establishing fine specificity(436).  
Two families, suppressors of cytokine signaling (SOCS, also called cytokine-inducible SH2 
protein (CIS)) and protein inhibitors of activated STATs (PIAS) negatively regulate the actions of 
IFNs(545), and by extension those of IFNb. Evidence is accumulating that STATs play important 
roles distinct from their well-known function as inducible transcription factors. For instance, STAT1 
is required for the constitutive expression of some genes, such as IRF-1(546), alone as monomers or, 
more likely, in combination with transcription partners still to be identified(547). Alternatively, 
 
Figure 13. Cardinal features of the IFNβ signalling pathway. IFNβ 
signals via its homologous receptor complex, IFNAR that is 
composed of at least two subcomponents, IFNAR-1 and IFNAR-2. 
Ligand binding results in the formation of a signalling complex with 
IFNAR-1 and IFNAR-2, leading to activation of the receptor-
associated Tyk2 and JAk1, respectively This is followed by the 
tyrosine phosphorylations of STAT1 and STAT2, leading to the 
formation of the heterotrimeric ISGF3 transcription factor together 
with IRF-9 (also referred to as p48). In addition, a STAT1 
homodimer, termed AAF, is formed. Subsequently, these 
transcriptional activator complexes translocate into the nucleus and 
activate the interferon-γ stimulated response element (ISRE) or the 
IFNγ-activated site (GAS). (Adapted from(9)). 
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STAT3 has been shown to display a scaffolding function by bringing PI3Ks to the activated IFNa/b 
receptor(548). This binding is followed by activation of PI3Ks. The fact that some of the STATs can 
fulfill alternative functions puts forward the possibility that STAT-null mice or cells may exhibit 
phenotypes that do not result solely from the lack of STAT activation in response to cytokines or 
growth factors. 
In this context, it is becoming increasingly clear that other pathways independent of the 
STAT pathway can initiate signal transduction by IFNb(545). Indeed, IFNb can modulate 
proliferative responses in phagocytes from STAT1-deficient mice(549;549;550). This specific 
purpose is one object of my thesis, which results are presented and discussed in Results, Section 3. 
7.3. Phosphoinositide 3-kinases (PI3Ks): regulators of the inflammatory responses 
As previously described (See section 1) the inflammatory process occurs in several 
successive steps involving the release of pro-inflammatory cytokines (e.g. IL-1, TNF, IL-6, IFNg) 
during the progression phase and the release of anti-inflammatory cytokines (e.g. IL-4, IL-10, IL-13, 
TGFb, sIL-1Ra) during the resolution phase. These mechanisms requires the sequential traffic of 
different cells (monocyte/macrophages, neutrophiles, T and B lymphocytes) between the blood 
stream and the inflamed tissue and are controlled not only at the extracellular level but also by tightly 
controlled transduction signaling into the cells. Indeed, the various functions of immune cells are 
ruled by surface receptors for various stimuli (i.e., antigen, co-stimulatory molecules, cytokines, 
chemokines, and other ligands), many of them signaling through the activation of PI3Ks(551). 
Consequently, signaling via PI3Ks has been shown to regulate important immune functions such as 
cell proliferation, survival, differentiation, chemotaxis, phagocytosis, degranulation, and respiratory 
burst(552). A role for PI3Ks in inflammatory responses has started to emerge from studies of 
signaling by receptors of the IL-1R and TNFR superfamilies. Indeed, PI3K inhibitors have been 
reported to block NF-kB activation triggered by IL-1, TNF, and anti-CD40 (a TNF receptor family 
member)(553-555). Because inflammation is an effective, tightly controlled, and self-limited process 
and imperfect executions of this “modus operandi” lead to pathological abnormalities, the 
mechanisms implicated in the resolution of the inflammatory response, such as the accumulation of 
intracellular negative regulatory factors, could give novel targets for the treatment of inflammatory 
diseases(19) (See review). This section aims at reviewing some of the functions of PI3Ks in the 
inflammatory responses. 
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7.3.1. Different classes of PI3Ks 
The term phosphoinositide 3-kinase refers to a family of enzymes that phosphorylate D-myo-
phosphatidylinositol (PtdIns) or its derivatives on the 3-hydroxyl of the inositol head group. In 
contrast, the term phosphatidylinositol 3-kinase specifies an enzyme that phosphorylates PtdIns only. 
Thus, the name phosphoinositide 3-kinase designates broader substrate specificity than 
phosphatidylinositol 3-kinase. Members of the PI3K family are divided into three classes according 
to their subunit structure, regulation, and in vitro substrate specificities selectivity and are referred to 
as class I, II and III (Figure 14)(1;552;556). Class III PI3K are heterodimeric phosphatidylinositol 3-
kinase that produce PtdIns(3)P; they are localized into endocytic vesicles where they might regulate 
protein and vesicle trafficking(557). Class II PI3Ks are large proteins (170-210 kD) whose activity 
and location seem to be regulated by extracellular signals, but at present little is known about their 
function downstream immune cell receptors(558). These enzymes may also function further 
downstream of surface receptors and associate with clathrin(559). Class II PI3Ks are using PtdIns as 
a substrate to produce PtdIns(3)P, although they may also contribute to the production of 
PtdIns(3,4)P2, thus they are phosphoinositide 3-kinases. Class I PI3Ks are heterodimeric enzymes 
composed of a catalytic subunit of 
about 110 kD, and a closely 
associated regulatory subunit that 
modulates its activity and cellular 
localization. Class I PI3Ks are 
subdivided into two classes (IA 
and IB) according to their 
catalytic subunit. Class IA PI3Ks 
are primarily activated by 
receptors triggering tyrosine kinase activation(560;561). They consist of multiple isoforms formed 
by three types of catalytic subunits (p110a, p110b, and p110d) encoded by three distinct genes 
which form heterodimeric complexes with different regulatory subunits (p85a, p85b, p55g, p55a, 
and p50a) encoded by three genes, p55a, and p50a being produced from alternate transcripts of the 
p85a gene. Each regulatory subunit contains two SH2 domains that mediate the binding to 
phosphotyrosine residues. Together with other protein-interaction domains in the catalytic and 
regulatory subunits, the SH2 domains help to recruit class IA PI3Ks to membrane associated 
signaling complexes following tyrosine kinase activation. There is some evidence that G protein-
coupled receptors (GPCR) are also able to activate the p85/p110 heterodimeric PI3Ks(562;563). 
Other studies showed that PI3Ks are also activated by small GTPase molecules such as Ras and 
 
Figure 14. Classes of PI3Ks and the defining features of their catalytic and regulatory 
subunits. (Adapted from(1)). 
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Rac1(564;565). These molecules activate PI3Ks by various, although not clearly defined, 
mechanisms. On the other hand, heterotrimeric G protein-based signaling pathways mainly activate 
the single class IB PI3K, p110g(566;567). This catalytic isoform is associated with a sole regulatory 
subunit, p101, which contributes to its regulation by G protein bg dimers. Class IB PI3K is more 
particularly expressed in cells of the immune system(566). In vivo, receptors located at the cell 
surface trigger the activation of class I PI3Ks, which are the only enzymes capable of producing in 
addition to PtdIns(4,5)P2 the critical second messenger PtdIns(3,4,5)P3. Localized at the plasma 
membrane, these transiently synthesized lipid products then serves as docking site for a subgroup of 
proteins containing pleckstrin homology (PH) domains, modular segments of about hundred amino 
acids found in many signaling proteins(568). It is these PH-domain-containing proteins that are able 
to transmit and drive further downstream signaling events, and the best-characterized PI3K effector 
molecule is PKB (also known as Akt). Mammalian Akt/PKB family comprises three highly 
homologous members bearing each two regulatory phosphorylation sites, threonine308 and 
serine473. Phosphorylation of threonine308 partially activates Akt/PKB, while phosphorylation of 
both sites is required for full activation(569). 
7.3.2. Class I PI3K in the immune system 
The expression of the two catalytic subunit isoforms, p110g and p110d, is mainly restricted to 
leukocytes, and growing evidence suggests that these isoforms play central roles in innate and 
adaptive immunity. A main feature of inflammatory responses is the migration of leukocytes to the 
inflammatory site in response to chemokines and other chemoattractants. In this context, it has been 
reported that PI3Kγ is the major isoform activated in response to chemoattractants(552), and as such, 
it is expected that selective inhibitors of PI3Kγ would be potentially helpful in preventing 
inflammatory cell recruitment in diseases including RA and MS (570). A key role for p110δ in 
immunity is assumed from studies of mice expressing a mutated and catalytically inactive p110δ that 
exhibit impaired antigen receptor signaling in T and B lymphocytes as well as impaired in vivo 
immune responses(571). Mast cells bearing a loss-of-function allele of p110d displayed defects in 
secretion of inflammatory cytokines such as TNF and IL-6 during an allergic inflammatory 
response(572).  
7.3.3. Regulation of PI3K activity 
PI3Ks deregulation by aberrant surface receptors or modulators lead to the accumulation of 
PtdIns(3,4,5)P3, a state that is linked to the formation of various diseases, including chronic 
inflammation(573). The regulation of negative feedback control of PI3Ks is accomplished by at least 
two major routes of PtdIns(3,4,5)P3 degradation: dephosphorylation by the phosphoinositide-lipid 3-
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phosphatase PTEN(574;575) and dephosphorylation by the 145-kD SH2-containing inositol 
(poly)phosphate 5-phosphatase SHIP (Figure 15)(576).  
Because evidence support that PI3Ks play a pivotal role in regulating the production by 
monocyte/macrophages of 
inflammatory mediators(577;578) 
implicated in various infectious and 
sterile inflammatory 
disorders(579), understanding the 
function of PI3Ks in cytokine 
production in such cells may lead 
to a better comprehension of these 
pathologies. This is one subject of 
my thesis, which results are presented and discussed in Results, section 4. 
7.3.4. PI3Ks in innate inflammatory responses 
Innate immunity that covers numerous areas of host defence against pathogenic microbes lies 
behind most inflammatory responses. These are triggered in the first instance by 
monocyte/macrophages and polymorphonuclear leukocytes through a limited number of germline-
encoded receptors, the innate immune receptors, capable to recognize pathogen-associated molecular 
patterns (PAMPs)(580). Upon recognition of their cognate ligands, innate receptors, such as TRLs, 
induce the expression of a variety of host defenses genes essential for the eradication of infectious 
microorganisms, including inflammatory cytokines. After activation, the inflammatory response has 
to be cautiously regulated to avoid injurious effects due to excessive reactions such as observed in 
some phases of fatal septic shock, a syndrome associated with exaggerated production of 
inflammatory cytokines(581). Whereas the mechanisms leading to activation of the inflammatory 
response in innate immunity are well understood, little is known about how the innate immune 
response is adjusted appropriately to the pathogenic microbial challenge, i.e. how excessive or 
prolonged reactions are prevented and how counter-regulatory mechanisms ultimately lead to a shut-
down of the response.  
Endotoxin tolerance (or LPS tolerance) is one such mechanism to prevent unrestricted 
immune activation whereby pre-exposure to PAMP LPS causes a reduced response to subsequent 
LPS challenge(582;583). Recent studies support that endotoxins tolerance in monocyte/macrophages 
is induced not only by LPS, but also by various others microbial components(528). LPS tolerance in 
monocyte/macrophages has been broadly studied and is characterized by a reduction in the 
production of inflammatory cytokines including TNF and IL-1(584). Endotoxin tolerance is achieved 
 
Figure 15. Schematic representation of pathways for degradation of D-myo-
phosphatidylinositol (PtdIns). SH-2 containing inositol 5’-phosphatase 1 (SHIP1) and 
SHIP2 selectively remove the 5-phosphate from PtdIns(3,4,5)P3 to generate PtdIns(3,4)P2, 
whereas the phosphatase and tensin homologue deleted on chromosome ten (PTEN) 
breaks it down to PtdIns (4,5)P2. (Adapted from(6)).. 
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through numerous routes, such as down-regulation of the LPS receptor(585), restricted activation of 
NF-κB(586), and alterations of LPS-induced activation of signaling cascades (e.g. IRAK-M and 
SOCS1)(530;531). In a similar manner, PI3Ks have been assumed to act as inducible negative 
regulators of TLR signaling(532). Noticeably, in TLR4 signaling, TGF-β-activated kinase 1 (TAK1) 
and TRAF6 pathways are operative in PI3K activation downstream of TLR4(587). More recently, 
interaction of PI3Ks with MyD88 in response to LPS has been reported(526), demonstrating the 
importance of the PI3K pathways in controlling innate immune responses. However, to date there is 
no information on the specificity of individual PI3K isoform to the TLR4 signaling. 
In the literature, there is a substantial controversy concerning the role of the PI3K pathways 
in regulating endotoxin tolerance and subsequent pro-inflammatory cytokine production, given that 
the literature is split on whether this pathway is a positive or negative regulator of these events(588). 
While some investigators claim that the PI3K pathways play a positive role(526;589-592), others 
have shown that it has a negative impact(578;593-596). Noticeably, the development of LPS 
tolerance strikingly increased PI3K expression in macrophages of rats, implicating PI3K cell 
signaling in attenuated macrophage responsiveness to LPS(532). In addition, pharmacological 
inhibition of the PI3K signaling pathways prevents the induction of LPS tolerance in an in vitro 
model of macrophage from endotoxin tolerant rats(597). Consequently, PI3K activity is considered 
by some investigators as a negative feedback mechanism ensuring a response with an appropriate 
magnitude to pathogens and/or avoiding responses to multiple waves of pathogenic stimuli(593;598). 
In contrast, the PI3K pathways are also suggested by others investigators, to be a positive regulator 
of LPS-stimulated events and, in such a case, its down-regulation is essential for endotoxin 
tolerance(599). Discrepancy relative to the role of PI3K pathways in endotoxin tolerance may be 
due, in part, to differences in the cell types used and to specificity problems with the use of 
pharmacological inhibitors.  
Endotoxin tolerance is not simply the result of a global shutdown of LPS-induced events 
since normal or even increased levels of anti-inflammatory mediators, including sIL-1Ra(600), are 
produced by LPS-tolerized cells(601). More specifically, in septic/LPS-tolerized human leukocytes, 
PI3K activity contributes to the elevated level of sIL-1Ra protein by an efficient translation of 
residual sIL-1Ra message(602). On the other hand, although the molecular mechanisms that regulate 
IL-1b expression in endotoxin tolerance are unclear, they might involve repressed transcription(603), 
rapid degradation of transcripts,(604) and altered cytokine processing and/or secretion(605), they do 
not seem to implicate the PI3K pathways(602).  
Studies suggest that PI3Ks could be implicated in diseases that are pathologically associated 
with a disorder of the TH1–TH2 balance, since cytokines (mostly IL-12 and IL-10) produced by 
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innate immune response can profoundly influence the subsequent adaptive immunity. Of interest, the 
PI3K pathway diminishes the induction of numerous key inflammatory mediators, such as IL-12, by 
Porphyromonas gingivalis LPS in human monocyte/macrophages, while simultaneously enhancing 
the production of the anti-/immuno-inflammatory cytokine IL-10(606). Of note, while the 
development of TH1 effector cells and macrophage activation are dictated in part by the levels of IL-
12 produced during the early innate immune response(607), IL-10 is a foremost counter-regulatory 
cytokine that can affect the immuno-modulatory effects of IL-12 directly or indirectly(608;609). In 
addition, transgenic mice devoid of the p85α regulatory subunit of class IA PI3Ks (PI3K−/− mice) 
have defective immunity against the intestinal nematode, Strongyloides venezuelensis, most likely 
because of an impaired TH2 response(610). Moreover, PI3K−/− mice revealed improved TH1 
responses and are resistant to Leishmania major infection, in contrast to wild-type mice(577). These 
data point out that in vivo, class IA PI3Ks could be important in the TH1 versus TH2 ratio, and 
controls induction of the TH2 response and/or suppression of the TH1 response. However these 
results should be carefully interpreted since optimal signaling through the PI3K pathway depends on 
a critical molecular balance between the regulatory and catalytic subunits(611). Consequently, it is 
obvious that knockout of class IA adaptor subunits affects the expression of the p110 subunits and 
vice versa(1). Indeed, the adapter isoforms encoded by the p85a gene appear to be critical for PI3K 
catalytic function, because p85a-deficient cells have greatly reduced p110 expression and 
activity(612). In addition, as class IA adaptors prove no selectivity for binding a specific p110 
isoform, gene targeting of these adaptors is therefore expected to have an impact on the function of 
all p110s. 
7.3.5. PI3Ks in non-septic inflammatory responses 
Many chronic/sterile inflammatory diseases are associated with deregulated intracellular 
signal transduction pathways. Of interest, direct cell-cell contact between stimulated T cells and 
monocyte/macrophages or cells of the monocytic lineage could be considered as a potent pro-
inflammatory antigen-independent mechanism perpetuating chronic organ-specific inflammatory 
reactions, such as in RA and MS, according to its ability to trigger massive up-regulation of the pro-
inflammatory cytokines IL-1 and TNF. Noticeably, PI3Ks act as negative regulators of TNF 
production by monocyte/macrophages induced through direct cellular contact with both RA-like and 
RA synovial T cells(382). Accordingly, one can assume that the PI3K pathways inflict a “braking” 
mechanism to limit the expression of pro-inflammatory cytokines in cellular contact-stimulated 
monocyte/macrophages to guarantee a transient expression of these inflammatory mediators.  
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An imbalance in cytokine homeostasis is considered to play a major part in the
pathogenesis of immuno-inflammatory diseases. Since the identification and
cloning of cytokines and their receptors, therapeutic approaches have been
developed with the purpose of impeding the interaction between the ligand
(cytokine) and its specific receptor, or interactions that involve the use of anti-
inflammatory cytokines to switch off inflammation. Although some diseases
have been treated successfully with cytokines or anti-cytokines (i.e., anti-TNF
and to a lesser extent recombinant IL-1 receptor antagonist in rheumatoid
arthritis; IFN-β in multiple sclerosis), the fact remains that these therapies do
not abrogate the concomitant usage of steroids or immuno-suppressive drugs,
and that a significant percentage of patients do not respond to such thera-
pies; these are important limitations. The identification of signalling pathways
preferentially used in inflammatory conditions has boosted approaches that
target these intracellular mechanisms. This review examines the different
therapeutic approaches that may be considered for the treatment of immuno-
inflammatory diseases, and discusses the advantages and disadvantages of
targeting extracellular or intracellular mechanisms.
Keywords: connective tissue disease, cytokines, cytokine inhibitor, cytokine receptor, immune 
intervention, inflammation, kinase inhibitor, signal transduction
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1. Introduction
The release of mediators such as inflammatory cytokines and the recruitment of
circulating leukocytes are the hallmarks of the inflammatory response. The infil-
trating cells become activated at the inflammatory site and release further media-
tors such as cytokines. In normal conditions, the inflammatory response is
regulated by the release of endogenous anti-inflammatory mediators (e.g., anti-
inflammatory cytokines) in the extracellular environment and by intracellular
negative regulatory mechanisms. Indeed, while the action of pro-inflammatory
cytokines is controlled at many levels outside the cell, anti-inflammatory mecha-
nisms of regulation occur within the cell, including the internalisation and degra-
dation of activated receptors with bound cytokines, the dephosphorylation of
activated signalling components and the induction of negative regulatory loops.
Current clinical approaches to the treatment of inflammatory diseases (rheuma-
toid arthritis [RA], Crohn’s disease, juvenile arthritis and psoriatic arthritis)
mainly focus on the inhibition of pro-inflammatory mediators and the subsequent
inflammatory response. Such types of intervention in immuno-inflammatory dis-
eases have exploded during the past 10 years, and biological agents are starting to
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supplant traditional immunosuppressive therapies (gluco-
corticoids, cyclosporin, non-steroidal anti-inflammatory
drugs [NSAIDs], corticosteroids and disease-modifying
antirheumatic drugs [DMARDs]). These agents are the out-
come of basic discoveries as to the structural and functional
biology of ligand–receptor interactions, mainly cytokines
and cytokine receptors. This has led to the design of multi-
ple tools interfering with ligand–receptor interactions, some
of which are currently used in the clinic (e.g., antibodies to
TNF; IL-1 receptor antagonist [IL-1Ra]), others still require
validation before use in human diseases. However, such
approaches present limitations in terms of percentage of
responding patients, side effects and the premise that these
therapies have often to be administered in combination with
steroids and immunosuppressive drugs. Even in the case of
administering different types of anti-TNF, combination
with methotrexate yields better results. Thus, attention has
increasingly focused on transduction pathways in the hope
that these might be suitable new targets for the treatment of
inflammatory diseases.
The aims of this review are: i) to provide a brief summary of
some aspects of the numerous possibilities of impeding the lig-
and–receptor interaction; ii) to describe the principal transduc-
tion pathways, potential new targets of therapeutic intervention
of different types; and iii) to discuss the advantages and draw-
backs of interfering at the level of the cell surface (known as
‘extracellular approach’) or inside the cell (‘intracellular
approach’), the issue of which is still open to debate.
2. Targeting ligand–receptor interaction in 
inflammation related to cytokines
Although each cytokine can be considered individually, they
interact in complex networks and cascades; therefore, the
final biological outcome of a response reflects the balance
between pro-inflammatory factors and anti-inflammatory
factors that are present in a given location at a given time.
Thus, these intricate relationships have to be taken into
account before attempting to interfere with the effect(s) of a
particular cytokine.
The biological activity of cell-associated or soluble
cytokines can be modulated by numerous mechanisms
(Table 1). These include physical interference (i.e., binding)
by soluble factors such as auto-antibodies and soluble recep-
tors, and cell-associated decoy receptors. This has been well
described for TNF, whose activity is controlled by soluble
receptors [1,2], and IL-1 whose activity is controlled jointly by
its soluble receptor II, its decoy receptor II at the cell surface,
and IL-1Ra that competes with the cytokine for the binding
to the signalling receptor [3-5].
All soluble ligands that display cytokine-binding capacity
may participate potentially in the regulation of cytokine deliv-
ery and homeostasis. Whether the net effect of their activities is
inhibition or enhancement of the cytokine action may depend
on both specific characteristics of the binding protein and the
binding kinetics. As long as the cytokine is prevented from
interacting with its membrane signalling receptor, inhibition is
maintained. However, soluble receptors and other soluble fac-
tors can increase the concentration of cytokines in body fluids
by increasing their stability (i.e., by decreasing their proteolytic
degradation). Upon dissociation from soluble ligands, biologi-
cally active cytokines can again bind and activate specific mem-
brane receptors. Thus, soluble molecules (e.g., soluble
receptors) might be compared to ‘double-edged swords’, in that
they may function as inhibitors or carriers of cytokines. Binding
affinity, therefore, plays an important part in determining the
relevance of soluble factors in cytokine homeostasis. For
instance, very high concentrations of soluble receptors are
required to compete effectively with membrane receptors when
the latter are associated with transducing subunits, which
increase their binding affinity (e.g., sIL-2Rα). In contrast, the
soluble forms of single chain receptors (sIL-1R; sTNF-R) are
strong competitors and they are required in lesser amounts [6].
This is also the case of the new class of anticytokine referred to
as cytokine traps [7].
An additional mechanism of inhibition is generated by
molecules that bind specifically to membrane receptors, thus
competing with biologically active cytokines for binding as
originally described for IL-1Ra [8]. Such receptor antagonists
are unable to generate a signal upon binding, thus resulting in
the inhibition of cytokine activity. Synthetic receptor antago-
nists have been generated, of which an antagonistic IL-15
mutant that targets IL-15R has been shown to display efficacy
in the treatment of collagen-induced arthritis (CIA) in mice
[9]. Although such molecules can display immunogenic prop-
erties, they can be improved to provide optimal characteristics
in terms of half-life, immunogenicity and specificity; for
example, to increase the half-life of a cytokine and decrease its
cytotoxicity, it can be produced as a fusion protein consisting
of a protective shell which is made of the latency-associated
protein of transforming growth factor-β (TGF-β) fused to a
matrix metalloprotease (MMP) cleavage site, thus allowing its
activation at the inflammatory site [10].
Decoy receptors are structurally unable to participate in
signalling receptor complexes, and sequester cytokines or
chemokines [11]. IL-1 receptor type II (IL-1RII) was the first
decoy receptor to be described [5]. Thus, structural and func-
tional decoy receptors represent a means of tuning inflamma-
tory responses by regulating the action of pro-inflammatory
cytokines and chemokines (Table 1) [12].
Chemokines have also been the subject of therapeutic
approaches based on the premise that they possess two distinct
binding sites: a high-affinity site responsible for specific lig-
and–receptor interactions, and a lower-affinity site for interac-
tions with proteoglycans responsible for the establishment and
presentation of chemokine gradients on the surface of
endothelial cells and within the extracellular matrix [13]. This
property was recently used to modulate the inflammatory
process in vivo through mutation of the essential heparin-bind-
ing site of a pro-inflammatory chemokine (RANTES), which
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abrogates the ability of the protein to form higher-order oli-
gomers (necessary for the biological activity of RANTES
in vivo), thereby impairing cellular recruitment [14]. Therefore,
the alteration of the lower affinity site of a pro-inflammatory
chemokine that retains receptor-binding capacity generates a
dominant-negative inhibitor with therapeutic potential.
Both membrane-bound cytokines and the exchange of
cognate signals between cells play a major part in immuno-
inflammatory reactions at the local level. Consequently, cell–
cell interactions that resort to the above mechanisms are
being subjected to deep scrutiny in order to determine suita-
ble approaches to treat T-cell-mediated diseases, such as RA
or multiple sclerosis (MS). This consists in the blockade of
the interactions between molecules present at the immune
synapse between T cells and antigen-presenting cells. Block-
ade of this interaction by a fusion protein can prevent T-cell
activation and has been shown to improve the symptoms of
RA in early clinical trials [15]. Inversely, the induction of pro-
inflammatory cytokines in monocytes/macrophages by cellu-
lar contact with stimulated T cells can be inhibited by apo A-
I/HDL, which might also be of therapeutic interest [16-18].
The potential levels of action of cytokine inhibitors and
receptor interactions are summarised in Table 1.
Despite the success of biological therapies targeting
cytokines and their receptors, the systemic administration of
anticytokine agents has revealed some problems. For instance,
about half of patients with RA do not respond to treatment
with TNF inhibitors, and blockade of pro-inflammatory
cytokines can increase risk of infections. In addition, although
TNF inhibition improves function and clinical status in RA,
the same biological agents exacerbate MS [19]. This is most
likely due to the fact that although excessive TNF is deleteri-
ous for myelin-producing cells in the brain and spinal cord it
is also an important growth factor for these same cells. Simi-
larly, the inhibition of a given cytokine to a specific extent
could also decrease a pathological inflammatory situation, and
might also compromise the response of the innate system to
challenge foreign antigens. Ultimately, because they act in
loops and cascades, their interactions can be nonlinear and
chaotic, thus demonstrating just how necessary it is to under-
stand the complex nature of protagonist biology in the disease
in pursuit of efficacious therapies that target only the cellular
mechanisms responsible for the pathogenesis.
3. Overview of some signalling pathways and 
nuclear factors involved in inflammation
Despite some improvements that have been observed follow-
ing the administration of cytokine antibodies, soluble inhibi-
tory receptors and receptor antagonists, not all patients
respond to this type of treatment, and both primary refracto-
riness or secondary escape phenomena occur and justify
approaches based on targeting intracellular pathways. The fol-
lowing section provides a brief overview of major signal trans-
duction pathways that are associated with the pathogenesis of
inflammatory diseases, and describes examples of the multiple
possible ways of interacting with these pathways via inhibitory
compounds of small molecular weight [20] (Table 2).
3.1 NF-κB, TNF/IL-1 and toll-like receptor signalling 
pathways
In both infectious and sterile inflammation, the innate
immune system uses receptors which are members of the toll-
like receptors (TLRs) and nucleotide-binding oligomerisation
domain (NOD)-protein families [21]. The signalling that
occurs in an innate immune response triggers two major
events: the activation of NF-κB and interferon regulatory fac-
tor 3 (IRF3). The NF-κB pathway controls the production of
pro-inflammatory cytokines, such as TNF and IL-1, whereas
the IRF3 pathway leads to the production of type I interfer-
ons (IFN-α and -β). Because dysregulation of NF-κB and
IκB phosphorylation is a hallmark of inflammatory diseases,
newly designed drugs targeting these constitutively activated
signalling pathways represent promising therapeutic tools.
In the cytoplasm, NF-κB, which is composed of mono- or
heterodimers of p50 (NF-κB1), p52 (NF-κB2), p65
(RelAS), RelB and c-rel, forms inactive trimeric complexes
with IκB. This pathway is activated by pro-inflammatory
cytokines such as TNF and IL-1, and by a variety of micro-
bial products. Indeed, TLRs and IL-1 receptor signalling via
TNF receptor-associated factors (TRAF)-6 and TNF recep-
tor via TRAF-2 converge at the level of IKK complex, which
Table 1. Points of control in cytokine bioactivities.
Targets Inhibitors
Ligands Antibodies
Soluble shed receptors, cytokine traps
Decoy receptors
Enzymes leading to degradation
HDL-associated apo A-I
Receptors Antibodies
Receptor antagonists
Dominant-negative ligands
Intracellular 
components
Post-translational 
mechanisms
i.e., IL-1β-converting enzyme (ICE)
TNF convertase enzyme (TACE)
Signal transduction Pharmacological inhibitors
Negative regulatory factors
Negative feedback inhibitors
Antisense oligonucleotides, siRNA, 
decoy oligonucleotides
Nuclear component Histone deacetylase
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consists of IKKα (IKK1) IKK-β (IKK2) and the regulatory
subunit IKKγ (or NEMO, NF-κB essential modifier). IKK
complex phosphorylates IκBs, leading to their degradation,
thereby allowing NF-κB to translocate to the nucleus, to
bind to the promoter region of the target gene and to activate
transcription. Alternatively, IKK complex is phosphorylated
by MEKK1, a member of the mitogen-activated protein
kinase/extracellular signal-regulating kinase (MAPK/ERK)
pathway (Figure 1). NF-κB activation then activates target
genes whose products are in turn NF-κB activators, for
instance, genes encoding pro-inflammatory cytokines, chem-
okines and adhesion molecules that induce the setting of a
signalling amplification loop. Dysregulation of the NF-κB
system and overexpression of inflammatory mediators are
often observed in association with autoimmune diseases.
One particular kinase that is part of the IKK complex,
IKK-β, is an attractive potential target for the regulation of
NF-κB activity [22]. Treatment by BMS-345541, a small
orally bioavailable inhibitor of IKK-β, resulted in the decrease
of inflammation and osteoarticular destruction in CIA in
mice [23]. Furthermore, another selective IKK-β inhibitor,
SPC839, administered to arthritic rats, reduced disease sever-
ity and joint damage [24]. Another approach consisting in the
transfection of dominant-negative (dn) IKKs demonstrated
that dnIKK-β, contrary to dnIKK-α, prevented TNF-medi-
ated NF-κB nuclear translocation and cytokine production by
synovial fibroblasts [25]. However, because IKK-α rules the
alternative pathway of NF-κB activation and displays an aux-
iliary function in the classical pathway, it might represent a
promising target in inflammation.
As mentioned above, the phosphorylated IκB molecules are
ubiquinated and degraded within the proteasome. The pro-
teasome inhibitors decrease the degradation of IκB and thus
block the activation of NF-κB. Because proteasome inhibitors
exhibit anti-inflammatory and antiproliferative effects, dis-
eases characterised by both inflammation and cell prolifera-
tion might benefit from such drugs [26]. However, inhibition
of proteasome activity could also entail a serious risk of side
effects, because proteasome displays many other cellular func-
tions. This might be the reason why the proteasome inhibitor,
bortezomib, is currently used in clinical trials for cancer ther-
apy and not immuno-inflammatory diseases, even though it
displays some efficacy in animal models of RA, asthma, MS
and psoriasis [27]. An alternative strategy, consisting of the
overexpression of the inhibitory subunit IκBα through aden-
oviral delivery, has also yielded interesting results in explants
of RA synovium [28]. However, all of these approaches have to
be assessed carefully considering the central role of NF-κB
and the potential risk that its blockade might entail. Indeed,
NF-κB also displays anti-inflammatory functions in vivo dur-
ing the resolution of inflammation, being involved in the
induction of both anti-inflammatory gene expression and
apoptosis [29].
Another interesting pharmacological approach consists in
blocking protein–protein interactions between the MyD88
adaptator and either upstream or downstream elements
(Figure 1) [30]. MyD88 has proved to play a key role in the
transduction of infectious and inflammatory signals triggered
by TLR/IL-1Rs. MyD88, which contains Toll/IL-1 receptor
(TIR) domains that form upstream TIR–TIR interactions
with the IL-1R/TLR after ligand binding, and TIR–TIR
interactions with downstream signalling elements lead to the
activation of gene transcription through NF-κB activation.
This suggests that disruption of TIR–TIR interaction would
be of therapeutic benefit in the treatment of infectious and
inflammatory diseases. Based on this observation, a cell-pene-
trating mimic of TIR domain that interferes with the interac-
tions between mouse MyD88 and IL-1RI was shown to
inhibit IL-1β-induced response [31]. This encouraging result
should prompt the design of selective inhibitors to accurately
modulate distinct players in intracellular pathways occurring
in inflammation.
3.2 The Janus kinase/signal transducer and activator 
of transcription pathway
Signal transducers and activators of transcription pathways
(STATs), originally described as ligand-induced transcription
factors in IFN-treated cells, were found to play a crucial part in
transduction pathways associated with mediators that modu-
late immunity and inflammation such as cytokines, of which
Table 2. Inhibitors of signal transduction (adapted from Morel & Berenbaum, 2004) [20].
Signalling pathways Inhibitors
p38 MAPK CSAID (i.e., SB203580, RW367657, L-167307, VX-745, RPR 200765A, Scio 469)
ERK1/2 i.e., Ro 09-2210, PD98059, U0126
JNK i.e., SP600125, CC-401
PI3K PTEN, SHIP, Ly 294002, wortmannin
NF-κB IKK-β inhibitor, IκB, PDTC (pyrrolidine dithiocarbamate), NAC (5N-acetyl cysteine), lactacystin
STAT CIS1, SOCS1, SOCS3
SMAD SMAD7
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ILs, IFNs, haematopoiesis (e.g., IL-6), and certain hormones
(e.g., leptin). STATs are also activated through receptor tyro-
sine kinases such as epidermal growth factor receptor and sev-
eral members of the G-protein-coupled receptor. Therefore,
STAT activation plays a pivotal part in inflammation. The
activation cascade starts with the ligand-induced activation of
receptor-bound Janus kinases (JAKs) and receptor dimerisa-
tion. JAKs subsequently phosphorylate additional targets,
including both the receptors and STATs. STATs are latent tran-
scription factors that reside in the cytoplasm. Once phosphor-
ylated, STATs undergo dimerisation and then rapidly
translocate to the nucleus. In the nucleus, the dimerised STATs
bind to specific regulatory sequences, such as γ-activated
sequence (GAS) and IFN-stimulated response element (ISRE)
in the promoter region of their target genes, to activate or
repress their transcription (Figure 2) [32,33].
In mammals, there are seven STAT genes (STAT 1, 2, 3, 4,
5A, 5B and 6) and four JAK proteins (JAK 1, 2, 3 and
TYK2). The phenotypes of STAT-deficient mice are of great
interest to immunologists. Indeed, both STAT1-/- and STAT2-
/- mice show impaired response to IFN-α/β/γ; STAT4-/- mice
show impaired Th1 differentiation due to the loss of IL-12
responsiveness, and STAT6-/- showed impaired Th2 differenti-
ation due to loss of IL-4 responsiveness. This demonstrates
the importance of the different STAT proteins in inflamma-
tion, autoimmunity, and allergic diseases [34]. However, this
might be different in the human system, because part of the
signalling of IFN-β and -γ has been shown to be independent
of STAT1 [35,36].
The JAK/STAT system also features a complex inhibitory
mechanism, as the STAT target gene comprises the suppres-
sors of cytokine signalling (SOCS) family. To date, the
SOCS family consists of eight members (CIS1 and
SOCS1–7), of which three (CIS1, SOCS1 and SOCS3)
have been demonstrated to negatively regulate signal trans-
duction. SOCS1 is an important anti-inflammatory pro-
tein, as the phenotype of SOCS1 knockout mice revealed
some similarities with autoimmune diseases [37]. Further-
more, recent studies based on an IL-1-driven model of
experimental arthritis demonstrated that mice lacking
SOCS1 display increasing synovial inflammation and joint
destruction that is dependent on a number of cytokines
TNF
TRADD
RIP
TRAF2
IL-1R TLR1/2 TLR3/4
TIR domain
TRIF
(MyD88-independent)
TBK1
IRF3
IFN-α, -β
TIR domain
MyD88
TRAK
TRAF6
Inactive IKKK
Activated IKKK
MEKK1
Inactive IKK
(IKK-α, -β, -γ) Phosphorylation and
activation of IKK by
activated IKKK
and/or MEKK1
Recruitment and
activation of IKKK
Activated IKK-β Phosphorylation of IκB
NF-κB–IκB
NF-κB–IκB–P
NF-κB
IκB–P Ubiquitinylation and
degradation of
phosphorylated IκB
in proteasome
Transcription of NF-κB target genes (e.g., TNF, IL-1, IL-18, COX-2)
Migration of NF-κB
into nucleus
Figure 1. TNF, IL-1 and TLR signalling pathways.
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including granulocyte/macrophage-colony stimulating fac-
tor (GM-CSF), TNF and IL-6. In the above animals, the
action of SOCS1 on synovial macrophages and fibroblasts
appeared to limit inflammation and joint destruction, and
to regulate T-cell proliferation [38]. This suggests that forced
SOCS expression by adenovirus gene transfer may inhibit
signalling triggered by a particular cytokine or a pro-
inflammatory stimulus. In this context, intra-articular
injections of SOCS3 and a dominant-negative form of
STAT3 have been shown to suppress the induction of
arthritis in two animal models of arthritis [39]. Furthermore,
SOCS1 and SOCS3 are induced in macrophages stimulated
by bacterial products (LPS or CpG-DNA), suggesting that
SOCS also control TLR signalling [40]. In addition to
SOCSs, STAT activity is modulated by protein inhibitors of
activated STAT (PIAS), a family consisting of four mem-
bers which prevent STAT dimers to bind DNA and might
thus be potential therapeutic targets [41]. The net outcome
of the biological events involves positive regulation, nega-
tive regulation and reprogramming of STAT activity.
Understanding the pathogenic role of STATs would help to
develop novel therapeutic strategies [42,43].
3.3 The transforming growth factors-β–Smad signal 
transduction pathway
Transforming growth factors-β (TGF-β1 – 3) are produced by
both immune and non-immune cells and display numerous
functions, the most important of which being the regulation
of immune responses. TGF-β rules the differentiation, prolif-
eration and state of activation of all immune cells. TGF-β has
been shown to be involved in immune defects associated with
fibrotic complications such as scleroderma [44], cancer,
autoimmunity and opportunistic infections. According to
studies in a variety of murine models, the genetic disruption
of TGF-β1 or abrogation of TGF-β signalling results in a
multifocal inflammatory response [45-47]. TGF-β ligands sig-
nal through a receptor complex that comprises the types I and
II receptor kinases. The main downstream transduction path-
way for TGF-β involves the proteins of the Smad family. The
eight Smad proteins fall into three classes: receptor-activated
Smads (R-Smad 1, 2, 3, 5 and 8), the co-mediator Smad
(Smad4) and the inhibitory Smads (I-Smads 6 and 7). Smad2
and Smad3 form a complex with Smad4 that translocates to
the nucleus where it regulates gene expression along with co-
activators and cell-specific DNA-binding factors. The agonis-
tic Smad4 competes with inhibitory Smads (Smad6 and
Smad7), which prevent Smad2 and Smad3 from binding to
the activated type I TGF-β receptor and the subsequent
nuclear translocation of Smad4. This is part of a negative-
feedback regulatory loop of this pathway because TGF-β also
triggers Smad7 expression. In inflammatory bowel disease,
Smad7 blockade of TGF-β1 signalling helps to maintain the
chronic production of pro-inflammatory cytokines that drives
the inflammatory process. The inhibition of Smad7 by spe-
cific antisense oligonucleotides enables endogenous TGF-β to
downregulate this response [48]. Therefore, targeting this sys-
tem may prove worthwhile but it could also entail a risk of
tumour development, because TGF-β displays a dual role: to
suppress or promote tumour growth. Consequently, one
should take into account the cellular background as a decisive
factor in the outcome of TGF-β signalling in both normal
and tumour cells. Indeed, differential gene expression in
Activation
Ligands
Activation of diverse
combinations of four different
JAKs and seven different
STATs
Activation of
different gene
patterns
Inhibition
(negative-feedback circuit)
• Protein inhibitor of activated
STATs (PIAS); four members
• Suppressors of cytokine signalling
(SOCS) (e.g., SOCS1, SOCS3 and
CIS1 [cytokine-inducible SH2-
containing protein])
• Ubiquitin–proteasome-
dependent degradation
Final biological outcome
Figure 2. Schematic representation of the JAK/STAT signalling pathway and its inhibitors.
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response to TGF-β depends on the levels of expression of the
TGF-β receptor complex, the expression of Smads, the
expression profile of cooperating transcription factors, and the
stage of activation of competing growth factor pathways. All
of these aspects determine for how long the Smad complexes
stay in the nucleus and control the pattern of gene induction
or repression [49].
3.4 The mitogen-activated protein kinase pathway
The mitogen-activated protein kinase (MAPK) pathways play
a crucial role in numerous phases of immune-mediated
inflammatory responses. Three major MAPK pathways exist:
(i) the extracellular signal-regulating kinase (ERK1/2); (ii) c-
Jun N-terminal protein kinases (JNKs); and (iii) p38 kinases.
In general, the MAPKs, ERK1 and ERK2 are mainly involved
in signalling by mitogens and growth factors, whereas
cytokines (IL-1, TNF) and cellular stress mainly induce the
activation of MAPKs p38 and JNK [50]. The activation of
MAPKs results from the phosphorylation of specific threo-
nine or serine and tyrosine residues by MAPK kinases
(MAPKK or MEK), which in turn are activated upstream by
MAPKK kinases (MAPKKK or MEKK). The latter are them-
selves activated by members of the family of small G proteins,
such as Ras, or directly by receptor tyrosine kinases (Figure 3)
[51]. MAPKs control the activation of particular transcription
factors, either directly (e.g., activator protein-1 [AP-1] and
activating transcription factor-2 [ATF-2]), or indirectly (e.g.,
NF-κB) [52]. The use of pyridinyl imidazole anti-inflamma-
tory drugs led both to the identification of p38 MAPK and
the subsequent proposal that altering the activity of the
MAPK family members would be a valuable approach to
treating inflammation. Pyridinyl immidazole derivatives are
part of the class of therapeutic compounds termed cytokine-
suppressive anti-inflammatory drugs (CSAIDs). The p38α
MAPK isoform plays a major part in the initiation of inflam-
mation. Indeed, pro-inflammatory cytokines trigger the acti-
vation of p38α, which in turn controls the production of pro-
inflammatory cytokines. The latter mechanism occurs either
via the direct activation of gene transcription or via mRNA
stabilization. Intense efforts are currently made to design
compounds that target components of MAPK pathways as
recently reviewed [53,54]. Several of these inhibitors are not
only effective in animal models of disease, but are also the
subject of clinical trials as summarised in Table 3. Testing the
efficacy of MAPK inhibitors in animal models of arthritis has
revealed a potential benefit of p38 MAPK inhibitors [55]. Fur-
thermore, several p38 MAPK inhibitors have been subjected
to Phase II and III clinical studies in humans as recently
reviewed [56].
JNKs also represent attractive therapeutic targets as they
regulate the AP-1 component c-Jun in cells exposed to TNF
[57]. The JNK proteins include three different isoforms, of
which JNK1 and JNK2 phosphorylate c-Jun. In a rat adju-
vant arthritis model, the use of SP600125, a selective inhibi-
tor of JNK 1, 2 and 3, slightly decreased paw swelling and
completely inhibited joint damage [58]. Interestingly, in a
TNF-driven animal model of arthritis, the selective inhibition
of JNK1 was not effective in blocking inflammation [59]. This
suggests that for clinical efficacy, the inhibition of both JNK1
and JNK2 isoforms is required.
Attempts at developing inhibitors of the MEK/ERK
pathway are also currently envisioned but, to the authors’
knowledge, trials lag far behind those of other MAPK
inhibitors [54,56].
3.5 The phosphoinositol-3 kinase pathway
Many extracellular ligands (hormones, growth factors and
cytokines) engage receptors that can activate phosphoinositol-
3 kinases (PI3Ks). Current knowledge indicates that PI3Ks
might qualify as drug targets for the treatment of chronic
inflammation [60] and might also prevent excessive innate
immune response [61]. PI3Ks can be allotted to three classes,
two of which are represented by multiple isoforms. Depend-
ing on the cell type, the engaged receptor(s) and the recruited
isoform(s), different effectors may respond to the signal and
collaborate with other pathways to produce distinct responses.
Class I PI3Ks catalyse the phosphorylation of the 3′-OH posi-
tion of the inositol ring of inositol phospholipids, producing
PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 (Figure 4).
The latter two products are the principal products found
in vivo and bind selectively to certain pleckstrin homology
(PH) domains of signalling proteins, the best-characterised
PI3K effector being serine/threonine kinases of the Akt/PKB
family [62]. Subsequently, PI3Ks regulate multiple crucial tran-
scription factors, such as NF-κB and AP-1 [63], and proteins
that participate in the regulation of mRNA translation such as
Mitogens
Growth factors
Cytokines (IL-1, TNF)
Cellular stress
G proteins (Ras)/receptor tyrosine kinases
MAPKKK
MAPKK
ERK1/2 JNK p38
Transcription factors
(e.g., AP-1, NF-κB, CREB1, ATF-2)
Figure 3. Schematic representation of the MAPK signalling
pathway.
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P70S6 kinase [64]. Importantly, the PI3K pathway is activated
in many cell types such as dendritic cells and monocytes/mac-
rophages by IL-1 receptors, TLRs and members of the TNF-
R family, including CD40 [65-67]. We and others have demon-
strated that PI3K is involved in the repression of pro-inflam-
matory cytokines (e.g., TNF, IL-1β and IL-12) and the
induction of anti-inflammatory cytokines (IL-1Ra and IL-10)
in human monocytes in conditions mimicking either chronic
(contact with stimulated T cells) or acute (LPS) inflammation
[68-70]. Thus, PI3Ks are key effectors that may act in a nega-
tive-feedback loop in order to regulate inflammation. There-
fore, PI3Ks may be a target for therapeutic intervention.
Depending on the type of pathological condition (i.e., cancer
versus inflammation) inhibition of PI3Ks may or may not be
beneficial  [61]. To determine if in inflammation it is beneficial
to induce the expression/activity of selective PI3K isoforms,
efforts are necessary to define their specificity. This in turn
may uncover means of modulating the PI3K pathway. Of
note, mice expressing a catalytically inactive form of p110δ
only developed inflammatory bowel disease (IBD) [71]. PI3K
signalling is regulated by two major mechanisms consisting in
the dephosphorylation of PI3K products by either phosphoi-
nositide-lipid 3-phosphatase (PTEN) or SH2-containing
inositol (poly)phosphate 5-phosphatases (SHIP1 and SHIP2)
[62]. PTEN blocks the activation of NF-κB by IL-1 and TNF
[72,73], and is markedly expressed in synovial fibroblasts in RA
[74]. SHIP is a positive regulator of LPS-induced inflamma-
tion. Recent reports indicate that the inflammatory response
to LPS is regulated by SHIP through the inactivation of Akt
[75]. To the authors’ knowledge, no therapeutic attempt has so
far been made to target PTEN or SHIP.
3.6 Protein kinase C
The protein kinase C (PKC)-δ signalling pathway is another
potential therapeutic target in RA. Indeed, in synovial fibro-
blasts, the upregulation of IL-1β and IL-8 mRNA by macro-
phage migration inhibitory factor (MIF) was inhibited by
staurosporine, a PKC inhibitor [76]. Furthermore, PKC is
important in that it induces anti-apoptotic signals in T cells
and neutrophils [77].
3.7 The cyclic adenosine monophosphate-dependent 
kinases
Phosphodiesterase (PDE) inhibitors and prostanoids (prosta-
cyclin) increase intracellular cyclic adenosine monophosphate
(cAMP) which activates cAMP-dependent kinases and con-
trols genes implicated in inflammation [78]. For instance, the
second messenger cAMP has been shown to downregulate
pro-inflammatory TNF production and to upregulate simul-
taneously the anti-inflammatory cytokine IL-10 [79]. This
pathway may, therefore, represent a good therapeutic target
due to its opposite effects on TNF and IL-10. In this context,
rolipram, a PDE-IV inhibitor, reduces the clinical and histo-
logical severity of CIA [80], thus confirming the potential ben-
efit of targeting the cAMP/protein kinase A (PKA) pathway in
the treatment of autoimmune diseases such as RA.
3.8 The peroxisome proliferation-activated receptors
Peroxisome proliferation-activated receptors (PPARs) are lig-
and-activated transcription factors that are part of the nuclear
hormone receptor superfamily. So far, three PPAR isotypes have
been identified and are commonly referred to as PPARα,
PPARβ and PPARγ. PPARα, a nuclear receptor family mem-
ber, regulates gene expression in response to certain fatty acids
Table 3. Advantages and disadvantages of ‘extracellular’ versus ‘intracellular’ approaches.
Levels Advantages Disadvantages
Extracellular
Selectivity Large molecule subjected to degradation
Buffering system (more physiological) Antibody formation (HACA), 
immunogenicity
Cell targeting Necessity for the presence of the receptor 
on the target cell
Rapid effect with i.v. administration Cost of production
Intracellular
Signal transduction Small molecules Complexity of the different pathways
Simple pharmacology Escape pathway
Use of prodrugs Specificity more difficult to determine
Low cost of production Toxicity less predictable
Stability of the drug
mRNA Specificity Delivery
RNA degradation
Induction of IFN response
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and fibric acid derivatives. For instance, PPARα has been
shown to downregulate the expression of tissue factor (TF) and
MMPs in LPS-activated human monocytes or monocyte-
derived macrophages [81]. In addition, PPARγ agonists, admin-
istered to patients with hypertriglyceridaemia, proved to have
anti-inflammatory properties and are thus of potential clinical
use [15,82]. Therefore, PPARγ agonists display promising benefi-
cial effects in controlling inflammation [83]. Indeed, PPARγ
transrepresses the expression of pro-inflammatory mediators at
the transcriptional level by inhibiting NF-κB, STAT1 and AP-1
signalling. LPS-induced MMP-9 secretion was downregulated
markedly by both PPARγ and PPARα agonists [84]. Thus,
effects of PPARs on MMP-9 may account for the beneficial
effect of PPAR agonists in animal models of atherosclerosis.
3.9 Histone deacetylase
Histone deacetylase (HDAC) is a family of enzymes that regu-
late chromatin structure and thereby affect inflammatory gene
expression [85]. In adjuvant arthritis, an animal model of RA,
HDAC inhibitors (phenylbutyrate and trichostatin A) abro-
gated the expression of TNF in affected tissues. In treated ani-
mals, the pannus formation was suppressed, and there was no
destruction of cartilage and bone [86]. Consequently, HDAC
inhibitors may represent a new class of compounds for the
treatment of RA.
4. New drugs targeting inflammatory and 
immunomodulatory mechanisms and possibly 
affecting intracellular pathways
Besides current biological therapies for inflammatory dis-
eases, the increased knowledge of the intracellular mecha-
nisms involved in inflammation has prompted a great deal
of interest in various novel therapeutic biologics and innova-
tive techniques that promise new methods of action. The
following section will briefly present some agents (e.g., stat-
ins and immunosuppressive drugs) and procedures (e.g., sin-
gle-stranded antisense oligonucleotides, double-stranded
short-interfering RNA [siRNA], decoy oligonucleotides and
gene therapy). The latter are currently used not only in ani-
mal models, but also in individuals with inflammatory dis-
eases. It is likely that biologicals will play an increasingly
important part in managing inflammatory diseases in the
near future.
4.1 Statins
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, which are approved for choles-
terol reduction in atherosclerosis and hypercholesterolaemia,
may also be beneficial in the treatment of other inflamma-
tory diseases. Most of the identified anti-inflammatory ben-
efits of statins rely on the reduction of cellular levels of
mevalonate, whose derivatives are involved in the post-trans-
lational modification of several small G proteins [87]. The
beneficial effects of statins include the inhibition of pro-
inflammatory cytokine and chemokine production, adhe-
sion molecule expression, and MMP secretion. Statins
reduce the inducible expression of MHC class II molecules
[88] and block the expression of co-stimulatory molecules
necessary for the induction of auto-aggressive T cells [89].
They can also shift the balance of cytokines (i.e., from T
helper-1 [Th1] pro-inflammatory cytokines to Th2 type
anti-inflammatory cytokines) [90]. Statins have been tested in
different animal models of chronic inflammatory disease in
which beneficial effects were observed for experimental
autoimmune encephalomyelitis [89] but not in experimental
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Figure 4. Schematic representation of the PI3K signalling pathway and its inhibitors.
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arthritis [91]. A pilot trial with various statins in MS resulted
in the reduction of inflammatory lesions [92]. In RA, statins
(atorvastatin) display modest anti-inflammatory effects with
a decrease in of vascular risk factors [93].
4.2 Immunosuppressive drugs
Major immunosuppressive drugs – initially used in transplan-
tation – are becoming more commonly administered in many
autoimmune diseases. They act by blocking the calcineurin
pathway leading to the activation of the transcriptional factor
called nuclear factor of activated T cells (NFAT) as in the case
of cyclosporin and tacrolimus. Other drugs, such as sirolimus
and everolimus, act on the molecular target of rapamycin
(mTOR). These new therapeutic tools have been discussed in
a recent review [94].
4.3 RNA interference, antisense, decoy 
oligonucleotides and gene therapy
Single-stranded antisense oligonucleotides and double-
stranded siRNA molecules, which specifically mark target
transcripts for degradation and thereby elimination of the
resulting protein, are a promising approach to modulate dis-
ease processes. RNA interference (siRNA, antisense) targets
RNA transcripts but not proteins. Therefore, all types of
molecular gene products can be inhibited, including many
particular transcription factors, kinases and phosphatases
for which no inhibitory molecules have been reported/
designed. However, these methods share many practical
problems such as site selection, toxicity at high concentra-
tion, and the difficulty of transfection in certain cell types
[95]. Once these problems have been overcome, this
approach may constitute a more specific way of interfering
within the cell.
Double-stranded oligonucleotides containing the con-
sensus binding sequence of a transcription factor (decoy oli-
gos) provide a rationally designed tool to manipulate gene
expression at the transcriptional level. However, a limita-
tion of this type of approach is the rapid degradation of
phosphodiester oligonucleotides by intracellular nucleases.
This problem might be avoided by resorting to modifica-
tion by locked nucleic acids (LNA) [96]. In this regard,
delivery of LNA-based decoy oligos to NF-κB is in
progress, which aims at a long-term modulation of NF-κB
activation and subsequent controlled release of pro-inflam-
matory mediators in pathological conditions such as
chronic inflammation and autoimmunity [97].
Gene therapy has been largely documented as an appro-
priate therapeutic approach to inflammation. However,
gene therapy will require a biosensing system with an
inducible transcriptional switch that allows robust but
adjustable transgene expression. For instance, in RA
patients, the challenge will be the regulation of transgene
expression to meet variable physiological demands during
the intermittent course of the disease [98].
Finally, an important condition for the success of every new
therapy is the ability to deliver therapeutic molecules to the
target cells or organ. This selective delivery is even more com-
plex when the therapeutic agents are peptides, modified oligo-
nucleotides or genes. In this regard, drug-loaded erythrocytes
have proved to be safe and useful carriers of both new and con-
ventional therapeutics and can be advantageous delivery sys-
tems for new clinical applications where proteins and
oligonucleotides are therapeutic agents [97].
5. Expert opinion
The present opinion focuses on the different advantages and disad-
vantages of different strategies to temper immuno-inflammatory
diseases. Briefly, two different therapeutic strategies, the
exogenous (extracellular milieu and cell surface) and endo-
genous strategies (intracellular components), represent the
main approaches to interfering with the inflammatory proc-
ess (Table 3). To predict which is preferable, the nature and
stage of the disease have to be known. From clinical trials
we have learned that: (i) a given compound or approach
cannot be used regardless of whether the disease is acute or
chronic, and to extrapolate may be risky; (ii) not all autoim-
mune diseases can be approached the same way; (iii) fre-
quently the clinical results are better when patient
treatment is associated with a conventional immunomodu-
lating agent; (iv) a strong synergism exists between different
pro-inflammatory molecules, and their effect can be linked
to certain subtypes of patients, stage of disease, location of
the inflammation, or type of clinical symptoms; (v) it is
essential to determine which inhibitors are more effective in
the initial induction of the treatment and, in contrast, dur-
ing the consolidation phase; (vi) despite the aim for a single
‘bullet’, it remains unlikely that a single inhibitor should
remove all of the usual symptoms such as pain, inflamma-
tion, tissue destruction, and lack of tissue repair; and (vii) it
is also important to take into account the genetic aspects
involved in immune-mediated adverse drug effects
(IMADEs) in the context of pharmacogenetics [99]. Insight
into these aspects will help to distinguish responders from
non-responders, and to predict the deleterious side effects
of a given drug.
When deciding to inhibit immuno-inflammatory reac-
tions for prosecution of host toxic inflammatory responses,
it is vital to safeguard the mechanisms of host defence. It
could be argued that targeting in the extracellular milieu
(ligand binding) or at the level of cell-surface receptors
(receptor inhibition) would carry fewer risks than blocking
the central machinery of cell biology, the latter being
strongly immunosuppressive and potentially more deleteri-
ous to the host defence mechanism. However, intervening at
a crucial stage in the signalling pathways of pro-inflamma-
tory mediators may cover more types/profiles of different
diseases. Thus, a larger patient population could benefit
Dayer, Molnarfi & Burger
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from such a treatment. Selecting the appropriate pathway(s)
will remain a great challenge, considering the huge variety
and redundancy of signalling pathways. The salient factor
emerging from clinical medicine is that the most specific
drugs are frequently those that act at the level of the ligand
receptor or during crucial enzymatic steps. When the target
is located between post-receptor binding events and the
transcriptional level, the specificity may be lesser. A more
specific effect may also appear when impeding the expres-
sion of a single gene. The best solution would probably be a
combination of the two approaches at the receptor level and
at the intracellular level, because, in that case, moderate
drug concentrations could be used and side effects avoided
as much as possible.
Bibliography
1. AGGARWAL BB, SAMANTA A, 
FELDMANN M: TNF receptors. In: 
Cytokine Reference. Oppenheim JJ, 
Feldmann M (Eds), London, Academic 
Press (2000):1619-1632.
2. AGGARWAL BB, SAMANTA A, 
FELDMANN M: TNF-alpha. In: Cytokine 
Reference. Oppenheim JJ, Feldmann M 
(Eds.), London, Academic Press 
(2000):413-434.
3. DINARELLO CA: Therapeutic strategies 
to reduce IL-1 activity in treating local and 
systemic inflammation. Curr. Opin. 
Pharmacol. (2004) 4:378-385.
4. BURGER D, DAYER JM: IL-1Ra. In: 
Cytokine Reference. Oppenheim JJ, 
Feldmann M (Eds), London, Academic 
Press (2000):319-336.
5. COLOTTA F, DOWER SK, SIMS JE et al.: 
The type II 'decoy' receptor: a novel 
regulatory pathway for interleukin 1. 
Immunol. Today (1994) 15:562-566.
6. CHIZZOLINI C, DAYER JM: Cytokine 
inhibitors. In: Encyclopedia of Immunology 
(2nd Ed.). Delves PJ, Roitt IM (Eds). 
London, Academic Press (1998):702-707.
7. ECONOMIDES AN, CARPENTER LR, 
RUDGE JS et al.: Cytokine traps: multi-
component, high-affinity blockers of 
cytokine action. Nat. Med. (2003) 9:47-52.
8. SECKINGER P, LOWENTHAL JW, 
WILLIAMSON K et al.: A urine inhibitor 
of interleukin 1 activity that blocks ligand 
binding. J. Immunol. (1987) 139:1546-
1549.
9. FERRARI-LACRAZ S, ZANELLI E, 
NEUBERG M et al.: Targeting IL-15 
receptor-bearing cells with an antagonist 
mutant IL-15/Fc protein prevents disease 
development and progression in murine 
collagen-induced arthritis. J. Immunol. 
(2004) 173:5818-5826.
10. ADAMS G, VESSILLIER S, DREJA H et 
al.: Targeting cytokines to inflammation 
sites. Nat. Biotechnol. (2003) 21:1314-
1320.
11. MANTOVANI A, BONECCHI R, 
MARTINEZ FO et al.: Tuning of innate 
immunity and polarized responses by decoy 
receptors. Int. Arch. Allergy Immunol. 
(2003) 132:109-115.
12. D'AMICO G, FRASCAROLI G, 
BIANCHI G et al.: Uncoupling of 
inflammatory chemokine receptors by IL-
10: generation of functional decoys. Nat. 
Immunol. (2000) 1:387-391.
13. MCFADDEN G, KELVIN D: New 
strategies for chemokine inhibition and 
modulation: you take the high road and I'll 
take the low road. Biochem. Pharmacol. 
(1997) 54:1271-1280.
14. JOHNSON Z, KOSCO-VILBOIS MH, 
HERREN S et al.: Interference with heparin 
binding and oligomerization creates a novel 
anti-inflammatory strategy targeting the 
chemokine system. J. Immunol. (2004) 
173:5776-5785.
15. STEINMAN L: Immune therapy for 
autoimmune diseases. Science (2004) 
305:212-216.
16. HYKA N, DAYER JM, MODOUX C et 
al.: Apolipoprotein A-I inhibits the 
production of interleukin-1beta and tumor 
necrosis factor-alpha by blocking contact-
mediated activation of monocytes by T 
lymphocytes. Blood (2001) 97:2381-2389.
17. BURGER D, DAYER JM: The role of 
human T lymphocyte-monocyte contact in 
inflammation and tissue destruction. 
Arthritis Res. (2002) 4(Suppl. 3):S169-
S176.
18. DAYER JM, BURGER D: Cell-cell 
interactions and tissue damage in 
rheumatoid arthritis. Autoimmun. Rev. 
(2004) 3(Suppl. 1):S14-S16.
19. STEINMAN L: Elaborate interactions 
between the immune and nervous systems. 
Nat. Immunol. (2004) 5:575-581.
20. MOREL J, BERENBAUM F: Signal 
transduction pathways: new targets for 
treating rheumatoid arthritis. Joint Bone 
Spine (2004) 71:503-510.
21. ULEVITCH RJ: Therapeutics targeting the 
innate immune system. Nat. Rev. Immunol. 
(2004) 4:512-520.
22. KARIN M, YAMAMOTO Y, WANG QM: 
The IKK NF-kappa B system: a treasure 
trove for drug development. Nat. Rev. Drug 
Discov. (2004) 3:17-26.
23. MCINTYRE KW, SHUSTER DJ, 
GILLOOLY KM et al.: A highly selective 
inhibitor of I kappa B kinase, BMS-
345541, blocks both joint inflammation 
and destruction in collagen-induced 
arthritis in mice. Arthritis Rheum. (2003) 
48:2652-2659.
24. HAMMAKER D, SWEENEY S, 
FIRESTEIN GS: Signal transduction 
networks in rheumatoid arthritis. Ann. 
Rheum. Dis. (2003) 62(Suppl. 2):ii86-ii89.
25. AUPPERLE KR, BENNETT BL, BOYLE 
DL et al.: NF-kappa B regulation by I kappa 
B kinase in primary fibroblast-like 
synoviocytes. J. Immunol. (1999) 163:427-
433.
26. ELLIOTT PJ, ZOLLNER TM, 
BOEHNCKE WH: Proteasome inhibition: 
a new anti-inflammatory strategy. J. Mol. 
Med. (2003) 81:235-245.
27. ADAMS J, KAUFFMAN M: Development 
of the proteasome inhibitor Velcade 
(bortezomib). Cancer Invest. (2004) 22:304-
311.
28. BONDESON J, FOXWELL B, 
BRENNAN F et al.: Defining therapeutic 
targets by using adenovirus: blocking NF- 
kappaB inhibits both inflammatory and 
destructive mechanisms in rheumatoid 
synovium but spares anti-inflammatory 
mediators. Proc. Natl. Acad. Sci. USA 
(1999) 96:5668-5673.
29. LAWRENCE T, GILROY DW, 
COLVILLE-NASH PR et al.: Possible new 
role for NF-kappaB in the resolution of 
inflammation. Nat. Med. (2001) 7:1291-
1297.
30. ARKIN MR, WELLS JA: Small-molecule 
inhibitors of protein-protein interactions: 
progressing towards the dream. Nat. Rev. 
Drug Discov. (2004) 3:301-317.
From cellular receptors to transduction–transcription pathways for cytokines
S12 Expert Opin. Biol. Ther. (2005) 5(Suppl.1)
31. BARTFAI T, BEHRENS MM, 
GAIDAROVA S et al.: A low molecular 
weight mimic of the Toll/IL-1 receptor/
resistance domain inhibits IL-1 receptor-
mediated responses. Proc. Natl. Acad. Sci. 
USA (2003) 100:7971-7976.
32. SCHINDLER C, DARNELL JE Jr: 
Transcriptional responses to polypeptide 
ligands: the JAK-STAT pathway. Ann. Rev. 
Biochem. (1995) 64:621-651.
33. PAUKKU K, SILVENNOINEN O: STATs 
as critical mediators of signal transduction 
and transcription: lessons learned from 
STAT5. Cytokine Growth Factor Rev. (2004) 
15:435-455.
34. PFITZNER E, KLIEM S, BAUS D et al.: 
The role of STATs in inflammation and 
inflammatory diseases. Curr. Pharm. Des. 
(2004) 10:2839-2850.
35. MOLNARFI N, HYKA-NOUSPIKEL N, 
GRUAZ L et al.: The production of IL-1 
receptor antagonist in IFN-{beta}-
stimulated human monocytes depends on 
the activation of phosphatidylinositol 3-
kinase but not of STAT1. J. Immunol. 
(2005) 174:2974-2980.
36. NAVARRO A, ANAND-APTE B, 
TANABE Y et al.: A PI-3 kinase-dependent, 
Stat1-independent signaling pathway 
regulates interferon-stimulated monocyte 
adhesion. J. Leukoc. Biol. (2003) 73:540-
545.
37. NAKA T, TSUTSUI H, FUJIMOTO M et 
al.: SOCS-1/SSI-1-deficient NKT cells 
participate in severe hepatitis through 
dysregulated cross-talk inhibition of IFN-
gamma and IL-4 signaling in vivo. Immunity 
(2001) 14:535-545.
38. EGAN PJ, LAWLOR KE, ALEXANDER 
WS et al.: Suppressor of cytokine signaling-
1 regulates acute inflammatory arthritis and 
T cell activation. J. Clin. Invest (2003) 
111:915-924.
39. SHOUDA T, YOSHIDA T, HANADA T 
et al.: Induction of the cytokine signal 
regulator SOCS3/CIS3 as a therapeutic 
strategy for treating inflammatory arthritis. 
J. Clin. Invest. (2001) 108:1781-1788.
40. DALPKE AH, OPPER S, 
ZIMMERMANN S et al.: Suppressors of 
cytokine signaling (SOCS)-1 and SOCS-3 
are induced by CpG-DNA and modulate 
cytokine responses in APCs. J. Immunol. 
(2001) 166:7082-7089.
41. O'SHEA JJ, WATFORD W: A peek at 
PIAS. Nat. Immunol. (2004) 5:875-876.
42. O'SHEA JJ: Targeting the Jak/STAT 
pathway for immunosuppression. Ann. 
Rheum. Dis. (2004) 63(Suppl. 2):ii67-ii71.
43. IVASHKIV LB, HU X: Signaling by 
STATs. Arthritis Res. Ther. (2004) 6:159-
168.
44. MORI Y, CHEN SJ, VARGA J: Expression 
and regulation of intracellular SMAD 
signaling in scleroderma skin fibroblasts. 
Arthritis Rheum. (2003) 48:1964-1978.
45. KULKARNI AB, HUH CG, BECKER D 
et al.: Transforming growth factor beta 1 
null mutation in mice causes excessive 
inflammatory response and early death. 
Proc. Natl. Acad. Sci. USA (1993) 90:770-
774.
46. SHULL MM, ORMSBY I, KIER AB et al.: 
Targeted disruption of the mouse 
transforming growth factor-beta 1 gene 
results in multifocal inflammatory disease. 
Nature (1992) 359:693-699.
47. GORELIK L, FLAVELL RA: Abrogation of 
TGFbeta signaling in T cells leads to 
spontaneous T cell differentiation and 
autoimmune disease. Immunity (2000) 
12:171-181.
48. MONTELEONE G, KUMBEROVA A, 
CROFT NM et al.: Blocking Smad7 
restores TGF-beta1 signaling in chronic 
inflammatory bowel disease. J. Clin. Invest. 
(2001) 108:601-609.
49. INMAN GJ, NICOLAS FJ, HILL CS: 
Nucleocytoplasmic shuttling of Smads 2, 3, 
and 4 permits sensing of TGF-beta receptor 
activity. Mol. Cell (2002) 10:283-294.
50. DONG C, DAVIS RJ, FLAVELL RA: 
MAP kinases in the immune response. 
Annu. Rev. Immunol. (2002) 20:55-72.
51. PEARSON G, ROBINSON F, BEERS GT 
et al.: Mitogen-activated protein (MAP) 
kinase pathways: regulation and 
physiological functions. Endocr. Rev. (2001) 
22:153-183.
52. NICK JA, AVDI NJ, YOUNG SK et al.: 
Selective activation and functional 
significance of p38alpha mitogen-activated 
protein kinase in lipopolysaccharide-
stimulated neutrophils. J. Clin. Invest. 
(1999) 103:851-858.
53. KARIN M: Mitogen activated protein 
kinases as targets for development of novel 
anti-inflammatory drugs. Ann. Rheum. Dis. 
(2004) 63(Suppl. 2):ii62-ii64.
54. ENGLISH JM, COBB MH: 
Pharmacological inhibitors of MAPK 
pathways. Trends Pharmacol. Sci. (2002) 
23:40-45.
55. SAKLATVALA J: The p38 MAP kinase 
pathway as a therapeutic target in 
inflammatory disease. Curr. Opin. 
Pharmacol. (2004) 4:372-377.
56. TAS SW, REMANS PH, REEDQUIST KA 
et al.: Signal transduction pathways and 
transcription factors as therapeutic targets in 
inflammatory disease: towards innovative 
antirheumatic therapy. Curr. Pharm. Des 
(2005) 11:581-611.
57. VENTURA JJ, KENNEDY NJ, LAMB JA 
et al.: c-Jun NH(2)-terminal kinase is 
essential for the regulation of AP-1 by 
tumor necrosis factor. Mol. Cell Biol. (2003) 
23:2871-2882.
58. HAN Z, BOYLE DL, MANNING AM et 
al.: AP-1 and NF-kappaB regulation in 
rheumatoid arthritis and murine collagen-
induced arthritis. Autoimmunity (1998) 
28:197-208.
59. KOLLER M, HAYER S, REDLICH K et 
al.: JNK1 is not essential for TNF-mediated 
joint disease. Arthritis Res. Ther. (2005) 
7:R166-R173.
60. WARD S, SOTSIOS Y, DOWDEN J et al.: 
Therapeutic potential of phosphoinositide 
3-kinase inhibitors. Chem. Biol. (2003) 
10:207-213.
61. FUKAO T, KOYASU S: PI3K and negative 
regulation of TLR signaling. Trends 
Immunol. (2003) 24:358-363.
62. CANTLEY LC: The phosphoinositide 3-
kinase pathway. Science (2002) 296:1655-
1657.
63. REDDY SA, HUANG JH, LIAO WS: 
Phosphatidylinositol 3-kinase in interleukin 
1 signaling. Physical interaction with the 
interleukin 1 receptor and requirement in 
NFkappaB and AP-1 activation. J. Biol. 
Chem. (1997) 272:29167-29173.
64. CONEJO R, DE ALVARO C, BENITO M 
et al.: Insulin restores differentiation of Ras-
transformed C2C12 myoblasts by inducing 
NF-kappaB through an AKT/P70S6K/p38-
MAPK pathway. Oncogene (2002) 21:3739-
3753.
65. FRUMAN DA, CANTLEY LC: 
Phosphoinositide 3-kinase in 
immunological systems. Semin. Immunol. 
(2002) 14:7-18.
66. MOREL JC, PARK CC, ZHU K et al.: 
Signal transduction pathways involved in 
rheumatoid arthritis synovial fibroblast 
interleukin-18-induced vascular cell 
adhesion molecule-1 expression. J. Biol. 
Chem. (2002) 277:34679-34691.
Dayer, Molnarfi & Burger
Expert Opin. Biol. Ther. (2005) 5(Suppl.1) S13
67. MOREL JC, PARK CC, WOODS JM et 
al.: A novel role for interleukin-18 in 
adhesion molecule induction through NF 
kappa B and phosphatidylinositol (PI) 3-
kinase-dependent signal transduction 
pathways. J. Biol. Chem. (2001) 276:37069-
37075.
68. BRENNAN FM, HAYES AL, CIESIELSKI 
CJ et al.: Evidence that rheumatoid arthritis 
synovial T cells are similar to cytokine-
activated T cells: involvement of 
phosphatidylinositol 3-kinase and nuclear 
factor kappaB pathways in tumor necrosis 
factor alpha production in rheumatoid 
arthritis. Arthritis Rheum. (2002) 46:31-41.
69. BURGER D, MOLNARFI N, GRUAZ L 
et al.: PI3-K is a checkpoint in the 
production of interleukin-1beta (IL-1beta) 
and IL-1 receptor antagonist [abstract]. Eur. 
J. Biochem. (2002) 269(Suppl. 1):106.
70. FOEY AD, GREEN P, FOXWELL B et al.: 
Cytokine-stimulated T cells induce 
macrophage IL-10 production dependent 
on phosphatidylinositol 3-kinase and 
p70S6K: implications for rheumatoid 
arthritis. Arthritis Res. (2002) 4:64-70.
71. OKKENHAUG K, BILANCIO A, 
FARJOT G et al.: Impaired B and T cell 
antigen receptor signaling in p110delta PI 
3- kinase mutant mice. Science (2002) 
297:1031-1034.
72. DI CRISTOFANO A, PANDOLFI PP: 
The multiple roles of PTEN in tumor 
suppression. Cell (2000) 100:387-390.
73. KOUL D, YAO Y, ABBRUZZESE JL et al.: 
Tumor suppressor MMAC/PTEN inhibits 
cytokine-induced NFkappaB activation 
without interfering with the IkappaB 
degradation pathway. J. Biol. Chem. (2001) 
276:11402-11408.
74. PAP T, FRANZ JK, HUMMEL KM et al.: 
Activation of synovial fibroblasts in 
rheumatoid arthritis: lack of Expression of 
the tumour suppressor PTEN at sites of 
invasive growth and destruction. Arthritis 
Res. (2000) 2:59-64.
75. FANG H, PENGAL RA, CAO X et al.: 
Lipopolysaccharide-induced macrophage 
inflammatory response is regulated by SHIP. 
J Immunol. (2004) 173:360-366.
76. ONODERA S, NISHIHIRA J, KOYAMA 
Y et al.: Macrophage migration inhibitory 
factor up-regulates the expression of 
interleukin-8 messenger RNA in synovial 
fibroblasts of rheumatoid arthritis patients: 
common transcriptional regulatory 
mechanism between interleukin-8 and 
interleukin-1beta. Arthritis Rheum. (2004) 
50:1437-1447.
77. WANG K, SCHEEL-TOELLNER D, 
WONG SH et al.: Inhibition of neutrophil 
apoptosis by type 1 IFN depends on cross-
talk between phosphoinositol 3-kinase, 
protein kinase C-delta, and NF-kappaB 
signaling pathways. J. Immunol. (2003) 
171:1035-1041.
78. TEIXEIRA MM, GRISTWOOD RW, 
COOPER N et al.: Phosphodiesterase 
(PDE)4 inhibitors: anti-inflammatory drugs 
of the future? Trends Pharmacol. Sci. (1997) 
18:164-171.
79. MEISEL C, VOGT K, PLATZER C et al.: 
Differential regulation of monocytic tumor 
necrosis factor-alpha and interleukin-10 
expression. Eur. J. Immunol. (1996) 
26:1580-1586.
80. ROSS SE, WILLIAMS RO, MASON LJ et 
al.: Suppression of TNF-alpha expression, 
inhibition of Th1 activity, and amelioration 
of collagen-induced arthritis by rolipram. J. 
Immunol. (1997) 159:6253-6259.
81. MARX N, MACKMAN N, 
SCHONBECK U et al.: PPARalpha 
activators inhibit tissue factor expression 
and activity in human monocytes. 
Circulation (2001) 103:213-219.
82. DELERIVE P, DE BOSSCHER K, 
BESNARD S et al.: Peroxisome proliferator-
activated receptor alpha negatively regulates 
the vascular inflammatory gene response by 
negative cross-talk with transcription factors 
NF-kappaB and AP-1. J. Biol. Chem. (1999) 
274:32048-32054.
83. KOTA BP, HUANG TH, ROUFOGALIS 
BD: An overview on biological mechanisms 
of PPARs. Pharmacol. Res. (2005) 51:85-94.
84. SHU H, WONG B, ZHOU G et al.: 
Activation of PPARalpha or gamma reduces 
secretion of matrix metalloproteinase 9 but 
not interleukin 8 from human monocytic 
THP-1 cells. Biochem. Biophys. Res. 
Commun. (2000) 267:345-349.
85. URNOV FD, WOLFFE AP: Chromatin 
remodeling and transcriptional activation: 
the cast (in order of appearance). Oncogene 
(2001) 20:2991-3006.
86. CHUNG YL, LEE MY, WANG AJ et al.: A 
therapeutic strategy uses histone deacetylase 
inhibitors to modulate the expression of 
genes involved in the pathogenesis of 
rheumatoid arthritis. Mol. Ther. (2003) 
8:707-717.
87. GOLDSTEIN JL, BROWN MS: 
Regulation of the mevalonate pathway. 
Nature (1990) 343:425-430.
88. KWAK B, MULHAUPT F, MYIT S et al.: 
Statins as a newly recognized type of 
immunomodulator. Nat. Med. (2000) 
6:1399-1402.
89. YOUSSEF S, STUVE O, PATARROYO JC 
et al.: The HMG-CoA reductase inhibitor, 
atorvastatin, promotes a Th2 bias and 
reverses paralysis in central nervous system 
autoimmune disease. Nature (2002) 
420:78-84.
90. STEINMAN L: Immunotherapy of 
multiple sclerosis: the end of the beginning. 
Curr. Opin. Immunol. (2001) 13:597-600.
91. PALMER G, CHOBAZ V, TALABOT-
AYER D et al.: Assessment of the efficacy of 
different statins in murine collagen-induced 
arthritis. Arthritis Rheum. (2004) 50:4051-
4059.
92. VOLLMER T, KEY L, DURKALSKI V et 
al.: Oral simvastatin treatment in relapsing-
remitting multiple sclerosis. Lancet (2004) 
363:1607-1608.
93. MCCAREY DW, MCINNES IB, 
MADHOK R et al.: Trial of Atorvastatin in 
Rheumatoid Arthritis (TARA): double-
blind, randomised placebo-controlled trial. 
Lancet (2004) 363:2015-2021.
94. HALLORAN PF: Immunosuppressive 
drugs for kidney transplantation. N. Engl. J 
Med. (2004) 351:2715-2729.
95. DORSETT Y, TUSCHL T: siRNAs: 
applications in functional genomics and 
potential as therapeutics. Nat. Rev. Drug 
Discov. (2004) 3:318-329.
96. CRINELLI R, BIANCHI M, GENTILINI 
L et al.: Transcription factor decoy 
oligonucleotides modified with locked 
nucleic acids: an in vitro study to reconcile 
biostability with binding affinity. Nucleic 
Acids Res. (2004) 32:1874-1885.
97. MAGNANI M, ROSSI L, FRATERNALE 
A et al.: Erythrocyte-mediated delivery of 
drugs, peptides and modified 
oligonucleotides. Gene Ther. (2002) 9:749-
751.
98. VAN DE LOO FA: Inflammation-
responsive promoters for fine-tuned gene 
therapy in rheumatoid arthritis. Curr. Opin. 
Mol. Ther. (2004) 6:537-545.
99. BUGELSKI PJ: Genetic aspects of 
immune-mediated adverse drug effects. Nat. 
Rev. Drug Discov. (2005) 4:59-69.
From cellular receptors to transduction–transcription pathways for cytokines
S14 Expert Opin. Biol. Ther. (2005) 5(Suppl.1)
Affiliation
Jean-Michel Dayer†, Nicolas Molnarfi & Danielle 
Burger
†Author for correspondence
University Hospital & Faculty of Medicine, 
Service of Immunology & Allergy,
24, Rue Micheli-du-Crest, 1211 Geneva 14, 
Switzerland
Tel: +41 22 372 94 09; 
Fax: +41 22 372 94 18;
E-mail: jean-michel.dayer@hcuge.ch
68 
AIMS OF THE THESIS 
A fundamental issue arising from the cell-cell contact model is the characterization of the 
factors on the stimulated T cell surface as well as their counter-ligands that are implicated in contact-
mediated signaling of monocyte/macrophage activation. The first part of this thesis aims at providing 
information relative to the contribution of the CD40L-CD40 interaction in the induction of cytokine 
production in T cell contact-mediated activation of three different types of human monocytic cells, 
i.e., freshly isolated monocytes, monocytes primed with IFNg (IFNg-macrophages), and THP-1 cells. 
In the past, in the absence of identification of a pathologic agent/mechanism responsible for 
cytokine induction in chronic/sterile inflammation, LPS, has been widely used as a substitute to 
stimulate immune/inflammatory responses in vitro to mimic this condition. As a result, a great 
majority of studies have considered LPS-stimulated peripheral blood monocyte/macrophages as well 
as LPS-stimulated synovial macrophages or macrophage/microglia as suitable systems for the 
clarification of pathogenic processes underlying chronic/sterile diseases. However, to date, growing 
evidence rather supports the relevance of the model of T-cell contact-mediated activation of 
monocyte/macrophages and macrophage/microglia in these pathologies. One should consider the 
LPS solely as a potent activator of the immune system to commonly induce models of 
acute/infectious inflammation. Accordingly, the second aim of this thesis aspires to underline the 
different immuno-modulatory effect of IFNb on the production of pro-and anti-inflammatory 
cytokines, including IL-1b, TNF, and sIL-1Ra in human monocyte/macrophages activated by LPS, 
and by contact with stimulated T cells; these stimuli being more prone to reflect the activation of 
monocyte/macrophages in acute/infectious and chronic/sterile inflammation, respectively.  
As previously stated, IFNb modulates cytokine production in vitro and in vivo and this is 
particularly noticeable for sIL-1Ra(187). Of interest, sIL-1Ra production by monocyte/macrophages 
is directly induced by IFNb(198). Accordingly, the third objective of this thesis aims at investigating 
the intracellular mechanisms elicited by IFNb and implicated in the control of sIL-1Ra production by 
monocyte/macrophages. The results reveal an important function for PI3Ks in sIL-1Ra induction by 
monocyte/macrophages. 
The crucial role of PI3Ks in the induction of sIL-1Ra production by IFNb-activated 
monocyte/macrophages led us to address the question of the role of the latter enzymes in the 
induction of sIL-1Ra, and consequently to that of IL-1b upon activation by stimuli which induce 
both cytokines. Accordingly, the fourth aim of this thesis contributes to the understanding of 
mechanisms of action of PI3K activity in regulating acute and chronic inflammatory reactions. The 
results reveal a considerable role of the PI3K signaling pathway in the regulation of the balance 
69 
between the pro-inflammatory cytokine and its inhibitor, which balance dictates in part the outcome 
of the inflammatory process. 
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RESULTS 
 
1. Differential induction of IL-1b and TNF by CD40 ligand or cellular contact 
with stimulated T cells depends on the maturation stage of human 
monocytes  
Burger, D., Molnarfi, N., Gruaz, L., and Dayer, J.M. 200. J.Immunol. 173:1292-1297.  
Differential Induction of IL-1 and TNF by CD40 Ligand or
Cellular Contact with Stimulated T Cells Depends on the
Maturation Stage of Human Monocytes1
Danielle Burger,2 Nicolas Molnarfi, Lyssia Gruaz, and Jean-Michel Dayer
Cellular contact with stimulated T cells potently induces cytokine production in monocytes, a mechanism that is likely to be
relevant to chronic inflammation. Although the identity of surface molecules involved in this process remains elusive, CD40 and
its ligand, CD40L, are thought to be implicated, considering that they are expressed at the inflammatory site. To ascertain the
involvement of CD40L, we compared the activation of three different types of human monocytic cells, i.e., freshly isolated mono-
cytes, monocytes primed with IFN- (IFN--macrophages), and THP-1 cells. These cells were activated by either membranes
isolated from stimulated T cells (HUT-78 or T lymphocytes) to mimic cellular contact, soluble extracts from isolated membranes,
or CD40L trimer (CD40LT). The production of TNF and IL-1 was induced by membranes of stimulated T cells in the three types
of target cells, whereas CD40LT induced TNF production in IFN--macrophages only. Similar results were obtained with soluble
extracts of T cell membranes, demonstrating that the difference between membranes and CD40LT was not due to the particulate
form of membranes. CD40LT induced neither transcript nor protein of cytokines in monocytes, whereas in IFN--macrophages,
IL-1 and TNF mRNA were observed, but only TNF was measured in cell supernatants. Finally, anti-CD40L Abs failed to inhibit
TNF and IL-1 production induced in IFN--macrophages by solubilized membranes, whereas TNF production induced by
CD40LT was inhibited. These results demonstrate that CD40L is not required in monocyte activation by direct cellular contact
with stimulated T cells, although soluble CD40LT induces the production of TNF in IFN--macrophages. The Journal of Im-
munology, 2004, 173: 1292–1297.
C D40L (CD154) is a member of the TNF family, which isexpressed on activated T cells (1). It binds to CD40, amember of the TNFR family, and plays an important part
in Th cell signal necessary for germinal center formation, isotype
class switching, and production of Abs (for review, see Refs. 1 and
2). In patients with rheumatoid arthritis and multiple sclerosis,
CD40L expression is enhanced in T lymphocytes of both periph-
eral blood and the inflammatory site (3–6). This suggests that
CD40-CD40L interaction might play a part in the pathogenesis of
these diseases. Because cellular interaction between stimulated T
cells and monocyte-macrophages is an important process in induc-
ing proinflammatory cytokines in the latter cells (for review, see
Ref. 7), it was tempting to hypothesize that CD40-CD40L inter-
action was involved in such a mechanism.
We previously demonstrated that direct contact with stimulated
T cells was a potent stimulus of human monocytic cells and mono-
cytes, which not only induces the production of IL-1 but also of
other cytokines such as TNF, IL-6, IL-8, and metalloproteinases
(8–10). We also observed that contact-mediated activation by
stimulated T cells is as potent as optimal doses of LPS in inducing
IL-1 and TNF production in monocytes and cells of the mono-
cytic lineage such as THP-1 cells (11). A dysregulated production
of proinflammatory cytokines, such as IL-1 and TNF, plays an
important part in the pathogenesis and persistence of chronic in-
flammatory diseases. Thus, the induction of cytokines by contact
between stimulated T cells and monocytes might be relevant to the
pathogenesis of such diseases.
Although several T cell surface molecules have been involved in
contact-mediated activation of monocyte-macrophages (for re-
view, see Ref. 11), the identity of the molecule that is required to
trigger the engagement of other surface factors leading to mono-
cyte-macrophage activation is still elusive. Controversial results
were obtained concerning the involvement of CD40L. Indeed,
CD40L was proved to be involved in T cell contact-mediated
activation of murine and human macrophages (12, 13). However,
when stimulated for 24 h, T lymphocytes isolated from CD40L-
deficient mice triggered macrophage activation to a similar extent
as T lymphocytes isolated from wild-type mice (12). Conse-
quently, CD40-CD40L might be involved in contact activation of
macrophages by T lymphocytes stimulated for short periods of
time, contrary to T lymphocytes stimulated for long periods, be-
cause the latter cells cease to express CD40L beyond a certain time
(14). A previous study of ours shows that, in cocultures of living
human T cell clones and monocytic cells stimulated with IL-15 or
IL-2, Th1 but not Th2 clones induced significant IL-1 production
in monocytes and THP-1 cells (15). Blockade of the CD40-CD40L
interaction in cocultures of Th1 cells and monocytes resulted in the
inhibition of IL-1 production. However, the levels of CD40L
expression did not differ in Th1 and Th2 cell clones, implying that
one or more additional, unidentified molecules preferentially ex-
pressed by Th1 cells were involved in their capacity to induce
IL-1. Furthermore, IFN-, which diminishes the ability of stim-
ulated T lymphocytes to induce IL-1 and TNF in monocytes,
does not simultaneously modulate CD40L expression on the T cell
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surface (16). In many of our previous studies related to cell-cell
contact, we used the T cell line HUT-78, which efficiently induces
cytokine production in monocytes and THP-1 cells (9, 16, 17), but
does not express CD40L mRNA in resting or activated
conditions (18).
Because the evidence of CD40L triggering the production of
IL-1 and TNF was not obtained on monocytes but monocyte-
derived macrophages, the present study was undertaken to deter-
mine whether membrane-associated CD40L was involved in cy-
tokine induction in different monocytic cells and to compare its
effects in various types of monocytic cells, i.e., THP-1 cells as a
model for monocyte-derived macrophages (19) that we have been
using previously (reviewed in Ref. 7), freshly isolated monocytes,
and IFN--macrophages. The technical approach consisted in the
activation of monocytic cells by CD40L trimer (CD40LT),3 the
most active form of CD40L (20), and membranes or soluble ex-
tracts from membranes isolated from stimulated T cells. The re-
sults show that only IFN--macrophages responded to CD40LT in
terms of TNF production, whereas direct contact with stimulated T
cells induced the production of both TNF and IL-1 in the three
types of target cells in a CD40L-independent way.
Materials and Methods
Materials
Streptomycin, penicillin, L-glutamine, PBS free of Ca2 and Mg2, and
TRIzol reagent (Invitrogen Life Technologies, Paisley, U.K.); purified
PHA (EY Laboratories, San Marco, CA); Ficoll-Paque (Pharmacia Bio-
tech, Uppsala, Sweden); and FCS, RPMI 1640, PMA, PMSF, pepstatin A,
leupeptin, iodoacetamide, neuraminidase, BSA, and polymyxin B sulfate
(Sigma-Aldrich, St. Louis, MO) were purchased from the designated sup-
pliers. Other reagents were of analytical grade or better.
Recombinant proteins and Abs
Recombinant human CD40L trimer/leucine zipper fusion protein
(CD40LT), which has been described (20, 21), was given by Dr. E. Wil-
liamson (Immunex, Seattle, WA). Anti-CD40L mAb (clone 5C8) was pro-
vided by Dr. P. Lipsky (University of Texas, Dallas, TX). F(ab)2 were
prepared as described (22) using immobilized papain (Sigma-Aldrich).
IFN- (5  106 IU/ml) was obtained from Biogen (Cambridge, MA).
Monocytes and THP-1 cells
The human monocytic cell line THP-1, derived from a patient with acute
monocytic leukemia (23), was obtained from the American Type Culture
Collection (Manassas, VA). Monocytes were isolated from buffy coats of
blood from healthy volunteers as previously described (17). Briefly, mono-
cytes purified from PBMC isolated by Ficoll-Paque density gradient were
washed in PBS and suspended (50  106 cells/ml) into RPMI 1640 me-
dium supplemented with 10% heat-inactivated FCS, 50 g/ml streptomy-
cin, 50 U/ml penicillin, 2 mM L-glutamine, and 1 g/ml polymyxin B
sulfate (medium). Cell suspension was incubated for 40 min at 4°C with
gentle agitation. Monocyte aggregates were sedimented on ice for 10 min,
overlaid on FCS, and incubated on ice for 10 more min. Monocytes con-
tained in the FCS lower layer were further depleted of remaining T and NK
cells by rosetting with neuraminidase-treated SRBC and Ficoll-Paque den-
sity centrifugation. Monocyte purity routinely consisted of 90% CD14
cells, 1% CD3 cells, and 1% CD19 cells as assessed by flow cy-
tometry. To avoid activation by endotoxin, polymyxin B was added to all
solutions during the isolation procedure (1 g/ml) and experiments (5 g/
ml). IFN--primed monocytes, referred to as IFN--macrophages, were
prepared by treating purified monocytes with 500 U/ml IFN-. After 7
days, IFN--macrophages were washed twice in RPMI 1640 medium sup-
plemented with 10% heat-inactivated FCS, 50 g/ml streptomycin, 50
U/ml penicillin, and 2 mM L-glutamine, and activated as indicated. IFN-
treatment resulted in the down-modulation of CD14 and the enhancement
of CD163 expression at the surface of IFN--macrophages.
T cell stimulation and membrane isolation
HUT-78, a human T cell line (24), was obtained from the American Type
Culture Collection. Cells were maintained in RPMI 1640 medium supple-
mented with 10% heat-inactivated FCS, 50 g/ml streptomycin, 50 IU/ml
penicillin, and 2 mM L-glutamine in 5% CO2-air-humidified atmosphere at
37°C. T lymphocytes were obtained from buffy coats of healthy donors as
previously described (8), and contained 94–98% CD2, 83–94% CD3, and
2% CD14 as assessed by flow cytometry. HUT-78 cells (2 106 cells/ml)
and T lymphocytes were stimulated for 6 and 48 h, respectively, by PHA (1
g/ml) and PMA (5 ng/ml). To avoid interferences by soluble products from
T cells, membranes of stimulated T cells were used as monocyte activator, the
latter preparations displaying similar activity to fixed, stimulated T cells (9,
17). Plasma membranes of stimulated (msHUT, msT) or unstimulated
(musHUT, musT) HUT-78 cells and T lymphocytes, respectively, were pre-
pared as previously described (25). When required, isolated membranes were
solubilized with 16 mM CHAPS for 1 h at 4°C and then centrifuged for 30 min
at 20,000 rpm in a JA20.1 rotor (Beckman Instruments, Fullerton, CA). The
supernatant was dialyzed in PBS containing 8 mM CHAPS and kept at20°C
before use. CHAPS extract of msHUT and musHUT was referred to as
CEsHUT and CEusHUT, respectively, and that of msT and musT as CEsT and
CEusT. Proteins were measured by the method of Bradford (26) and cytokines
as described below. IL-1 was not detected in membrane preparations. TNF
was present at 713 pg/mg of proteins in msHUT, 551 pg/mg of proteins in
musHUT, 294 pg/mg of proteins in CEsHUT, 68 pg/mg of proteins in CEusHUT,
and 8.3 ng/mg of proteins in msT, 65 pg/mg of proteins in musT, 4.2 ng/mg
of proteins in CEsT, and 4 pg/mg of proteins in CEusT.
Cytokine production
THP-1 cells, monocytes, or IFN--macrophages (50  103 cells/well/200
l) were activated with the indicated stimulus in RPMI 1640 medium
supplemented with 10% heat-inactivated FCS, 50 g/ml streptomycin, 50
U/ml penicillin, 2 mM L-glutamine, and 5 g/ml polymyxin B sulfate
(medium) in 96-well plates (Costar, Corning, NY) and cultured for 48 h or
as otherwise stated. The production of cytokines was measured in culture
supernatants by commercially available enzyme immunoassay: IL-1 (Im-
munotech, Marseille, France) and TNF (Quantikine; R&D Systems,
Minneapolis, MN).
mRNA
IFN--macrophages or monocytes (5  106 cells/well/500 l) were cul-
tured in medium in 24-well plates (Costar) for 1 h with the indicated stim-
ulus. Total RNA was isolated with TRIzol and analyzed by a commercially
available RNase protection assay system kit with hck2 template set (BD
Pharmingen, San Diego, CA) to which an antisense riboprobe for TNF was
added as previously described (17).
Flow cytometry
The expression of CD40L and CD40 on T cells and monocytes was as-
sessed by flow cytometry as previously described (16, 17) with 5C8 anti-
CD40L and anti-CD40 (DakoCytomation, Carpinteria, CA) Abs.
Results
CD40LT induces the production of TNF in IFN--macrophages
but not in freshly isolated monocytes and THP-1 cells
To compare the effect of cellular contact and CD40LT on cytokine
induction in different types of monocytic cells, THP-1 cells, mono-
cytes, and IFN--macrophages were activated by either CD40LT
or membranes isolated from HUT-78 cells stimulated (msHUT) or
not (musHUT) by PHA/PMA, the latter mimicking direct cellular
contact. Because preliminary data and previous studies showed
that the amount of msHUT required to stimulate THP-1 cells and
IFN--macrophages was 10 times higher than that to activate
monocytes, THP-1 cells and IFN--macrophages were activated
with 60 g/ml proteins of msHUT or musHUT, whereas mono-
cytes were activated with 6 g/ml proteins of msHUT or musHUT.
As shown in Fig. 1, musHUT did not induce cytokine production
in monocytic cells. The production of cytokines in either IFN--
macrophages or THP-1 cells was 10 times lower than in mono-
cytes, although 10 times lower doses of msHUT were used to
3 Abbreviations used in this paper: CD40LT, CD40L trimer; msHUT, membranes of
stimulated HUT-78 cells; musHUT, membranes of unstimulated HUT-78 cells; msT,
membranes of stimulated T lymphocytes; musT, membranes of unstimulated T lym-
phocytes; CEsHUT, CHAPS extract of msHUT; CEusHUT, CHAPS extract of
musHUT; CEsT, CHAPS extract of msT; CEusT, CHAPS extract of musT; MMP,
matrix metalloproteinase.
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activate the latter (Fig. 1). CD40LT was inefficient in inducing TNF
and IL-1 in either freshly isolated human monocytes or THP-1 cells
(Fig. 1, A–D). However, in IFN--macrophages, CD40LT triggered
the production of TNF but not of IL-1 (Fig. 1, E and F). In contrast,
msHUT triggered the production of both cytokines in the three types
of monocytic cells. Together, these results suggest that CD40L was
not involved in IL-1 induction in the three types of monocytic cells
used in this study upon activation by msHUT, although it induced
TNF production in IFN--macrophages.
Because macrophages might be activated by particles such as
those formed by isolated plasma membranes, to assess whether the
difference between membranes and CD40LT was due to the par-
ticulate form of msHUT, the latter were solubilized with CHAPS
(see Materials and Methods). As shown in Fig. 1, CEusHUT (7
g/ml proteins) did not trigger TNF and IL-1 production in any
of the target cells. In contrast, CEsHUT triggered TNF and IL-1
production in isolated monocytes, although to different extents
than msHUT, CEsHUT being more potent than msHUT in inducing
IL-1 (Fig. 1). This demonstrates that the particulate form of
membranes was not required for the activation of monocytes, and
that soluble extracts from membranes can be used to induce cyto-
kine production.
Solubilized membranes from both HUT-78 cells and T
lymphocytes, but not CD40LT, induce IL-1 in monocytes and
IFN--macrophages
Because CD40L is not expressed in HUT-78 cells (18) but might
be expressed by freshly isolated T lymphocytes upon stimulation,
solubilized membranes from both types of T cells were compared
in terms of induction of TNF and IL-1 production in THP-1 cells,
monocytes, and IFN--macrophages. CEsT and CEsHUT induced
TNF and IL-1 production in all target cells (Fig. 2). This did not
apply to CD40LT, which, once more, induced TNF production
only in IFN--macrophages. These results imply that CD40L,
which might be present in CEsT, could be involved in the produc-
tion of TNF but not that of IL-1 in IFN--macrophages.
CD40L is not involved in the induction of TNF and IL-1 in
IFN--macrophages upon cell-cell contact
To assess the involvement of CD40L in the induction of cytokines
by CEsHUT and CEsT, IFN--macrophages were activated by
CD40LT, CEsHUT, or CEsT in the presence or absence of anti-CD40L
blocking Abs. The Ab 5C8, which blocks the binding of CD40L to
CD40, activated the production of TNF and IL-1 in IFN--
macrophages (not shown). This was likely to be due to cross-
linking of FcRs by anti-CD40L Abs bound to the trimeric form of
CD40LT; indeed, in the absence of CD40LT, 5C8 did not activate
cytokine production. To avoid nonspecific effects of anti-CD40L
Ab, we generated F(ab)2 from 5C8 Ab. As shown in Fig. 3A,
F(ab)2 from 5C8 inhibited the CD40LT induction of TNF pro-
duction in IFN--macrophages. F(ab)2 of 5C8 did not affect TNF
and IL-1 production triggered by either CEsHUT or CEsT (Fig. 3,
B and C). Because TNF levels induced by CEsT and CD40LT were
similar in this experiment, it is likely that the lack of inhibition was
not due to an excessive activation of IFN--macrophages by CEsT
whose other activating factors could putatively overcome the effect
FIGURE 1. Induction of TNF and IL-1 production in THP-1 cells,
monocytes, and IFN--macrophages. THP-1 cells (A and B), monocytes (C
and D), and IFN--macrophages (E and F) were cultured (50  103 cells/
200 l/well) with the indicated stimulus for 48 h. Freshly isolated human
blood monocytes were activated by 6 g/ml proteins of msHUT or
musHUT, 7 g/ml proteins of CEsHUT or CEusHUT, or 3 g/ml CD40LT.
THP-1 cells and IFN--macrophages (i.e., isolated peripheral blood mono-
cytes primed with 500 U/ml IFN- for 7 days) were activated with 60
g/ml proteins of msHUT or musHUT, 70 g/ml proteins of CEsHUT or
CEusHUT, or 3 g/ml CD40LT. TNF (A, C, and E) and IL-1 (B, D, and F)
were measured in supernatants as described in Materials and Methods.
FIGURE 2. Comparison of TNF and IL-1 induction in THP-1 cells,
monocytes, and IFN--macrophages by CD40LT and solubilized mem-
branes from stimulated HUT-78 cells and isolated T lymphocytes. A and B,
THP-1 cells (50  103 cells/200 l/well) were cultured for 48 h in the
presence or absence of CD40LT (3 g/ml), CEsHUT (70 g proteins/ml), or
CEsT (70 g proteins/ml). C and D, Monocytes (50  103 cells/200 l/
well) were cultured for 48 h in the presence or absence of CD40LT (3
g/ml), CEsHUT (7 g/ml proteins), or CEsT (7 g/ml proteins). E and F,
IFN--macrophages (50  103 cells/200 l/well) were cultured for 48 h in
the presence or absence of CD40LT, CEsHUT, or CEsT (at the same doses
as for THP-1 cells). TNF (A, C, and E) and IL-1 (B, D, and F) were
measured in supernatants as described in Materials and Methods.
FIGURE 3. CD40L is not required for the induction of TNF and IL-1
production upon contact-mediated activation of IFN--macrophages. IFN-
-macrophages (50  103 cells/200 l/well) were cultured for 48 h in the
presence of CD40LT (3 g/ml) (A), CEsHUT (70 g/ml) (B), or CEsT (70
g/ml) (C), or absence of stimulus (D) with or without 10 g/ml anti-
CD40L F(ab)2 of 5C8 Ab (5C8F), or 10 g/ml control IgG1. Culture
supernatants were analyzed for their content in the indicated cytokine.
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of CD40L. In the absence of stimulus, neither F(ab)2 of 5C8 nor
control IgG displayed any effect (Fig. 3D). These results correlated
with CD40L and CD40 expression at the surface of T lympho-
cytes, monocytes, and IFN--macrophages, as determined by flow
cytometry (Figs. 4 and 5).
Although the expression of low or undetectable levels of stim-
ulating factors or receptors might be sufficient to induce/transduce
signals, we assessed the expression of CD40 and CD40L at the
surface of monocytic and lymphocytic cells used in this study.
CD40 was expressed at the surface of 63  11% (mean of three
experiments  SD) of monocytes and to a higher level on 97 
5% of IFN--macrophages but not on THP-1 cells (Fig. 4). The
expression of CD40L was not observed in HUT-78 cells, whether
unstimulated or stimulated (Fig. 5, A and B), or in T lymphocytes
stimulated for 48 h (C). However, CD40L was up-regulated at the
surface of T lymphocytes stimulated for 6 h (Fig. 5C). These re-
sults demonstrate that CD40L expression was very low in both
types of stimulated T cells used in this study, i.e., PHA/PMA-
stimulated HUT-78 cells and T lymphocytes stimulated for 48 h,
consistent with the lack of or minor involvement of this factor in
cell-cell contact activation of monocyte-macrophages. Further-
more, although CD40 was expressed on monocytes, the latter cells
were not activated by CD40LT.
CD40LT induces TNF and IL-1 transcript expression in
IFN--macrophages but not in monocytes
Considering that the production of proinflammatory cytokines is
controlled at several levels (i.e., transcriptional, translational, post-
translational, and/or transcript stability), and because monocytes
expressed significant levels of CD40 (Fig. 5), we ascertained
whether CD40LT would induce cytokine mRNA in monocytes,
despite the lack of cytokine production, and compared it to
IFN--macrophages. CD40LT did not induce TNF or IL-1 tran-
script expression nor the production of proteins in monocytes (Fig.
6, A, B, and E). However, in IFN--macrophages, CD40LT in-
duced the expression of TNF and IL-1 mRNA (Fig. 6, C and D)
without triggering the production of IL-1 protein (F). As ex-
pected, both CEsHUT and CEsT induced the expression of TNF and
IL-1 mRNA in monocytes and in IFN--macrophages (Fig. 6).
This result confirms that CD40LT did not induce cytokine expres-
sion and production in freshly isolated monocytes, thus ruling out
the possibility that CD40L is involved in cell-cell contact activa-
tion of monocytes by stimulated T cells.
Discussion
This study shows that CD40LT induces TNF production in IFN-
-macrophages, but not in freshly isolated monocytes or THP-1
cells. Furthermore, the present data demonstrate that CD40L is not
required for the induction of IL-1 and TNF production in freshly
isolated monocytes, THP-1 cells, or IFN--macrophages upon
contact with stimulated T cells. Additionally, cells of the mono-
cytic lineage display different degrees of sensitivity to activation
by direct cell-cell contact with stimulated T cells, which depend on
the maturation stage of the target cells, freshly isolated monocytes
being more sensitive than THP-1 cells or IFN--macrophages.
This suggests either possibility: 1) THP-1 cell and IFN--macro-
phage receptors for the surface activating factor(s) on stimulated T
cells were down-regulated upon cell differentiation/maturation; 2)
the usage of signaling pathways varied as a function of the mono-
cytic cell type. This might also be the case for monocytes that
expressed CD40 but failed to respond to CD40LT activation.
The premise that macrophages derived from monocytes by
priming with different agents or macrophage cell lines respond
differentially to various stimuli has been observed for a long time
(27, 28). This might be due to a differential usage of signaling
pathways in these cells (29, 30). It is thus not surprising that
THP-1 cells, blood monocytes, and IFN--macrophages display
differential responses to stimuli used in this study. Although all
three types of cells were activated by msHUT, msT, and their
soluble extracts (CEsHUT and CEsT), higher doses were required to
FIGURE 4. Expression of CD40 in monocytes, IFN--macrophages,
and THP-1 cells. Monocytes (A), IFN--macrophages (B), and THP-1 cells
(C) were analyzed for CD40 expression by flow cytometry as described in
Materials and Methods.
FIGURE 5. Expression of CD40L in HUT-78 cells and isolated T lym-
phocytes. Unstimulated (A) and stimulated (B) HUT-78 cells, and unstimu-
lated and 6- or 48-h-stimulated T lymphocytes (C) were analyzed for
CD40L expression by flow cytometry.
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activate THP-1 cells and IFN--macrophages than for activating
blood monocytes. Indeed, a dose of CD40LT that induced TNF in
IFN--macrophages, which displayed low sensitivity to stimulus,
did not induce TNF or other cytokines in highly sensitive mono-
cytes. This further confirms that CD40L was not required for cy-
tokine induction by contact with stimulated T cells.
In accordance with the present results, it was previously dem-
onstrated that, although monocytes express CD40, they needed to
be primed by GM-CSF, IL-3, or IFN- to respond to activation by
CD40L (31). Furthermore, to display optimal activation ability,
CD40L requires cross-linking, i.e., either expressed at the surface
of transfected cells (31) or trimerized (21). In this context, it was
previously demonstrated that, when expressed at the surface of
transfected cells, CD40L activated human monocytes primed with
GM-CSF, IL-3, or IFN-, to produce TNF and IL-6 (31), in ac-
cordance with the present data. Because contact between stimu-
lated T cells and monocytes induces cytokine production in the
latter cells (8) and stimulated T lymphocytes may express CD40L,
the role of CD40-CD40L interaction in this mechanism has been
investigated. When T cells were stimulated for 6 h, they induced
the expression of pro-IL-1 in adherent monocytes via engage-
ment and cross-linking of CD40 (32), but the latter study did not
demonstrate that pro-IL-1 was processed to mature form and se-
creted. These results are in agreement with the present data, be-
cause adherent monocytes do not have the same characteristics as
freshly isolated blood monocytes. Indeed, in this study, we dem-
onstrate that, although the protein production was not detected in
cell culture supernatants, CD40LT induced the expression of
IL-1 transcript in IFN--macrophages. This is also consistent
with a study showing that, in IFN--macrophages, cellular contact
with a transfectant cell line expressing CD40L enhanced the pro-
duction of IL-1 around six times that observed on a control cell
line transfected with an empty vector (28). Thus, CD40L, when
expressed in stimulated T cells might play a part in increased cy-
tokine production in macrophages (including IL-1), although, ac-
cording to the present results, it is not required for the latter mech-
anism. Furthermore, we observed that the levels of expression of
TNF and IL-1 mRNA that CD40LT induced in IFN--macro-
phages were similar to those observed with CEsT (Fig. 4C). How-
ever, IL-1 production occurred only when IFN--macrophages
were activated by CEsT. The premise that CD40LT failed to trigger
IL-1 protein production is reminiscent of the observation that
stimuli such as the complement component C5a, hypoxia, adher-
ence to surfaces, and clotting of blood, all induced the synthesis of
large amounts of IL-1 mRNA in monocytic cells without signif-
icant translation into the IL-1 protein (for review, see Ref. 33).
This further emphasizes that distinctive mechanisms rule the trans-
lation and production of TNF and IL-1.
It has been demonstrated that, although monocytes do not ex-
press CD40 mRNA in the absence of priming, they express low
levels of CD40 at their surface (31). In this study, CD40 was
detected at the surface of 63% of freshly isolated monocytes, and
its expression was enhanced when cells were primed for 7 days
with IFN- (IFN--macrophages). The fact that cytokine produc-
tion was not induced by CD40LT in monocytes might be due to the
level of CD40 expression being too low for signal transduction, the
threshold being surpassed after priming with IFN-. Another pos-
sibility is that transduction pathway usage and cytokine production
depend on cell differentiation/maturation stage (34, 35) or the route
of monocyte differentiation (28). This is reminiscent of previous
results showing that human alveolar macrophages and lung tissue
macrophages display distinct responses to activation by msT (36).
Indeed, msT strongly induced the production of matrix metallo-
proteinases-1 (MMP-1), MMP-9, and tissue inhibitor of MMP-1
exclusively in lung tissue macrophages but not in alveolar macro-
phages, indicating that the activating capacity is not only related to
the difference in phenotype of mononuclear phagocytes, but that it
might also depend on cell localization.
In conclusion, this study rules out the possibility that CD40L is
a major stimulus involved in the induction of cytokines in mono-
cyte-macrophages upon cellular contact with stimulated T cells.
This does not answer the question of the identity of the surface
factors involved in this process. Our studies and others have shown
that LFA-1 (CD11a/CD18) and CD69 play a role in the activation
of human monocytic cells by stimulated T cells (8, 37). The latter
data were confirmed in a study showing that IL-15 induces syno-
vial T cells from rheumatoid arthritis patients to activate the pro-
duction of TNF by macrophages. This effect was inhibited by Abs
to CD69, LFA-1, and ICAM-1 (38). Other studies have shown that
cytokine production is induced in monocytes by soluble CD23 (39,
40). In monocytes, the counterligands for CD23 are CD11b/CD18
and CD11c/CD18 rather than CD21 (41). We demonstrated that
cross-linking of 2-integrin induces IL-1 in freshly isolated
monocytes (42); however, blocking Abs to 2-integrins inhibited
but did not abolish IL-1 induction (8, 9). Although some of the
FIGURE 6. Induction of TNF and IL-1 transcripts in monocytes and
IFN--macrophages. A and B, Monocytes (5 106 cells/500 l/well) were
cultured for 3 h in the presence or absence of CD40LT (3 g/ml), CEsHUT
(7 g/ml proteins), or CEsT (7 g/ml proteins). C and D, IFN--macro-
phages (5  106 cells/500 l/well) were cultured in the presence or ab-
sence of CD40LT (3 g/ml), CEsHUT (70 g/ml proteins), or CEsT (70
g/ml proteins). Total RNA was isolated by TRIzol and analyzed by
RNase protection assay. Autoradiography of the gel (A and C); densitom-
etry analysis of A and C, normalized with GAPDH (B and D). E and F,
Cytokine production in the same experiments after activation of either
monocytes or IFN--macrophages by the indicated stimulus for 48 h.
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above molecules as well as CD40L might be involved to some
extent in contact-mediated monocyte activation by T cells, the fac-
tor(s) to first engage monocytes in the activation processes in turn
leading to cytokine production, remain to be identified.
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In the previous study, we ruled out the controversial implication of CD40L-CD40 interaction 
in T cell-contact-mediated activation of monocyte/macrophages, a mechanism that appears to play an 
important part in the initiation and persistence of chronic/sterile inflammatory diseases such as RA 
and MS. Because other collaborators of our team currently carried out the identification of T cell 
surface molecules implicated in this mechanism, we then investigated the effects of IFNb, a 
molecule with beneficial outcome in MS and likely in RA, on T cell-contact activated monocyte 
function, in regard to cytokine production. In parallel, in order to compare two inflammatory 
conditions, we also assessed the effects of IFNb on monocyte inflammatory functions in activating 
conditions relevant to acute/infectious inflammation. This is described in the following study. 
2. Opposite effects of IFNb on cytokine homeostasis in LPS- and T cell 
contact-activated human monocytes 
Molnarfi, N., Gruaz, L., Dayer, J.M., and Burger, D. 2004. J.Neuroimmunol. 146:76-83.  
www.elsevier.com/locate/jneuroim
Journal of Neuroimmunology 146 (2004) 76–83Opposite effects of IFNh on cytokine homeostasis in LPS- and T cell
contact-activated human monocytes
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Multiple sclerosis (MS) is an immune-mediated disease improved by interferon-h (IFNh) therapy. IFNh may owe its anti-inflammatory
property to its ability to induce interleukin-1 receptor antagonist (IL-1Ra) without triggering IL-1h synthesis in human monocytes.
Furthermore, we recently demonstrated that IFNh inhibits the production of IL-1h and tumor necrosis factor-a (TNF) in human monocytes
activated by cellular contact with stimulated T cells, a mechanism which we suspected of playing an important part in the pathogenesis of
chronic inflammatory diseases including MS. Here we compare modulatory effects of IFNh on the production of proinflammatory cytokines
(IL-1h, IL-1a, TNF, and IL-6) and IL-1Ra in human monocytes stimulated by lipopolysaccharides (LPS) and isolated plasma membranes of
stimulated T cells (msHUT), which are likely to reflect monocyte activation in acute and chronic inflammation, respectively. In monocytes
activated by either LPS or msHUT, IFNh did not modulate the secretion of IL-1a and IL-6, but it enhanced the production of IL-1Ra in a
dose-dependent manner. However, in monocytes activated by msHUT, the expression of cell-associated and intracellular IL-1a was inhibited
by IFNh, correlating with the inhibition of IL-1a transcript. IFNh inhibited the expression (mRNA) and production (protein) of IL-1h and
TNF, while enhancing those of IL-1Ra in monocytes activated by msHUT. In contrast, in monocytes activated by LPS, IFNh enhanced the
expression and production of IL-1h, TNF, and IL-1Ra, suggesting that it did not display anti-inflammatory properties in these conditions.
This study demonstrates that IFNh displays opposite effects depending on the type of activation of human monocytes, suggesting that it may
affect different pathogenic mechanisms in opposite ways.
D 2003 Elsevier B.V. All rights reserved.Keywords: Interferon-h; Cytokines; Inflammation; Multiple sclerosis
1. Introduction action of IFNh in MS are still elusive, it has been shown toMultiple sclerosis (MS) is a common inflammatory dis-
ease of the central nervous system (CNS), characterized by
demyelination and accumulation of macrophages and lym-
phocytes in the perivascular regions (Raine, 1984; Keegan
and Noseworthy, 2002). Interferon-h (IFNh) reduces relapse
rate, magnetic resonance imaging activity, and progression
of disability, and is thus, to date, one of the most successful
medications of relapsing–remitting MS. Furthermore, IFNh
also reduces clinical and radiographic evidence of disease
activity in secondary progressive MS, although no benefit
has been demonstrated in primary progressive MS (Keegan
and Noseworthy, 2002). While the precise mechanisms of0165-5728/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.jneuroim.2003.10.035
* Corresponding author. Tel.: +41-22-372-93-76; fax: +41-22-372-93-
69.
E-mail address: danielle.burger@hcuge.ch (D. Burger).act on various types of cells involved in the disease including
T cells, monocyte–macrophages, microglial cells, and en-
dothelial cells (Kunzi and Rowe, 2000). Since MS is
currently considered an immune-mediated disorder and since
cytokines are key regulators of the immune system, the
effects of IFNh on cytokine homeostasis have been studied
(Yong et al., 1998). Indeed, IFNh decreases interferon-g
(IFNg), tumor necrosis factor-a (TNF), and IL-13 produc-
tion by activated T cells while enhancing that of IL-2 and IL-
10 (Noronha et al., 1993; Rep et al., 1996; Jungo et al.,
2001). In human monocyte–macrophages, IFNh directly
induces the production of interleukin-1 receptor antagonist
(IL-1Ra), the specific inhibitor of the proinflammatory
cytokine, IL-1 (Jungo et al., 2001; Sciacca et al., 2000;
Burger and Dayer, 2000). The production of TNF, IL-6, and
IL-1h was diminished in mitogen-activated peripheral blood
mononuclear cells (PBMCs) from volunteers receiving IFNh
N. Molnarfi et al. / Journal of Neuroimmunology 146 (2004) 76–83 77(Rothuizen et al., 1999). Intramuscular injections of IFNh in
MS patients result in a transient enhancement of circulating
IL-1Ra (Perini et al., 2000).
T cells are considered to be crucial to the mediation of
the immunopathological cascade that results in damage to
the myelin sheath. Indeed, current data support the assump-
tion that myelin-reactive T cells are actively involved in the
pathogenesis of MS (Martin et al., 1992; Iglesias et al.,
2001; Liu et al., 2001; Hellings et al., 2002). Our recent
results demonstrate that direct cell–cell contact with stim-
ulated, but not resting, T lymphocytes is a potent mecha-
nism inducing the production of the proinflammatory
cytokines IL-1 and TNF and tissue-destructive metallopro-
teases in monocytes and monocytic cells (Burger and
Dayer, 2002). To date, this is the only mechanism in vitro
to induce the production of high levels of cytokines in
monocytes in the absence of exogenous pathogens and
bacterial products. IL-1 and TNF as well as IL-6 are
thought to play a predominant role in MS since they are
involved at multiple levels of neuroimmune regulation
(Benveniste, 1997; Tyor et al., 1993; Maeda and Sobel,
1996). In the CNS, microglial cells are likely to play the
role of monocyte–macrophages in that they display a
similar response upon activation, thus being the primary
source of proinflammatory cytokines in CNS inflammation
(Pahan et al., 1999; Dasgupta et al., 2003; Gonzalez-
Scarano and Baltuch, 1999). IFNh affects the production
of cytokines induced by cell–cell contact by decreasing the
production of IL-1h and TNF in human monocytes and
PBMCs (Jungo et al., 2001; De´age et al., 1998). Contact
with stimulated T cells is also an important mechanism of
cytokine induction in human and mouse microglial cells,
confirming their similarities with monocyte–macrophages
(Chabot et al., 1997, 2001; Chabot and Yong, 2000;
Dasgupta et al., 2003). By using lipopolysaccharides
(LPS) and contact with stimulated T cells as models of
monocyte activation in acute and chronic inflammatory
diseases, respectively, here we show that the modulation
by IFNh of cytokine production in isolated human mono-
cytes depends on the stimulus.2. Materials and methods
2.1. Materials
Fetal calf serum (FCS), streptomycin, penicillin, L-gluta-
mine, RPMI 1640, phosphate-buffered saline (PBS) free of
Ca2+ and Mg2+, and TRIzolk reagent (Gibco, Paisley,
Scotland, UK); purified phytohemagglutinin (PHA) (EY
Laboratories, San Mateo, CA); Ficoll-Paque (Pharmacia
Biotech, Uppsala, Sweden); phorbol myristate acetate
(PMA), phenylmethylsulfonyl fluoride (PMSF), pepstatin
A, leupeptin, iodoacetamide, polymyxin B sulfate, neur-
aminidase, bovine serum albumin (Sigma Chemicals Co.,
St. Louis, MO), and LPS from Escherichia coli 055:B5(Difco Laboratories, Sparks, MI) were purchased from the
designated suppliers. Human rIFNh-1a (IFNh) with a spe-
cific activity of 3.97108 IU/ml was a kind gift from
ARES-Serono (IPL, Rehovot, Israel). Other reagents were
of analytical grade or better.
2.2. Monocytes
Monocytes were isolated from buffy coats of the blood of
healthy donors as previously described (Hyka et al., 2001).
In order to avoid activation by endotoxin, polymyxin B (5
Ag/ml) was added to all solutions during the isolation
procedure and in experiments where monocytes were acti-
vated by stimuli other than LPS.
2.3. T cells and preparation of T cell plasma membranes
HUT-78, a human T cell line (Gazdar et al., 1980), was
obtained from the ATCC (Rockville, MD). Cells were
maintained in RPMI 1640 medium supplemented with
10% heat-inactivated FCS, 50 Ag/ml streptomycin, 50 IU/
ml penicillin, and 2 mM L-glutamine (complete RPMI
medium) in 5% CO2–air humidified atmosphere at 37 jC.
HUT-78 cells (1106 cells/ml) were stimulated for 6 h by
PHA (1 Ag/ml) and PMA (5 ng/ml). Plasma membranes of
stimulated HUT-78 cells (msHUT) were prepared as previ-
ously described (Burger et al., 1998) and used to activate
monocytes since their activity is similar to that of living T
cells (i.e., in cocultures) or fixed T cells as previously
described (Jungo et al., 2001; Hyka et al., 2001).
2.4. Cytokine production
Monocytes (50103 cells/well/200 Al) were preincubated
for 30 min at the indicated concentration of IFNh and then
activated by msHUT or LPS for 24 h in RPMI 1640 medium
supplemented with 10% heat-inactivated FCS, 50 Ag/ml
streptomycin, 50 U/ml penicillin, 2 mM L-glutamine (medi-
um) containing (msHUT) or not (LPS) 5 Ag/ml polymyxin B
sulfate. All conditions were carried out in triplicate. The
production of cytokines was measured in culture super-
natants by commercially available enzyme immunoassay:
IL-1h and IL-1a (Immunotech, Marseille, France), TNF, IL-
6, and IL-1Ra (Quantikine; R&D, Minneapolis, MN). Since
IL-1a is primarily expressed intracellularly or associated
with membranes (Dinarello, 2000), cell-associated IL-1a
(icIL-1a) was measured in cell lysates. Briefly, after removal
of supernatants, cells were solubilized in PBS containing 1%
Nonidet P40 (200 Al/well; 96-well plates). Cell lysates were
analyzed for their content in icIL-1a by commercially
available enzyme immunoassay (Immunotech).
2.5. Cytokine mRNA
Monocytes (5106 cells/well/500 Al) were cultured in a
medium containing (msHUT) or not (LPS) 5 Ag/ml poly-
Fig. 1. Production of cytokines by human monocytes stimulated by LPS (A)
and msHUT (B). Isolated human blood monocytes (5104 cells/200 Al/
well) were stimulated for 24 h with increasing doses of LPS or msHUT.
Culture supernatants were analyzed for their content in the indicated
cytokine. Results represent mean values of triplicates FS.D. from one of
two separate experiments with similar results.
Table 1
Cytokine production in activated human monocytes
Cytokine Cytokine production (ng/ml)a
N. Molnarfi et al. / Journal of Neuroimmunology 146 (2004) 76–8378myxin B sulfate in 24-well plates for 30 min with IFNh (104
U/ml or otherwise indicated) and then for 1 h with the
indicated stimulus. Total RNA was isolated with TRIzolR
and analyzed by a commercially available ‘‘RNase protec-
tion assay system’’ kit with hck2 template set (PharMingen,
San Diego, CA) to which a TNF template was added as
previously described (Hyka et al., 2001).
2.6. Statistics
Significance of differences between groups was evaluat-
ed using Student’s paired t test; p<0.05 was considered to be
significant.
Medium LPS msHUT
IL-1a 0.01F0.01 0.36F0.08 0.05F0.01
IL-6 <0.01F0.00 21.7F4.7 21.3F1.6
IL-1h <0.01F0.00 4.1F0.5 0.33F0.09
TNF 0.01F0.01 2.5F0.3 1.4F0.3
IL-1Ra 0.63F0.29 1.7F0.3 9.0F3.4
a Isolated human blood monocytes (5104 cells/well/200 Al; 96-well
plate) were cultured for 24 h in the presence or absence of 100 ng/ml LPS
or 3 Ag/ml proteins of msHUT as described in Materials and Methods.
Harvested supernatants were tested for cytokine content as described in
Materials and Methods. Values represent the meanFS.D. of three different
experiments (i.e., different monocyte preparations from different donors),
all carried out in triplicate.3. Results
3.1. LPS and membranes of stimulated HUT-78 cells
differentially induce cytokine production in human
monocytes
In order to compare the effect of IFNh on the production
of cytokines induced in human isolated monocytes by LPS
or msHUT, we first assessed the induction of cytokineproduction by using different doses of the two above
stimuli. LPS induced cytokines in a dose-dependent man-
ner. The production of IL-1h, IL-1a, and TNF reached a
plateau between 10 and 100 ng/ml LPS, while 1 ng/ml LPS
sufficed to trigger optimal levels of IL-1Ra and IL-6 (Fig.
1A), demonstrating the high sensitivity of monocytes to
LPS. Although msHUT induced the production of all
cytokines measured, it proved impossible to reach saturat-
ing doses of msHUT because they displayed cytotoxicity
towards monocytes at doses higher than 3 Ag/ml proteins
(Fig. 1B). Significant amounts of IL-1h, IL-1a, IL-6, and
TNF were observed at 0.6 Ag/ml proteins of msHUT,
whereas IL-1Ra production was already as high as that
induced by optimal doses of LPS at 0.3 Ag/ml proteins of
msHUT (Fig. 1B). This suggests that msHUT was a potent
inducer of IL-1Ra. Since 100 ng/ml LPS was an optimal
dose for all cytokines measured in this study and since 3 Ag/
ml proteins of msHUT was the highest possible dose
without inducing cytotoxicity, these concentrations were
used to assess the effect of IFNh. Although some variations
were observed, the cytokine levels obtained with such
stimulus concentrations were consistent from one experi-
ment to another (Table 1).
3.2. IFNb differentially modulates cytokine production
induced by LPS and msHUT in human monocytes
Isolated monocytes were treated for 30 min with 104 U/
ml IFNh or medium before the addition of 100 ng/ml LPS
or 3 Ag/ml proteins of msHUT for 24 h. Although the
production of IL-1Ra was increased by IFNh regardless of
the stimulus, the increase observed with an optimal dose of
LPS (2.5-fold) was twofold higher than that observed with a
suboptimal dose of msHUT (1.3-fold). The production of
IL-1h and TNF was slightly (1.4- to 1.5-fold) but consis-
tently enhanced by IFNh when monocytes were activated
by LPS (Fig. 2A). In contrast, IFNh inhibited the production
of proinflammatory cytokines, IL-1h and TNF, by 60% and
35%, respectively, in msHUT-activated monocytes (Fig.
Fig. 3. Low doses of IFNh affect cytokine production in human monocytes.
After preincubation for 30 min with the indicated concentration of IFNh,
N. Molnarfi et al. / Journal of Neuroimmunology 146 (2004) 76–83 792B). The production of IL-6 and IL-1a was not modulated
by IFNh when monocytes were activated by either LPS or
msHUT (Fig. 2). However, since IL-1a occurs mainly in
intracellular and cell-associated forms, we evaluated the
effect of IFNh on the latter production. After supernatant
removal, cells were solubilized in PBS containing 1%
Nonidet P40, and cell lysates were analyzed for their content
in IL-1a. The expression of cell-associated IL-1a was
strongly induced by both LPS and msHUT, reaching
4.7F0.1 and 4.9F0.2 ng/ml, respectively, whereas nonacti-
vated monocytes produced less than 0.03 ng/ml IL-1a. The
production of cell-associated IL-1a induced by LPS was not
significantly inhibited by 104 U/ml IFNh, displaying
14F8% inhibition, whereas cell-associated IL-1a induced
by msHUT was inhibited by 39F5%.
The modulation of IL-1Ra, IL-1h, and TNF production
depended on the dose of IFNh. The enhancement of IL-1Ra
was observed with both LPS and msHUT at 100 U/ml IFNh
and increased at higher IFNh concentrations (Fig. 3). The
enhancement of IL-1h and TNF triggered by IFNh in LPS-
activated monocytes was observable at 100 U/ml IFNh (Fig.
3A). Simultaneously, the inhibition of proinflammatoryisolated monocytes were stimulated or not by LPS (A) or msHUT (B), as
described in the legend of Fig. 2. Culture supernatants were analyzed for
their content in the indicated cytokine. Results represent the meanFS.D. of
triplicates in a representative experiment.
Fig. 2. IFNh differentially modulates cytokine production in monocytes as
a function of the stimulus. Isolated human blood monocytes (5104 cells/
200 Al/well; 96-well plate) were stimulated for 24 h with 100 ng/ml LPS
(A) or 3 Ag/ml proteins of msHUT (B) in the presence or absence of 104 U/
ml IFNh that was added 30 min before the stimulus. Culture supernatants
were analyzed for their content in the indicated cytokine. Results are
expressed in percentage of the cytokine production induced by the stimulus
in the absence of IFNh as shown in Table 1, and represent the meanFS.D.
of three experiments (i.e., three different donors); *Student’s t test with
p<0.05; **Student’s t test with p<0.01.cytokine production induced by msHUT was already ob-
served at 10 and 100 U/ml IFNh for IL-1h and TNF,
respectively, suggesting a differential sensitivity to IFNh
in the production of these cytokines.
3.3. Modulation of cytokine transcript levels by IFNb
depends on the stimulus
To assess whether IFNh would affect cytokine produc-
tion by modulating the expression of their mRNA, mono-
cytes were treated for 30 min with 104 U/ml IFNh before
the addition or not of 100 ng/ml LPS or 3 Ag/ml proteins of
msHUT for 1 h. Total RNA was analyzed by RNase
protection assay with a modified commercial kit (see
Materials and Methods) allowing the detection of TNF,
IL-12 (p40 and p35), IL-10, IL-1a, IL-1h, IL-1Ra, IL-6,
and IFNg transcripts. IL-12, IL-10, and IFNg transcripts
were not detected in the present experimental conditions.
IL-1Ra mRNA was strongly induced by IFNh regardless of
the presence of polymyxin B sulfate (Fig. 4). In accordance
with the results obtained at the protein level, IL-6 and IL-1a
transcript levels induced by LPS were not modulated by
IFNh (Fig. 4A and B). Although IL-6 mRNA levels induced
by msHUT were low, no significant modulation was ob-
served in the presence of IFNh, contrasting with IL-1a
mRNA that was drastically inhibited (Fig. 4). This latter
result did not correlate with the level of IL-1a in cell
supernatants that remained unchanged in the presence of
IFNh, but instead it reflected the effect of IFNh on the
Fig. 5. Pretreatment of monocytes for 24 h amplified the opposite effects of
IFNh on cytokine production triggered by LPS (A) and msHUT (B).
Monocytes (5104 cells/200 Al/well; 96-well plate) were treated with IFNh
(104 U/ml) for 24 h before the addition of LPS (1 Ag/ml) or msHUT (6 Ag/
ml). After another 24 h of incubation, culture supernatants were analyzed
for their contents in the indicated cytokines. Results represent the
meanFS.D. of triplicates in a representative experiment.
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above and Fig. 2). The level of IL-1Ra transcript induced by
msHUT was lower than that observed in the presence of
LPS or IFNh alone, contrasting with the huge amount of IL-
1Ra proteins produced in the presence of msHUT. The TNF
transcript expression induced by LPS was enhanced in the
presence of IFNh, while it was only slightly inhibited when
msHUT was the stimulus (Fig. 4). The inhibition of IL-1h
mRNA was marked when induced by msHUT in the
presence of IFNh, whereas only a slight increase was
observed with LPS (Fig. 4). This demonstrates that the
effect of IFNh on cytokine production at the protein level
was reflected at the mRNA level and further confirms that
IFNh did not display the same immunomodulatory effect
when monocytes were activated by LPS or msHUT.
3.4. The effects of IFNb were amplified by long duration of
pretreatment
In order to determine whether long periods of pretreat-
ment with IFNh (i.e., relevant to the long-term treatment of
MS patients), LPS- and msHUT-induction of cytokines was
assessed in monocytes pretreated with IFNh for 24 h. Since
a preliminary experiment revealed that monocytes culturedFig. 4. IFNh modulates the induction of cytokine transcripts in human
monocytes. Isolated monocytes (5106 cells/500 Al/well; 24-well plate)
were cultured for 30 min with 104 U/ml IFNh before the addition of LPS or
msHUT for 1 h. Cells were harvested and their isolated total RNA analyzed
by RNase protection assay as described in Materials and Methods.
Polymyxin B sulfate (poly B), 5 Ag/ml, was added to the medium of cells
that were stimulated by msHUT and their respective controls. (A)
Autoradiography. (B) Densitometry analysis of autoradiography normalized
to the L32 housekeeping probe.for 24 h were less responsive to either LPS or msHUT,
experiments were carried out with 1 Ag/ml LPS and 6 Ag/ml
msHUT, the latter dose proving noncytotoxic to 24-h-
cultured monocytes. In three different experiments IL-1h
and TNF levels induced by LPS were low but detectable:
<10 and 47F8 pg/ml, respectively (Fig. 5A), confirming
that monocytes cultured for 24 h were less responsive to
LPS than freshly isolated cells. However, in 24-h-pretreated
cells, IFNh drastically enhanced the production of IL-1h
and TNF production, whereas the enhancement of IL-1Ra
production was comparable to that observed with freshly
isolated monocytes pretreated for 30 min with IFNh (Fig.
2A). In 24-h-cultured monocytes, msHUT induced signifi-
cant amounts of cytokines (Fig. 5B). The msHUT-triggered
production of IL-1h was abolished in monocytes treated for
24 h with IFNh, whereas that of TNF was inhibited by
around 80%. Together, these results demonstrate that IFNh
treatment of monocytes for long periods results in the
amplification of IFNh effects observed in freshly isolated
cells. Thus, long periods of monocyte treatment by IFNh
ensured higher sensitivity of cells to LPS, but strongly
inhibited proinflammatory cytokine production induced by
cell–cell contact.4. Discussion
This study demonstrates that the modulatory effects of
IFNh on the production of cytokines can be opposite,
depending on the stimulus. When monocytes were activated
by LPS, a typical monocyte stimulus in innate immunity,
N. Molnarfi et al. / Journal of Neuroimmunology 146 (2004) 76–83 81IFNh enhanced the production of both IL-1h and TNF
along with that of IL-1Ra, the production of IL-6 and
secreted IL-1a being unchanged. When monocytes were
activated by msHUT (i.e., conditions mimicking cellular
contact with stimulated T cells), IFNh enhanced the pro-
duction of IL-1Ra, but decreased the production of IL-1h
and TNF. These effects were more pronounced when
monocytes were pretreated for a long period (24 h) with
IFNh (i.e., in conditions relevant to regular treatment of MS
patients). This demonstrates that the anti-inflammatory
functions exerted by IFNh, at least in terms of cytokine
production, are specifically directed to monocyte activation
in conditions mimicking those possibly involved in chronic
inflammation. When monocytes respond to a stimulus likely
to occur during infection, the inflammatory response tends
to be enhanced by IFNh.
Although the comparison of efficiency displays by stim-
uli at saturating and nonsaturating doses might not be
significant, some differences observed in the proportions
of cytokine production induced by LPS and msHUT in
human monocytes in the present study might be relevant.
Indeed, while LPS and msHUT induced the expression of
similar amounts of cell-associated IL-1a, only a very small
amount of IL-1a was released into the medium upon
monocyte activation by msHUT, in contrast with activation
by LPS. However, although IFNh did not modulate the
expression of either secreted or cell-associated IL-1a nor IL-
1a mRNA in monocytes activated by LPS, IL-1a transcript
expression induced by msHUT was inhibited by IFNh,
consistent with the inhibition of cell-associated IL-1a ex-
pression. The fact that the amount of IL-1h induced by
msHUT was more than 10 times lower than that induced by
LPS might be due to the usage of a suboptimal dose of
msHUT. In contrast, the same dose of msHUT was fivefold
more potent in inducing IL-1Ra than an optimal dose of
LPS. The strong induction of IL-1Ra upon contact-mediated
activation of monocytes corroborates the premise that in
MS, IL-1Ra level is elevated at the systemic level during
relapses and in IFNh-treated MS patients (Nicoletti et al.,
1996; Heesen et al., 2000). Elevated blood levels of IL-1Ra
were also observed in rheumatoid arthritis, another chronic
inflammatory disease in which contact-mediated activation
of monocyte–macrophages might be involved (Burger and
Dayer, 2002).
IFNh enhanced, rather than diminished, the production
of IL-1h and TNF induced by LPS in human monocytes.
This suggests that IFNh might tend to enhance the innate
inflammatory response, rather than diminish it—a phenom-
enon that was particularly marked in monocytes pretreated
for 24 h with IFNh. In contrast with the present results,
IFNh inhibits the expression of IL-1h at both protein and
mRNA levels in LPS-activated microglial cells (Liu et al.,
1998). However, in the same study, IFNh enhanced LPS-
induced TNF mRNA. Thus, there are differences in the
response of peripheral blood monocytes and microglial cells
to IFNh modulation of IL-1h production at any rate whencells were stimulated by LPS. It is not surprising that IFNh
should fail to display inhibitory activity towards products
induced by LPS because part of the signal trigger by the
latter is due to an autocrine loop of IFNh, which is encoded
by an immediate early LPS-inducible gene (Toshchakov et
al., 2002). Thus, the presence of IFNh in the culture
medium at the moment of LPS-activation would precede
the IFNh autocrine production and in turn anticipate the
triggering of the autocrine loop, thus enhancing the produc-
tion of cytokines controlled by this loop. Besides, the
premise that IFNh does not inhibit the production of IL-
1h, TNF, and IL-6 in LPS-activated monocytes might
explain why MS patients or healthy volunteers receiving
IFNh were not more prone to infection than normal indi-
viduals (Keegan and Noseworthy, 2002).
In contrast with other cytokines, the production of IL-6
and secreted IL-1a was not modulated by IFNh. However,
cell-associated IL-1a, whose expression was strongly in-
duced by both LPS and msHUT, was inhibited by IFNh in
monocytes activated by msHUT but not by LPS. Conse-
quently, only IL-6 production that was not changed and IL-
1Ra production that was enhanced by IFNh displayed a
similar behavior in both activation systems. Interestingly,
both cytokines were optimally induced at very low LPS
concentrations (i.e., 1 ng/ml). This could imply that the
signaling pathways involved in the induction of IL-1Ra and
IL-6 might be different from those involved in TNF and IL-
1 productions (i.e., being differently affected by IFNh). In
accordance with this, it was recently demonstrated that IL-6
expression was not dependent on the induction of IFNh by
LPS (Schilling et al., 2002). Like others, we demonstrated
that IFNh induced IL-1Ra production in monocytes and
monocytic cells in the absence of another stimulus (Jungo et
al., 2001; Sciacca et al., 2000). Thus, the enhancement of
IL-1Ra production in LPS- and msHUT-activated mono-
cytes might be due, at least in part, to the direct effect of
IFNh. This is strongly suggested in the case of LPS since
the enhancement of LPS-induced IL-1Ra by increasing
doses of IFNh equaled the production of IL-1Ra triggered
by IFNh itself (Fig. 3).
The IFNh-modulation of cytokine production in mono-
cytes activated by contact with msHUT was comparable to
data obtained in microglial cells, contrasting with the
difference between the present results obtained from LPS-
activated monocytes and those obtained by others with LPS-
activated microglial cells (Liu et al., 1998). Indeed, cytokine
production is induced in human and mouse microglial cells
by contact with stimulated T cells, a system in which IFNh
inhibits TNF and IL-1h production (Chabot and Yong,
2000). This is in accordance with the present results, which
show that IFNh inhibits IL-1h and TNF expression induced
by msHUT in monocytes at both protein and mRNA levels.
Since the latter mechanism (i.e., direct contact between
stimulated T cells and cells of the monocyte–macrophage
lineage) is likely to occur at the inflammatory site in MS
(Chabot and Yong, 2000; Dasgupta et al., 2003), the anti-
N. Molnarfi et al. / Journal of Neuroimmunology 146 (2004) 76–8382inflammatory effect of IFNh may be more specifically
directed to chronic inflammation.
In conclusion, this study shows that although IFNh
diminishes the production of IL-1h and TNF in cell con-
tact-activated monocytes, it enhances their production in
LPS-activated monocytes. Although the molecular mecha-
nisms involved in these processes remain to be determined,
this differential effect of IFNh depending on the stimulus
highlights the importance of exercising caution when results
obtained in vitro are extrapolated to in vivo experimental
models or diseases. Furthermore, this observation might
account for the premise that infective episodes are not a
common side effect of IFNh-treatment in MS patients.Acknowledgements
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In the previous study, we demonstrate that IFNb directed monocyte functions towards an 
anti-inflammatory status in activation conditions relevant to chronic, but not acute inflammation. 
These results both strengthen the hypothetical in vivo relevance of T cell contact-mediated activation 
of monocytes/macrophages and provide a rationale for the observation that IFNb-treated MS patients 
are not more prone to infection than normal individuals. Because an important anti-inflammatory 
feature of IFNb is the triggering of sIL-1Ra production by monocytes, in the following study, we 
address the question of the signaling pathways implicated in the induction of the latter by IFNb. 
3. The production of IL-1 receptor antagonist in IFNβ-stimulated human 
monocytes depends on the activation of phosphatidylinositol 3-kinase but 
not of STAT1 
Molnarfi, N., Hyka-Nouspikel, N., Gruaz, L., Dayer, J.M., and Burger, D. 2005. J.Immunol. 
174:2974-2980 
The Production of IL-1 Receptor Antagonist in
IFN--Stimulated Human Monocytes Depends on the
Activation of Phosphatidylinositol 3-Kinase but Not of STAT11
Nicolas Molnarfi, Nevila Hyka-Nouspikel, Lyssia Gruaz, Jean-Michel Dayer, and
Danielle Burger2
IFN- induces the production of secreted IL-1R antagonist (sIL-1Ra) without triggering synthesis of the agonist IL-1 in human
monocytes. This might account for its anti-inflammatory properties. Canonically, IFN- signals through activation of JAK/STAT
pathway, although PI3K and MAPK have also been involved. In this study, the role of PI3K, MEK1, and STAT1 in IFN--induced
sIL-1Ra production is investigated in freshly isolated human blood monocytes. PI3K, but not MEK1 activation is essential for
sIL-1Ra production in monocytes treated with IFN-, as demonstrated by using the respective inhibitors of PI3K and MEK1,
Ly294002 and PD98059. The use of cycloheximide and actinomycin D shows that sIL-1Ra was an immediate early gene induced
by IFN- and that PI3K was controlling sIL-1Ra gene transcription. Although both inhibitors of PI3K and MEK1 diminished the
Ser727 phosphorylation of STAT1 induced by IFN-, only Ly294002 inhibited sIL-1Ra production. Furthermore, the inhibition of
STAT1-Ser727 phosphorylation by Ly294002 did not affect STAT1 translocation, suggesting that STAT1 was not involved in
sIL-1Ra gene induction. This was confirmed in monocytes that were transfected with small interfering RNA specifically targeting
STAT1. Indeed, monocytes in which effective STAT1 gene knockdown was achieved were fully responsive to IFN- in terms of
sIL-1Ra production. Taken together, the present data demonstrate that the induction of sIL-1Ra transcription and production by
IFN- in human monocytes involved PI3K, but not STAT1 activation. The Journal of Immunology, 2005, 174: 2974–2980.
I nterleukin-1 receptor antagonist (IL-1Ra)3 is a member of theIL-1 family. Three protein forms of IL-1Ra resulting fromthe same gene have been described, two of them being in-
tracellular and the third secreted (sIL-1Ra) (1). The function(s) of
the intracellular forms of IL-1Ra is still elusive, but sIL-1Ra binds
competitively to IL-1RI without inducing signal transduction, and
thus inhibits IL-1 and IL-1 actions. Some stimuli induce sIL-
1Ra in the absence of IL-1 production in human monocytes, in-
cluding IL-3, IL-4, GM-CSF, leptin, and IFN- (2–5). Other stim-
uli, such as LPS and direct cellular contact with stimulated T cells,
induce the production of both sIL-1Ra and IL-1 (6–8).
An imbalance between pro- and anti-inflammatory cytokines
has been involved in the pathology of chronic immunoinflamma-
tory diseases, such as multiple sclerosis and rheumatoid arthritis
(9, 10). IFN- has proved beneficial to patients with relapsing-
remitting multiple sclerosis (11) and could be a potential therapy
for rheumatoid arthritis (12–14). The therapeutic effects of IFN-
might be due to the restoration of the balance between pro- and
anti-inflammatory cytokines (15–17). However, cellular mecha-
nisms involved in cytokine production and targeted by IFN- in
chronic inflammatory diseases remain unclear (11). In human
monocytes activated by proinflammatory stimuli, IFN- displays
opposite effects depending on the type of stimulus. Indeed, IFN-
inhibits TNF and IL-1 production in cell contact-mediated T lym-
phocyte signaling of monocytes (4, 18), in contrast with LPS-ac-
tivated monocytes in which IFN- enhances the production of both
IL-1 and TNF (19). However, with the latter stimuli, the produc-
tion of sIL-1Ra is enhanced upon addition of IFN-, which as such
potently induces the production of sIL-1Ra in monocytes (4). In
contrast, IFN- does not induce IL-1 protein or transcript (4, 19).
The type I IFN receptor complex (IFNAR) is expressed on most
cell types and consists of two structurally related polypeptides, one
of which binds the cytokine (IFNAR-2) and the other transduces
the signal (IFNAR-1) (for review, see Ref. 20). The canonical
pathway of intracellular signaling used by IFN- involves the ac-
tivation of the two receptor-associated Janus protein tyrosine ki-
nases JAK1 and Tyk2, which in turn activate by tyrosine phos-
phorylation members of the STAT family, STAT1, STAT2, and
STAT3 (20, 21). This leads to the formation of transcriptional
activator complexes, i.e., STAT1-STAT1, STAT1-STAT2,
STAT1-STAT3, and STAT3-STAT3 (22–24). In addition, recep-
tor ligation leads to the recruitment of downstream signaling ele-
ments, including STAT3 (25) and insulin receptor substrate (IRS)
proteins to IFNAR-1 (26). Both IRS-1 and STAT3 have been
shown to function as adapter proteins, linking IFNAR-1 to the p85
subunit of PI3K, resulting in enzyme activation (26). However,
another study demonstrates a direct interaction between PI3K and
IFNAR-1, but not with STAT3 (27). Other transduction pathways
involving MAPK have been shown to modify the JAK-STAT
pathway by interacting with IFNAR-1 (28).
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Several intracellular pathways leading to sIL-1Ra production in
human monocytes have been described that might depend on the
stimulus or the cell differentiation/maturation stage. MAPK such
as Raf-1 and ERK1/ERK2 have been involved in sIL-1Ra induc-
tion by LPS and leptin (29, 30). In contrast, serine/threonine phos-
phatases are involved in the induction of sIL-1Ra in monocytic
cells activated by cellular contact with stimulated T cells (31), and
STAT6 mediates the induction of sIL-1Ra by IL-4 (32). Further-
more, an LPS-inducible PI3K-dependent signaling pathway con-
tributes to the elevated translation of sIL-1Ra in septic/LPS-
adapted leukocytes, a pathway that does not affect the production
of IL-1 (33). The present study addresses the question as to the
signaling pathways involved in IFN- induction of sIL-1Ra in hu-
man monocytes. PI3K, but not MEK1 activation is essential for
sIL-1Ra production, as demonstrated by using pharmacological
inhibitors of PI3K and MEK1. Furthermore, although PI3K is in-
volved in Ser727 phosphorylation of STAT1, the latter factor,
which is part of the canonical IFN- signaling pathway, is not
involved in sIL-1Ra expression, as shown by knocking down
STAT1.
Materials and Methods
Materials
FCS, streptomycin, penicillin, L-glutamine, RPMI 1640, PBS free of Ca2
and Mg2, and TRIzol reagent (Invitrogen Life Technologies); Ficoll-
Paque (Pharmacia Biotech); PMSF, neuraminidase, and polymyxin B sul-
fate (Sigma-Aldrich); and Complete Mini EDTA-free (Roche Diagnostics)
were purchased from the designated suppliers. Human rIFN--1a (IFN-)
with a sp. act. of 3.97  108 IU/ml was a gift from ARES-Serono. IFN-
(5  106 IU/ml) was obtained from Biogen Idec. Kinase inhibitors
Ly294002, PD98059, and genistein were purchased from Calbiochem-No-
vabiochem. Other reagents were of analytical grade or better.
Monocytes
Monocytes were isolated from buffy coats of blood of healthy volunteers
provided by the Geneva Hospital blood transfusion center, as previously
described (4, 34). To avoid activation by endotoxin, polymyxin B sulfate
(2 g/ml) was added in all solutions during isolation procedure.
Cytokine production
Monocytes were activated with the indicated stimulus in RPMI 1640 me-
dium supplemented with 10% heat-inactivated FCS, 50 g/ml streptomy-
cin, 50 U/ml penicillin, 2 mM L-glutamine, and 5 g/ml polymyxin B
sulfate (medium) in 96-well plates (5 104 cells/well/200 l) and cultured
for 24 h or as otherwise stated. The production of sIL-1Ra was measured
in culture supernatants by commercially available enzyme immunoassay
for sIL-1Ra (Quantikine; R&D Systems).
sIL-1Ra mRNA
Monocytes (5  106 cells/well/500 l) were cultured in 24-well plates for
1 h with the indicated inhibitor and then for an additional 1 h with IFN-
(104 U/ml). Total RNA was isolated with TRIzol and analyzed by a com-
mercially available RNase protection assay system kit with hck2 template
set (BD Pharmingen), as previously described (34).
Western blot analysis
Monocytes were starved for 16 h at 37°C in RPMI 1640 medium supple-
mented with 1% heat-inactivated FCS in nonadherent conditions, i.e., in
polypropylene tubes (Falcon; BD Biosciences). Cells were harvested and
resuspended at 8  106 cells/ml in medium supplemented with 1% heat-
inactivated FCS, and 500 l was placed in 2-ml polypropylene tubes (Ep-
pendorf) at 37°C. After 1 h, inhibitors were added or not for 45 min, and
then cells were stimulated with IFN- (104 U/ml). After the indicated time
of incubation, the reaction was stopped by the addition of 800 l of ice-
cold PBS and centrifugation. Total cell lysate was prepared and subjected
to Western blot analysis, as described previously (35). The blots were
probed with anti-STAT1, anti-phospho Ser727 STAT1, and anti-phospho
Tyr701 STAT1 (Upstate Biotechnology). Secondary HRP-conjugated goat
anti-rabbit Abs were from DakoCytomation. Ab-bound proteins were de-
tected by the Uptilight hrp Blot Chemiluminescent substrate (Uptima).
Preparation of nuclear extracts and EMSA
Cell nuclear extracts were prepared, as described previously (36). Protein
concentrations were determined by the method of Bradford (37). Nuclear
extracts were analyzed for STAT1-binding activity by EMSA. The binding
reaction mixture contained 5 g of protein, 2 g of poly(dI-dC), and 10 g
of BSA in a final volume of 15 l of extraction buffer containing 20%
glycerol. Each reaction contained 5  104 cpm of unblunted dsSTAT1
oligonucleotide (5-GTGCATTTCCCGTAAATCTTGTC-3 and 5-TG
TAGACAAGATTTACGGGAAAT-3) that was labeled by fill-in with
DNA polymerase I large (Klenow) fragment in the presence of
[-32P]dCTP, as described (30). The reaction mixtures were incubated for
1 h at room temperature. Supershift was conducted by adding 100 g/ml
anti-STAT1 Ab (Upstate Biotechnology) 30 min before the end of the
reaction. Free and bound DNA were separated by electrophoresis on a 4%
nondenaturing polyacrylamide gel in 50 mM Tris, pH 8.0, containing 380
mM glycine and 2 mM EDTA. Gels were dried and subjected to
autoradiography.
STAT1 knockdown
STAT1 was silenced by using the 4-for-Silencing kit provided by Qiagen.
The four small interfering RNA (siRNA) sequences targeting human
STAT1 were as follows: 1) 5-GACCCAAUCCAGAUGUCUA-3; 2) 5-
AAGTCATGGCTGCTGAGAATA-3; 3) 5-GUUCGGCAGCAGCUU
AAAA-3; and 4) 5-GUCCUGAGUUGGCAGUUUU-3. siRNAs were
annealed according to manufacturer’s instructions, and then stored at
20°C before use. Monocytes were transfected with siRNA in Nucleofec-
tor device (Amaxa) by using Nucleofector human CD34 kit. Briefly, 5.6 g
of siRNA mixture (i.e., 1.4 g of each STAT1-specific siRNA) was added
to 3  106 monocytes that were previously washed in PBS, and resus-
pended in 100 l of human CD34 cell kit transfection solution. Cells
were subjected to nucleofection using the U08 program. Control cells were
either mock transfected or transfected with 6 g of nonsilencing rhodam-
ine-labeled siRNA (rho-siRNA). Transfected cells were immediately di-
luted in 2 ml of 37°C prewarmed RPMI 1640 complete medium and seeded
into 12-well plates (2.1 ml/well). After 3 h, 30–40% of -siRNA-trans-
fected cells were labeled, as assessed by light and fluorescent microscopy.
After 24 h, transfected cells were harvested, and their ability to produce
sIL-1Ra upon IFN- treatment was assessed, as described above. STAT1
knockdown was ascertained by quantitative real-time PCR and Western
blot. Western blot was conducted, as described above, using anti-STAT1-
specific Ab and anti-ERK1/2-specific Ab (Cell Signaling Technology) as a
control. To ascertain that STAT1-knocked down cells were defective in
STAT1-dependent responses, transfected cells were stimulated for 3 h with
either IFN- (1  104 U/ml) or IFN- (500 U/ml), and total mRNA was
analyzed by real-time PCR for the expression of STAT1, sIL-1Ra, and the
STAT1-dependent gene, FcR1 (38, 39). Quantitative real-time PCR anal-
ysis (TaqMan quantitative ABI PRISM 7900 Detection System) was con-
ducted after reverse transcription of mRNA prepared by RNeasy minikit
(Qiagen). The expression level of mRNAs was normalized to the expres-
sion of a housekeeping gene (18S). STAT1, FcR1, sIL-1Ra, and 18S
probes were obtained from Applied Biosystems. All measurements were
conducted in triplicates.
Statistics
When required, significance of differences between groups was evaluated
using Student’s paired t test; p  0.05 was considered to be significant.
Results
Activation of PI3K, but not of MEK1, is essential for optimal
sIL-1Ra production in human monocytes stimulated by IFN-
To determine whether MEK1 and PI3K were involved in sIL-1Ra
production induced by IFN-, monocytes were treated for 1 h with
Ly294002 and PD98059, which inhibit PI3K and MEK1 activity,
respectively, before stimulation with IFN-. After 24-h incubation,
the production of sIL-1Ra induced by 104 IU/ml IFN- reached
9.8  1.3 ng/ml (Fig. 1A), no IL-1 being detectable (data not
shown). Ly294002 inhibited the production of sIL-1Ra in a dose-
dependent manner, reaching 60  9% inhibition with 20 M
Ly294002, whereas PD98059 had no effect (Fig. 1A). Confirming
the inhibitor effects on protein production, Ly294002 inhibited
sIL-1Ra mRNA level by 80% at the highest dose, whereas
PD98059 had no effect (Fig. 1B). These results did not depend on
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monocyte preparation. Indeed, as shown in Fig. 1C, sIL-1Ra pro-
duction was significantly inhibited (40  20%) by 10 M
Ly294002, a suboptimal dose that was used to avoid cytotoxicity
often observed at higher concentrations in long-term (24-h) cul-
tures. Similarly, IFN--induced expression of sIL-1Ra transcript
was inhibited by 58  23% in the presence of 20 M Ly294002
(Fig. 1D). Together these results suggest that contrary to MEK1,
PI3K was involved in the signaling pathway leading to sIL-1Ra
production in monocytes stimulated by IFN-.
PI3K is involved in the induction of sIL-1Ra gene transcription
Because the production of sIL-1Ra might be regulated at several
levels, the involvement of PI3K in sIL-1Ra transcription or trans-
lation mechanisms was assessed. To ascertain that sIL-1Ra was an
immediate early gene in IFN--treated monocytes, cycloheximide
was used to interfere with the expression of a putative protein
intermediate. The IFN- induction of sIL-1Ra transcript was not
inhibited, but enhanced, by cycloheximide (Fig. 2A), demonstrat-
ing that sIL-1Ra was indeed an immediate early gene induced by
IFN- in human monocytes. Despite its enhancing effect on sIL-
1Ra mRNA, cycloheximide effectively inhibited sIL-1Ra produc-
tion in treated monocytes (Fig. 2B). The inhibitory effect of the
PI3K inhibitor Ly294002 was not affected by cycloheximide, the
expression of sIL-1Ra transcript induced by IFN- being inhibited
1.8-fold in the presence and absence of cycloheximide (Fig. 2C).
This further suggests that PI3K activation was directly involved in
the induction of sIL-1Ra gene transcription or mRNA stabilization,
and that this effect did not require protein neosynthesis. Levels of
mRNA may be reduced by inhibiting transcription or by decreas-
ing mRNA stability. To discriminate between effects of Ly294002
on transcription vs mRNA turnover, the stability sIL-1Ra tran-
script in the presence and absence of inhibitor was measured. As
shown in Fig. 3A, the transcription inhibitor, actinomycin D, abol-
ished the induction of sIL-1Ra mRNA by IFN-, thereby allowing
the determination of mRNA stability in the absence of transcrip-
tion. However, because sIL-1Ra mRNA reached a steady-state
level between 12 and 15 h and remained stable at least until 24 h
(data not shown) (4), the effect of Ly294002 on sIL-1Ra transcrip-
tion or mRNA stability was conducted by adding actinomycin D 3
and 4 h after the addition of IFN- and Ly294002, respectively, to
avoid cytotoxic effect display by the inhibitor in long-term activa-
tion. In the absence of actinomycin D, sIL-1Ra mRNA levels en-
hanced as a function of incubation time with IFN- (Fig. 3, B and
C). The sIL-1Ra transcript levels were lower in the presence of
Ly294002 throughout the experiment (Fig. 3, B and C). When
actinomycin D was added to monocytes (i.e., 3 h after activation
by IFN-), the levels of sIL-1Ra transcript remained unchanged
throughout the experiment regardless of the presence of Ly294002
(Fig. 3, B and C). This demonstrates that PI3K activation by IFN-
controlled sIL-1Ra gene transcription rather than contributing to
sIL-1Ra mRNA stabilization.
IFN--induced phosphorylation of STAT1 on Ser727 involves
PI3K activation
Because the canonical signaling pathway used by IFN- occurs
through the activation and transduction of STAT1, the effect of
kinase inhibitors on STAT1 phosphorylation on both Ser727 and
Tyr701 residues was examined. The phosphorylation of STAT1 on
Ser727 was already observed after 15 min of monocyte treatment
with IFN-, reached a maximum at 30–60 min, and lasted for at
FIGURE 1. PI3K is required for sIL-1Ra production and mRNA ex-
pression in human monocytes activated by IFN-. Isolated monocytes were
preincubated for 45 min with the indicated dose of Ly294002 (Ly) and
PD98059 (PD) and then stimulated or not with 1  104 U/ml IFN- for
either 24 h (A and C) or 3 h (B and D) in 96- and 24-well plates, respec-
tively, as described in Materials and Methods. A, sIL-1Ra production was
assessed in supernatants of triplicate cultures and is presented as mean 
SD. The results from one representative experiment of three are presented.
B, sIL-1Ra mRNA was analyzed by RNase protection assay in total RNA
isolated from 3-h stimulated cells. The RNase protection assay autoradiog-
raphy was quantified by densitometry and expressed as the ratio of sIL-1Ra
mRNA vs L32 mRNA that was used as housekeeping gene. The autora-
diography is typical of three different experiments. C, sIL-1Ra production
was assessed in supernatants of triplicate cultures of monocytes obtained
from five different donors. Monocytes were stimulated, as described above
(A), in the presence or absence of 10 M Ly294002. Results are presented
as mean  SD of percentage of sIL-1Ra production induced by 1  104
U/ml IFN- in the absence of inhibitor in each experiment; , p  0.01 as
determined by Student’s t test. D, sIL-1Ra mRNA expression in monocytes
obtained from five different donors. Monocytes were stimulated, as de-
scribed above (B), in the presence or absence of 20 M Ly294002. Den-
sitometric measurements of RNase protection assay autoradiographies are
presented as mean  SD of percentage of sIL-1Ra transcript induced by
1  104 U/ml IFN- in the absence of inhibitor; , p  0.005, as deter-
mined by Student’s t test.
FIGURE 2. sIL-1Ra is an immediate early gene induced by IFN-
through PI3K activation in human monocytes. A, Isolated monocytes (5 
106 cells/500 l) were preincubated with 10 g/ml cycloheximide (CHX)
for 30 min before the addition of 1  104 U/ml IFN- and activation for
the indicated time. Total mRNA was analyzed by RNase protection assay.
B, Monocytes (5  104 cells/well/200 l) were preincubated with 10
g/ml CHX before the addition of 1  104 U/ml IFN-. After 24 h, cell
supernatants were analyzed for sIL-1Ra content; results are expressed as
mean  SD of triplicates. The results from one representative experiment
of three are presented. C, Isolated monocytes (5  106 cells/500 l) were
preincubated in the presence or absence of 20 M Ly294002 (Ly) for 30
min before the addition of 10 g/ml CHX as indicated for another 30 min.
The cells were then activated with 1  104 U/ml IFN- for 60 min, and
total mRNA was analyzed by RNase protection assay. The autoradiogra-
phies (A and C) are typical of three different experiments.
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least 2 h (Fig. 4A). The phosphorylation of Tyr701 was observed
after 15 min and was virtually undetectable after 2 h (Fig. 4A).
Treatment of monocytes with IFN- in the presence of Ly294002
or PD98059 resulted in the inhibition of STAT1 phosphorylation
on Ser727 by 22 and 63%, respectively (Fig. 4B). The Tyr701 phos-
phorylation was significantly affected only by genistein, an unspe-
cific tyrosine kinase inhibitor used as control, which also inhibited
Ser727 phosphorylation of STAT1 (Fig. 4B). Both Ly294002 and
genistein inhibited sIL-1Ra production, in contrast with PD98059
that affected Ser727 phosphorylation without inhibiting the produc-
tion of sIL-1Ra (Fig. 4, B and C). Although indirectly, this strongly
suggests that the phosphorylation state of STAT1 was not related
to the production of sIL-1Ra. Together these data imply that the
production of sIL-1Ra induced by IFN- in human monocytes
depended on the activation of PI3K, but not of STAT1.
STAT1 nuclear translocation and binding to consensus DNA
sequence are not inhibited by Ly294002
To further assess that Ly294002 inhibition of STAT1 Ser727 phos-
phorylation was not involved in sIL-1Ra inhibition, the effect of
the inhibitor on STAT1 translocation and binding to IFN- acti-
vation site (GAS) consensus sequence was tested. As shown in
Fig. 5, STAT1 translocation and binding to consensus sequence
were inhibited in the presence of genistein, but not in the presence
of Ly294002, confirming that the modulation of STAT1 Ser727
phosphorylation by PI3K was not important in STAT1 transloca-
tion. This demonstrates that PI3K did not inhibit STAT1 translo-
cation and binding to GAS consensus sequence, further suggesting
FIGURE 3. PI3K controls sIL-1Ra transcription induced by IFN-. A, Isolated monocytes (5  106 cells/500 l) were activated with 1  104 U/ml
IFN- in the presence or absence of 10 g/ml actinomycin D (Act D) and cultured for the indicated time. Isolated total RNA was analyzed by RNase
protection assay. B, Isolated monocytes (5  106 cells/500 l) were preincubated in the presence or absence of 20 M Ly294002 (Ly) for 30 min before
the addition of 1  104 U/ml IFN-. Cells were then stimulated for 3 h with IFN- before the addition or not of 10 g/ml Act D. Cell culture was stopped
at the indicated time after Act D addition and total RNA analyzed by RNase protection assay. C, Densitometric analysis of B. The autoradiographies are
typical of three different experiments.
FIGURE 4. Both PI3K and MEK1 contribute to IFN--induced phos-
phorylation of STAT1. A, Isolated monocytes (4  106 cells/500 l) were
incubated with 1  104 U/ml IFN- for the indicated time. Cell lysates
were analyzed by Western blot, as described in Materials and Methods,
with Abs to STAT1, Ser727-phosphorylated STAT1 (PS-STAT1), and
Tyr701-phosphorylated STAT1 (PY-STAT1). B, Isolated monocytes (4 
106 cells/500 l) were treated with 20 M Ly294002 (Ly), 40 M
PD98059 (PD), and 100 M genistein (Genist.) for 45 min and then stim-
ulated with 104 U/ml IFN- for 30 min. Cell lysates were then analyzed by
Western blot. The presented autoradiographies are typical of three different
experiments. C, Isolated monocytes (5  104 cells/well/200 l) were pre-
incubated for 45 min with 10 M Ly294002 (Ly), 20 M PD98059 (PD),
and 100 M genistein (Genist.) and then stimulated or not with 1  104
U/ml IFN- in 96-well plates. sIL-1Ra production was assessed after 24 h
in culture supernatants of triplicate cultures and is presented as mean 
SD. The results from representative experiments of three are presented.
FIGURE 5. PI3K activation is not required for STAT1 nuclear translo-
cation and binding to GAS consensus sequence. Isolated monocytes (8 
106 cells/500 l) were treated with 20 M Ly294002 (Ly) and 100 M
genistein (Genist.) for 45 min and then stimulated with 104 U/ml IFN- for
30 min. Cell lysates were then analyzed by EMSA, as described in Mate-
rials and Methods. The autoradiography is typical of three different
experiments.
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that STAT1 activation was not involved in the induction of sIL-
1Ra expression mediated by PI3K in IFN--treated human
monocytes.
STAT1 is not required for sIL-1Ra induction
To assess that STAT1 was not involved in the IFN--triggered
signaling pathway leading to sIL-1Ra production, STAT1 was si-
lenced in monocytes by using siRNA duplex interference. STAT1
mRNA expression level was silenced by 90  1% in monocytes
transfected with siRNA directed against STAT1 as compared with
mock-transfected cells (Fig. 6). In monocytes transfected with the
control siRNA, STAT1 mRNA expression level was slightly de-
creased by 23  19% (Fig. 6A). However, this decrease was not
observed at the STAT1 protein levels. Indeed, the Western blot
analysis showed that STAT1 protein expression was not affected in
either mock-transfected cells or cells transfected with control
siRNA, in contrast with cells transfected with siRNA directed
against STAT1 (Fig. 6B). As shown in Fig. 6C, STAT1 knock-
down did not affect sIL-1Ra production in monocytes activated by
IFN-, because similar levels of sIL-1Ra production were obtained
in monocytes mock-transfected or transfected with control or
STAT1-specific siRNA. To ascertain that STAT1 silencing af-
fected genes, which expression depends on STAT1 activation,
STAT1-knocked down monocytes were activated by either IFN-
or IFN-, and the expression of FcR1 transcript was measured by
real-time PCR. The activation of monocytes by either IFN- or
IFN- enhanced 10 times the basal expression of STAT1 tran-
script whether cells were transfected or not with STAT1 siRNA
(Fig. 6D). However, in monocytes knocked down for STAT1, the
latter was inhibited by 80% independently of the stimulus.
STAT1 silencing was effective, because of the expression of
FcR1 being significantly inhibited by 76  3% and 38  4% in
STAT1 siRNA-transfected monocytes activated by IFN- and
IFN-, respectively, as compared with mock-transfected cells (Fig.
6D). Noticeably, IFN- was 3 times more efficient than IFN- in
inducing FcR1 transcript expression (Fig. 6D). This demonstrates
that STAT1 silencing affected the expression of STAT1-dependent
genes, as exemplified by FcR1. The difference in inhibition per-
centage between IFN-- and IFN--activated monocytes might be
due to the premise that FcR1 induction by IFN- depends on both
STAT1 and PU.1 activation (39). IFN- slightly inhibited the basal
expression of sIL-1Ra transcript (Fig. 6D), but did not induce sIL-
1Ra protein production (data not shown). sIL-1Ra mRNA was not
affected by STAT1 knockdown in either IFN-- or IFN--acti-
vated monocytes (Fig. 6D), confirming the results obtained at the
protein level (Fig. 6C). Together these results demonstrate that
STAT1 activation was not required for the IFN- induction of
sIL-1Ra production in human monocytes.
Discussion
The major finding of this study is that in human monocytes treated
by IFN-, sIL-1Ra production is controlled by PI3K through a
STAT1-independent pathway. Like PI3K, MEK1 activation con-
tributes to Ser727 phosphorylation of STAT1. However, MEK1
does not regulate sIL-1Ra production. PI3K controls the induction
of sIL-1Ra gene transcription, which is an immediate early gene
triggered by IFN- in human monocytes. This differs from data
obtained on so-called septic leukocytes. Indeed, in the latter cells,
PI3K regulates efficient translation of sIL-1Ra residual transcripts
induced by LPS, without affecting its transcription (33). Thus, de-
pending on the stage of monocyte maturation and/or type of stim-
ulation, PI3K may regulate sIL-1Ra production at different levels,
i.e., at the transcriptional level in monocytes and at the transla-
tional level in LPS-treated macrophages (33). The experiments
conducted with actinomycin D in this study reveal that PI3K reg-
ulated the transcription of sIL-1Ra, but was not involved in the
stabilization of sIL-1Ra mRNA, further confirming that different
signal transduction pathways might be engaged depending on the
cell type, i.e., monocytes or septic leukocytes, representing differ-
ent pathophysiological conditions.
Experiments conducted with cycloheximide showed a superin-
duction of sIL-1Ra transcript. The superinduction of cytokine
mRNA in monocytes-macrophages has been described previously
(40, 41). However, in the latter studies, this phenomenon was de-
scribed for proinflammatory cytokines, i.e., IL-1 and TNF; to our
knowledge, this is the first time that this is observed for sIL-1Ra.
There is no clear-cut explanation for this phenomenon, although it
was hypothesized that superinduction of immediate early genes by
protein synthesis inhibitors might occur via at least three ways,
including: mRNA stabilization; activation of intracellular signal-
ing cascades; and interference with transcriptional down-regula-
tion (42).
It has been shown that PI3K may be cross-activated upon IF-
NAR-1 engagement by IFN- (43), which triggers the activation
of the IRS signaling system. Indeed, in hemopoietic cells, IFN-
triggers Tyr phosphorylation of IRS-1 and IRS-2 and their subse-
quent association with the Src homology 2-containing p85 regu-
latory subunit of PI3K (26). In Daudi cells, STAT3 rather than IRS
fulfills the function of adapter protein between IFNAR-1 and PI3K
FIGURE 6. Inhibition of STAT1 expression in human monocytes by
siRNA does not affect IFN--induced sIL-1Ra production. Human mono-
cytes were mock transfected without siRNA addition (), transfected with
5.6 g of siRNA duplexes directed against the coding region of STAT1
(f), or with 6 g of a nonsilencing control siRNA (siControl, o). Twenty-
four hour postnucleofection, the following analyses were conducted: A, the
expression level of STAT1 mRNA, determined by quantitative real-time
PCR analysis, normalized to the expression of the 18S mRNA; B, STAT1
protein expression was determined by Western blot analysis with ERK1/2
as a control of protein loading; and C, monocytes (5  104 cells/200 l)
were stimulated or not with 1  104 U/ml IFN- in 96-well plates, and
sIL-1Ra production was assessed after 24 h in culture supernatants of trip-
licate cultures and is presented as mean  SD. D, Transfected monocytes
were stimulated for 3 h by IFN- (1 104 U/ml) or IFN- (500 U/ml), and
the indicated mRNA was measured by real-time PCR and expressed in
relative expression, the value of mRNA expression in unstimulated Mock-
transfected monocytes being arbitrarily considered as 1. The results from a
representative experiment are presented.
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(25), although experiments conducted in Tyk2-null cells demon-
strate a direct interaction between PI3K and IFNAR-1 (27). From
the present study, it appears that similarly to IFN-, IFN- triggers
the activation of PI3K, leading to the production of sIL-1Ra, which
pathway does not require STAT1 activation. The identity of the
adapter protein (if any) coupling IFNAR-1 to PI3K in human
monocytes stimulated by IFN- remains to be determined. The
possibility of STAT3 involvement was investigated by using JSI-
124, a so-called STAT3-specific inhibitor (44). JSI-124 inhibited
IFN--induced sIL-1Ra production, but failed to inhibit STAT3
phosphorylation (data not shown), suggesting that in human mono-
cytes, the latter inhibitor affected another mechanism.
In accordance with previous studies (20, 23), IFN- induces a
sustained Ser727 phosphorylation of STAT1 that peaks at 30–60
min and persists up to 2 h. The PI3K inhibitor, Ly294002, inhib-
ited both Ser727 phosphorylation of STAT1 and sIL-1Ra produc-
tion, suggesting that both mechanisms are regulated by PI3K.
However, the two events were not related. Indeed, although
PD98059, a MEK1 inhibitor, and genistein, an unspecific tyrosine
kinase inhibitor, inhibited Tyr701 and Ser727 phosphorylation of
STAT1, only genistein inhibited sIL-1Ra production. Conse-
quently, STAT1 was not involved in the IFN--triggered signaling
pathway leading to sIL-1Ra production. This was also suggested
by EMSA, in which Ly294002 did not inhibit STAT1 translocation
to the nucleus and binding to GAS consensus sequence, in contrast
with genistein. The inhibitory effect of genistein on STAT1 trans-
location and phosphorylation might be due to the inhibition of
Tyk2, which in turn might hamper PI3K activation (45). This was
reminiscent of previous studies that demonstrated that although
Tyr701 phosphorylation is essential for nuclear translocation and
DNA binding, additional phosphorylation of STAT1 at Ser727 gen-
erates maximal activation of transcription (46, 47). It was previ-
ously demonstrated that the MEK1 substrate, ERK2, is implicated
in Ser727 phosphorylation of STAT1 (28, 48); in this study, we
show that in addition to MEK1, PI3K also controls Ser727-STAT1
phosphorylation. The lack of involvement of STAT1 in sIL-1Ra
induction by IFN- was strongly established by the premise that
sIL-1Ra production was fully induced in human monocytes that
were knocked down for STAT1. Thus, in addition to JAK/STAT,
IFN- signals through other pathway(s) and particularly through
PI3K-dependent pathways that lead to the expression of genes
such as sIL-1Ra. These data are consistent with a recent study
demonstrating that a PI3K-dependent, STAT1-independent signal-
ing pathway regulates IFN-stimulated human monocyte adhesion
(49). However, in the latter study, the evidence supported the
PI3K-dependent, STAT1-independent adhesion of monocytes was
obtained with bone marrow-derived macrophages isolated from
STAT1/ mice. In the present study, this is demonstrated directly
in human monocytes that were knocked down for STAT1.
It was recently demonstrated that the engagement of TLR4 in
mouse macrophages induced the phosphorylation of STAT1 in
both Ser727 and Tyr701 residues (50). However, in contrast with the
present results, the phosphorylation of Ser727 precedes that of
Tyr701, which occurs only after 4-h stimulation by LPS. In the
latter condition, PI3K markedly contributed to Tyr701-STAT1, but
not to Ser727-STAT1 phosphorylation. Because part of TLR4 sig-
naling occurs through the induction of an autocrine loop of IFN-,
it is possible that differences in signaling exist between monocytes
and macrophages and/or between human and murine cells. How-
ever, the results obtained in the present study in freshly isolated
monocytes are in accordance with previous observations in human
monocyte-derived macrophages. Indeed, PI3K, but not the MAPK,
ERK1/ERK2, proved to be involved in the induction of the anti-
inflammatory cytokine IL-10 and the repression of TNF (51, 52).
Together with our results, the latter studies demonstrate that PI3K
plays an important part in the induction of anti-inflammatory cy-
tokines such as IL-10 and sIL-1Ra in cells of the monocytic lin-
eage. This contrasts with the requirement of PI3K in the chemo-
kine-dependent migration of neutrophils and macrophages, i.e., a
proinflammatory process, and should be taken into account when
considering PI3K as a pharmaceutical target in inflammation (53).
In conclusion, this study demonstrates that PI3K displays a key
regulatory function in sIL-1Ra production in human monocytes by
regulating its transcription. Because sIL-1Ra is an important anti-
inflammatory molecule, insight into the signaling mechanisms that
control its production might contribute to the development of
agents specifically interfering with inflammatory processes.
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The previous study ruled out a putative role of the STAT1 transcription factor in the 
induction of IL-1Ra by IFNb. This was surprising because STAT1 is currently believed to be an 
absolute requisite for all IFNb-elicited effects. In contrast, we pinpointed the crucial role of PI3Ks in 
the transcriptional regulation of the sIL-1Ra gene. This observation led us to investigate the functions 
of PI3Ks in the regulation of pro- and anti-inflammatory cytokine production by monocytes in 
conditions related to sterile and infectious inflammation. This is the subject of the following 
manuscript that is in preparation. 
4. Opposite regulation of IL-1b and sIL-1Ra production by 
phosphatidylinositide-3 kinases in human monocytes: involvement of 
different mechanisms upon acute and chronic inflammatory conditions 
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Abstract 
The unbalanced production of interleukin-1b (IL-1b) and its specific inhibitor secreted IL-1 
receptor antagonist (sIL-1Ra) plays an important role in chronic inflammation. Relevant to this 
condition, direct cellular contact with stimulated T cells is a potent inducer of cytokine production 
in human monocytes/macrophages. We previously demonstrated that activation of 
phosphatidylinositide-3 kinases (PI3Ks) controls the transcription of sIL-1Ra gene in human 
monocytes activated by IFNb. In this study we addressed the question of PI3K involvement in the 
production of IL-1b and sIL-1Ra in monocytes activated by cellular contact with stimulated T cells 
(mimicked by CHAPS-solubilized membranes of stimulated T cells, CEsHUT), or LPS, in order to 
compare stimuli involved in conditions relevant to chronic and acute inflammation, respectively. In 
monocytes activated by either CEsHUT or LPS, the PI3Ks inhibitor, Ly294002 reverted sIL-1Ra 
transcript expression and sIL-1Ra production to basal level. This demonstrates that PI3Ks 
controlled the induction of sIL-1Ra gene transcription. In contrast, Ly294002 increased the 
production of IL-1b protein, in both CEsHUT- and LPS-activated monocytes, the enhancement being 
drastically higher in the former. This was not due to changes in IL-1b mRNA steady-state levels 
and transcript stability as demonstrated by using actinomycin D in time-course experiments. In 
addition, the determination of intracellular and secreted IL-1b levels suggests that PI3Ks were 
mainly implicated in the repression of IL-1b release when cells were activated by LPS, whereas in 
CEsHUT-activated monocytes PI3Ks repressed both IL-1b protein secretion and yet-undefined 
mechanism(s). Interestingly, while IL-1b transcripts induced by CEsHUT displayed a higher degree 
of instability after 3 h activation (i.e., when steady-state was reached) than those induced by LPS, 
sIL-1Ra transcript half-life was shorter in LPS-activated monocytes than in CEsHUT-activated cells. 
Together, the present results demonstrate that PI3Ks are involved in the repression of IL-1b 
production and in the induction of that of sIL-1Ra in isolated human blood monocytes by 
controlling different mechanisms in conditions mimicking chronic/sterile (CEsHUT) and 
acute/infectious (LPS) inflammation. Thus PI3Ks represent key effectors that might be uncontrolled 
in pathological conditions. This further suggests that the stimulation of PI3K pathways may be an 
effective approach for preventing or treating chronic/sterile or dysregulated acute inflammation. 
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Introduction  
Interleukin-1 (IL-1a and IL-1b) is a critical mediator of the inflammatory response, playing 
an important part in the development of pathologic conditions leading to chronic inflammation. In 
humans, because IL-1a is predominantly an intracellular molecule, IL-1b is thought to mediate 
most of the IL-1 inflammatory effects. The production and effects of IL-1b are controlled at many 
levels, a critical one being the inhibition of its activities by the secreted form of IL-1 receptor 
antagonist (sIL-1Ra) (1). Both IL-1b and sIL-1Ra belong to the IL-1 gene family originating from 
the duplication of a common gene (2). IL-1b is synthesized as a precursor inactive protein that 
requires to be co-localized with and cleaved by caspase-1 into secretory lysosomes before being 
released to fulfill biological activity (3). The precursor of sIL-1Ra has a leader sequence requiring 
cleavage to be secreted as a mature protein. It is currently thought that an imbalance between IL-1b 
and sIL-1Ra production influences the development of inflammatory diseases and resulting tissue 
damage. This has recently been highlighted by studies demonstrating the efficiency of sIL-1Ra 
administration to patients with systemic inflammatory diseases (4-6) or rheumatoid arthritis (7,8). 
Upon inflammation, the main IL-1b producing cells are the monocytes/macrophages that 
concomitantly produce sIL-1Ra (1,9). In health, the latter cells do not constitutively express IL-1b 
(10-12).  
Upon acute inflammation, the production of IL-1b by monocytes/macrophages is induced by 
microbial activators through binding to members of the Toll-like receptor (TLR) family (13) as 
exemplified by lipopolysaccharides (LPS) that bind to TLR4. The activator(s) of IL-1b production 
in monocytes/macrophages upon chronic/sterile inflammation remain to be identified, but current 
evidence suggests that direct cellular contact with stimulated T cells might play a major part in this 
process. Indeed, contact-mediated activation of human monocytes/macrophages by stimulated T 
lymphocytes is a potent pro-inflammatory mechanism that triggers massive up-regulation of pro-
inflammatory cytokines (14-16). T cell contact-mediated activation of monocytes/macrophages by 
stimulated T cells is comparable to LPS in inducing IL-1b and tumor necrosis factor a (TNF) 
production (17). Concomitantly to IL-1b, LPS and cellular contact with stimulated T cells induce 
the production of sIL-1Ra in monocytes/macrophages. Because the production of IL-1b and sIL-
1Ra is tightly controlled in time, the signaling pathways leading to their production have to be 
distinct whilst trigger by the same stimulus. We previously demonstrated that serine-threonine 
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phosphatases play a part in the differential regulation of IL-1b and sIL-1Ra production by the 
monocytic cell line THP-1 when activated by contact with stimulated T cells (18). Furthermore, 
IFNβ, which induces the production of sIL-1Ra without inducing that of IL-1β in isolated human 
blood monocytes (19), differentially modulates the production of cytokines induced by either 
cellular contact or LPS (20). This suggests that the pathways leading to IL-1b and sIL-1Ra 
production are different in monocytes activated by cellular contact and LPS. More recently, we 
demonstrated that the induction of sIL-1Ra gene transcription and production by IFNβ in human 
monocytes depends on the activation of phosphatidylinositide 3-kinases (PI3Ks) (21). Because 
numerous studies support the premise that PI3Ks play a pivotal role in regulating the production of 
pro- and anti-inflammatory mediators in human monocytes/macrophages (22-24), the present study 
was undertaken to determine the functions of PI3Ks in the production of sIL-1Ra and IL-1b in 
conditions related to acute (LPS) and chronic/sterile (T cell contact) inflammation.  
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Experimental procedures 
Materials. ¾ Fetal calf serum (FCS), streptomycin, penicillin, L-glutamine, RPMI-1640, PBS free 
of Ca2+ and Mg2+ (Gibco, Paisley, Scotland); purified phytohemagglutinin (PHA) (EY 
Laboratories, San Marco, CA); Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden); TriÒReagent, 
phorbol myristate acetate (PMA), phenylmethylsulfonyl fluoride (PMSF), endotoxin-free 
dimethylsulphoxide (DMSO), pepstatin A, leupeptin, iodoacetamide, neuraminidase, bovine serum 
albumin (BSA), polymyxin B sulfate, actinomycinD (Sigma Chemicals Co., St. Louis, MO); LPS 
from Escherichia Coli 055:B5 (Difco Laboratories, Sparks, MI); and the kinase inhibitors 
Ly294002, SH-5 (Akt Inhibitor II), and genistein (Calbiochem-Novabiochem Corp., San Diego, 
CA) were purchased from the designated suppliers. All other reagents were of analytical grade or 
better. 
Monocytes. ¾ Monocytes were isolated from buffy coats of blood from healthy volunteers 
provided by the Geneva Hospital blood transfusion center as previously described (25). In order to 
avoid activation by endotoxin, polymyxin B sulfate was added to all solutions during the isolation 
procedure (2 mg/ml) and in experiments (5 mg/ml), where monocytes were activated by stimuli 
other than LPS.  
T cells and preparation of T cell plasma membranes.¾ HUT-78, a human T cell line (26), was 
obtained from the ATCC (Rockville, MD). Cells were maintained in RPMI 1640 medium 
supplemented with 10% heat-inactivated FCS, 50 g/ml streptomycin, 50 IU/ml penicillin, and 2 
mM -glutamine (complete RPMI medium) in 5% CO2–air humidified atmosphere at 37 °C. HUT-
78 cells (2×106 cells/ml) were stimulated for 48 h by PHA (1 mg/ml) and PMA (5 ng/ml). Plasma 
membranes of stimulated HUT-78 cells and their soluble CHAPS-extract (CEsHUT) were prepared as 
previously described (27). CEsHUT displays similar activation ability toward monocytes than that of 
living T cells (i.e., in cocultures) or fixed T cells as previously described (19,27,28). Proteins were 
 100 
measured by the method of Bradford (29) and cytokines as described below. IL-1a and IL-1b were 
not detected in membranes preparation. TNF was present 294 pg/mg proteins in CEsHUT. 
Cytokine production. ¾ Monocytes (50 x 103 cells/well/200 ml) were preincubated for 60 min at the 
indicated concentration of kinase inhibitor and then activated by CEsHUT (3 mg/ml proteins), or LPS 
(100 ng/ml) for 24 h in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 50 
mg/ml streptomycin, 50 U/ml penicillin, 2 mM -glutamine (medium) containing (CEsHUT) or not 
(LPS) 5 mg/ml polymyxin B sulfate. All conditions were carried out in triplicate. In indicating 
experiments, after removal of supernatants, cells were lysed in 200 ml of PBS containing 1% NP40. 
The production of cytokines was measured in culture supernatants or cell lysates by commercially 
available enzyme immunoassay: IL-1b (Immunotech, Marseille, France), TNFa and sIL-1Ra 
(Quantikine; R&D, Minneapolis, MN). 
Cytotoxicity assay. ¾ Monocytes (50 x 103 cells/well/200 ml) were preincubated for 60 min at the 
indicated concentration of kinase inhibitor and then activated by CEsHUT (3 mg/ml proteins), or LPS 
(100 ng/ml). After 24 h activation, 20 µl/well of EZ4U dye solution (Biomedica, Wien, Austria) 
was added and cells were cultured for additional 3 h. The cytotoxicity of kinase inhibitors was 
measured by absorbance at 450 nm.  
mRNA. ¾ Monocytes (3 x 106 cells/well/3 ml) were cultured in a medium containing (CEsHUT) or 
not (LPS) 5 mg/ml polymyxin B sulfate in 6-well plates for 60 min with 10 mM Ly294002 and then 
activated by CEsHUT (3 mg/ml proteins), or LPS (100 ng/ml) for the indicated time. Alternatively, in 
transcriptional arrest experiments, 10 mg/ml actinomycinD (ActD) was added 3 hours after 
monocyte activation. Total mRNA was prepared by TriÒReagent (Sigma). Quantitative real-time 
multiplex PCR analysis (TaqMan quantitative ABI PRISM 7900 Detection System, Applied 
Biosystems) was conducted after reverse transcription by the RQ1 kit (Promega). The mRNA 
expression levels were normalized with the expression of a housekeeping gene (18S) analyzed 
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simultaneously. IL-1b, sIL-1Ra, and 18S probes were obtained from Applied Biosystems. All 
measurements were conducted in triplicates. 
Western blot analysis. ¾ Human monocytes were starved for 16 h at 37°C in RPMI 1640 medium 
supplemented with 1% heat-inactivated FCS in non-adherent conditions, i.e., in polypropylene 
tubes (Falcon). Cells were harvested, resuspended at 8 x 106 cells/ml in medium supplemented with 
1% heat-inactivated FCS and 500 ml was placed in 2-ml polypropylene tubes (Eppendorf) at 37 °C. 
After 1 h, inhibitors were added for 45 min and then cells were activated by CEsHUT (3 mg/ml 
proteins), or LPS (100 ng/ml). At the indicating time, the reaction was stopped by the addition of 
800 ml of ice-cold PBS and centrifugation. Total cell lysate was prepared and subjected to Western 
blot analysis as described previously (21). The blots were probed with anti-p44/42 Map Kinase, 
anti-Akt/PKB, anti-phospho Akt/PKB [pS473] (Cell signaling Technology), and anti-b-tubulin 
(Sigma). Secondary horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse 
antibodies were from DAKO (Copenhagen, Denmark). Antibody-bound proteins were detected by 
the Uptilight hrp Blot Chemiluminescent substrate (Uptima, Interchim, Monluçon, France). 
Statistics. ¾ When required, significance of differences between groups was evaluated using 
Student’s paired t test; p < 0.05 was considered significant and p < 0.01 very significant.  
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Results 
PI3Ks differentially modulate IL-1b and sIL-1Ra production induced by LPS and CEsHUT in 
monocytes 
In order to assess the role of PI3Ks in the production of IL-1b and sIL-1Ra by human 
monocytes, freshly isolated cells were stimulated by LPS or CEsHUT in the presence or absence of 
Ly294002 a PI3K inhibitor. Huge differences were observed in the production of cytokines by 
different preparations of monocytes, depending on individual donors. In the absence of stimulus, 
IL-1b was not detected in cell supernatants, whereas sIL-1Ra production reached 825 ± 844 pg/ml 
and 823 ± 605 pg/ml, in the presence and absence of the endotoxin inhibitor, polymyxin B, 
respectively. Because high doses of CEsHUT displayed cytotoxicity (20), a sub-optimal dose of 
CEsHUT (3 mg/ml proteins) was used throughout this study. Such a dose of CEsHUT induced the 
production of 541 ± 134 pg/ml IL-1b and 9399 ± 1434 pg/ml sIL-1Ra in three different preparation 
of monocytes (from three different blood donors), whereas an optimal dose of LPS (100 ng/ml) 
induced the production of 2931 ± 1758 pg/ml IL-1b and 3251 ± 2976 pg/ml sIL-1Ra. This 
demonstrates that in the conditions used in this study, LPS appears to be more efficient in 
increasing IL-1b production than CEsHUT. In contrast, CEsHUT was a more potent inducer of sIL-1Ra 
production than LPS. These results confirm that CEsHUT (i.e., cell-cell contact with stimulated T 
cells) is a potent way of activating the release of large amounts of IL-1b and sIL-1Ra. Because the 
levels of cytokine production greatly varied as a function of monocyte preparation, throughout this 
study, the results are presented as percentages of cytokine production in the absence of inhibitor. 
As shown in Fig. 1, the PI3K inhibitor Ly294002 inhibited the induced production of sIL-1Ra, 
whereas it enhanced that of IL-1b. In the presence of Ly294002, the production of sIL-1Ra induced 
by CEsHUT was reduced by 77 ± 13%, while it was reverted to basal level upon LPS stimulation 
(Fig. 1). The inhibition of PI3Ks increased the production of IL-1b when monocytes were activated 
by either CEsHUT or LPS, although this enhancement was higher when monocytes were activated 
with CEsHUT (18-fold) than with LPS (1.5-fold). The enhancement of IL-1b upon LPS-activation in 
the presence of Ly294002 was consistently observed, although not statistically significant (p = 
0.067). This demonstrates that IL-1b and its specific inhibitor sIL-1Ra were inversely regulated by 
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PI3Ks upon LPS or contact with CEsHUT. In the absence of stimulus, Ly294002 did not affect 
cytokine production by monocytes (Fig. 1). These results suggest that PI3K signaling differentially 
modulated the production of sIL-1Ra and IL-1b cytokines, being required for the induction of the 
former and the repression of the latter. This was unique to PI3Ks, because inhibitors of MAPK 
signaling such as SB203580 (p38 MAPK) and UO126 (MEK1/2) inhibited the production of both 
IL-1b and sIL-1Ra (not shown). 
PI3K downstream elements involved the differential production of sIL-1Ra and IL-1b 
Because kinase inhibitors may display defects in specificity, we ascertained that Ly294002 
inhibited PI3K activation in the conditions used in this study. As shown in Fig. 2, both CEsHUT and 
LPS induced the phosphorylation of Akt, a kinase canonically activated downstream PI3Ks. When 
monocytes were activated by CEsHUT, the phosphorylation of Akt was already observed after 5 min 
activation and reached a maximum after 60 min before declining (Fig. 2A). Upon LPS activation, 
Akt phosphorylation also reached a maximum at 60 min, but was observed after 30 min activation. 
Thus both stimuli triggered the activation of the PI3K/Akt signaling pathway, the latter being 
activated early and persistently after the application of CEsHUT, whereas 30 min activation by LPS 
were required to observed a transient phosphorylation of Akt. In the presence of Ly294002, Akt 
phosphorylation was abolished in both CEsHUT- and LPS activated monocytes (Fig. 2B). This was 
also the case when cells were treated with genistein, a non-specific tyrosine kinase inhibitor. The 
solvent DMSO did not display any effect. This demonstrates that Ly294002 inhibited the PI3K/Akt 
pathway in monocytes activated by either CEsHUT or LPS. However, the differences in kinetics of 
Akt phosphorylation induced by LPS or CEsHUT, suggest that PI3K activities might be differentially 
used by the stimuli to regulate cytokine production.  
Akt is involved in the differential production of sIL-1Ra and IL-1b 
In order to assess the involvement of the PI3K/Akt pathway in the control of IL-1b and sIL-
1Ra production, monocytes were pre-incubated with the cell-permeable Akt inhibitor, SH-5, and 
then stimulated with either CEsHUT or LPS. SH-5 inhibited sIL-1Ra production by 54 ± 25% and 32 
± 16% in monocytes activated by CEsHUT and LPS, respectively (Fig. 3). Similarly to Ly294002, 
SH-5 slightly but significantly enhanced (1.5-fold) the production of IL-1b by monocytes activated 
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with LPS (Fig. 3). The Akt inhibitor was 8-times less efficient than that of PI3Ks to enhance the 
production of IL-1b induced by CEsHUT, the latter being increased only 2.2-fold. These results 
indicate that the activation of Akt downstream PI3Ks mediated part but not all the effects of PI3Ks 
on sIL-1Ra and IL-1b production by monocytes activated by either LPS or CEsHUT. However, Akt 
activity might be mandatory to control the repression of IL-1b downstream PI3Ks in LPS-activated 
monocytes. 
The enhancement of IL-1b production did not result from putative cytotoxic effect of kinase 
inhibitors 
To rule out the possibility that the enhancement of IL-1b release was due to a non-specific cytotoxic 
effect of the cell-permeable inhibitors, Ly294002 and SH-5, monocyte viability was assessed by 
using the tetrazolium reduction assay EZ4U. As shown in Fig. 4, monocyte treatment with SH-5, 
but not with Ly294002, caused only a small, not significant reduction in absorbance (over control) 
after 3 hours of dye-exposure (Fig. 4). This demonstrates that the enhancement of IL-1b production 
observed in the presence of Ly294002 (Fig. 1) or SH-5 (Fig. 3) was not a consequence of cytokine 
release by dying cells. This was confirmed by trypan blue exclusion analyses (data not shown) 
demonstrating that after 24 h of culture in the presence or absence of inhibitors cell viability was 98 
to 99%. These results prove that the increase of IL-1b production triggered by inhibition of PI3Ks 
or Akt did not result from acute cell death and the subsequent release of intracellular pool of pro-IL-
1b. 
PI3Ks control sIL-1Ra gene transcription 
To further investigate the molecular mechanisms underlying the control of sIL-1Ra 
production, we ascertained whether the decreased sIL-1Ra production in Ly294002-treated 
monocytes was accompanied by changes in sIL-1Ra mRNA steady-state levels. sIL-1Ra mRNA 
was not observed in the absence of stimulus (Fig. 5). Activation of monocytes by both LPS and 
CEsHUT increased sIL-1Ra mRNA levels as a function of incubation time, the steady-state being not 
reached after 9 h activation. In contrast, in Ly294002-treated monocytes, sIL-1Ra mRNA remained 
undetectable after 7 h activation by both stimuli (Fig. 5). Together with results of Figs. 1 and 3, 
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these data suggest that the inhibition of sIL-1Ra production in activated monocytes treated with 
Ly294002 was mainly due to the inhibition of gene transcription. In other words, CEsHUT and LPS 
triggered sIL-1Ra production through transcriptional mechanisms controlled by PI3Ks.  
PI3Ks do not control IL-1b mRNA steady-state levels or stability  
In order to determine by which mechanism(s) PI3Ks enhanced the production of IL-1b, the 
effects of Ly294002 on IL-1b mRNA levels was assessed. The IL-1b mRNA reached steady-state 
levels after 3 h stimulation by either CEsHUT or LPS (not shown), both stimuli inducing similar 
levels of IL-1b transcript. At this time point, the levels of IL-1b mRNA induced by either LPS or 
CEsHUT were not affected in the presence of the PI3K inhibitor (Fig. 6A). This suggests that PI3Ks 
were not involved in the control IL-1b mRNA steady-state levels. This was confirmed in time-
course experiments showing that IL-1b transcript steady-state levels were stable in the presence or 
absence of Ly294002 until 9 h after the addition of either LPS or CEsHUT (Fig. 6B). To gain 
insights into the mechanisms by which PI3K inhibition increased the induction of IL-1b in 
monocytes, the effect of Ly294002 on IL-1b mRNA stability was assessed in time-course 
experiments in the presence or absence of the transcription inhibitor, ActD. As shown in Fig. 7A, 
the presence of Ly294002 did not affect the rate of IL-1b mRNA decay in the presence of ActD 
whether monocytes were activated by CEsHUT or LPS. Thus, the increase of IL-1b production 
observed when PI3Ks were inhibited could be attributed to neither an enhancement of mRNA 
steady-state levels nor to mRNA stabilization. The results of Fig. 7A also indicate that IL-1b 
transcript induced by LPS was more stable than that induced by CEsHUT. In contrast the stability of 
sIL-1Ra mRNA was higher in CEsHUT- than in LPS-activated monocytes (Fig. 7B). 
PI3Ks control IL-1b secretion 
Because PI3Ks did not control IL-1b production by affecting its mRNA steady-state level or 
stability, they might affect either its translation rate or its secretion process. To assess these 
hypotheses, monocytes were activated by LPS and CEsHUT in the presence or absence of Ly294002 
and the production of both secreted IL-1b and intracellular pro-IL-1b was measured. In agreement 
with results of Fig. 1, IL-1b production was enhanced in monocytes whose PI3K activity was 
inhibited. In both CEsHUT- and LPS-activated monocytes, the intracellular content of pro-IL-1b was 
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diminished in the presence of Ly294002 (Fig. 8). Indeed, upon CEsHUT-activation, the levels of 
intracellular pro-IL-1b reached 10.3 ± 3.7 ng/ml in three different monocyte preparations and were 
decreased to 5.5 ± 3.3 ng/ml. In LPS-activated monocytes the induced production of pro-IL-1b (7.3 
± 6.1 ng/ml) was decreased to 4.2 ± 4.6 pg/ml in the presence of Ly294002. This suggests that 
PI3Ks played a part in controlling IL-1b secretion. When monocytes were activated by LPS, the 
total production of IL-1b was not changed in the presence of Ly294002, i.e., the addition of the 
amounts of IL-1b (extracellular) and pro-IL-1b (intracellular) was similar upon LPS-activation in 
the absence or presence of Ly294002. This suggests that in LPS-activated monocytes, PI3Ks 
controlled mechanisms involved in IL-1b secretion. This was not the case when monocytes were 
activated by CEsHUT. Indeed, in the latter condition, the enhancement of extracellular IL-1b 
production did not equal the diminution of pro-IL-1b inside the cell. This suggests that upon 
contact-mediated activation, PI3Ks controlled mechanisms involved in IL-1b secretion, but also 
other mechanisms that remain to be identify. Taken together, these results indicate that the 
activation of PI3Ks is a checkpoint controlling the release of pro-IL-1b from monocytes activated 
by LPS or CEsHUT.  
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Discussion 
The main finding of this study is that PI3Ks represent key signaling effectors controlling the 
differential production of IL-1b and sIL-1Ra by monocytes in conditions related to chronic/sterile 
and acute/infectious inflammation. Indeed, we demonstrated that PI3Ks control different 
mechanisms leading to the induction of sIL-1Ra gene transcription and the repression of IL-1b 
secretion. Importantly, PI3K activation is mandatory to the induction of sIL-1Ra gene transcription 
independently of the stimulus, being required when monocytes were activated by LPS, CEsHUT and 
IFNb (21). Although the repressing effect of PI3Ks on IL-1b production induced by LPS are mainly 
due to the inhibition of secretion, the latter mechanism explains only a part of IL-1b repression 
when monocytes were activated by CEsHUT.  
The enhancement of IL-1b production upon PI3K inhibition is reminiscent of a previous study 
showing that, in vivo, the inhibition of PI3Ks by its inhibitor wortmannin results in increased serum 
levels of cytokines including IL-1b in septic mice (30). The differential control of pro- and anti-
inflammatory factors by PI3Ks was described in monocytes activated by P. gingivalis LPS, i.e., 
through toll-like receptor 2. In the latter system, the inhibition of PI3Ks diminished the production 
of the anti-inflammatory cytokine IL-10 and concomitantly enhanced that of IL-12, a pro-
inflammatory cytokine (31). The repressing effects of PI3Ks on pro-inflammatory cytokine 
production have also been described in monocytes activated by contact with stimulated T cells. 
Indeed, cytokine-activated T cells and synovial T cells isolated from rheumatoid arthritis patients 
induce TNF production in human monocytes, the latter being enhanced upon PI3K inhibition (32). 
In contrast, cytokine-activated T cells-induced IL-10 production in macrophages was suppressed 
upon inhibition of PI3Ks (33).  
Our study brings new insights into the molecular mechanisms controlling sIL-1Ra production 
induced by stimulated T lymphocytes or LPS. In accordance with a recent study of ours 
demonstrating that IFNb regulates sIL-1Ra synthesis at the transcriptional level (21), here we show 
that monocyte activation by contact with stimulated T lymphocytes or LPS results in the activation 
of PI3Ks which is mandatory to the induction of sIL-1Ra gene transcription. In contrast, in 
septic/LPS-adapted monocytic THP-1 cells, LPS-induced PI3K activation contributes to the 
elevated translation of sIL-1Ra, displaying no effect at the transcriptional level (34). Hence, 
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according to monocyte condition, i.e., normal or septic/adapted, PI3K pathways might control 
different mechanisms to ensure sIL-1Ra production. 
Our data suggest that the PI3K inhibition increases IL-1b production in monocytes activated 
by CEsHUT or LPS by affecting mainly post-transcriptional processes. This is supported by the 
premise that neither IL-1b mRNA steady-state levels nor IL-1b mRNA stability were affected by 
the inhibition of PI3Ks. Moreover, the increase of extracellular levels of IL-1b in monocytes upon 
PI3K inhibition was accompanied by a decrease of the intracellular pro-IL-1b levels. This suggests 
that PI3Ks repress the release of pro-IL-1b from intracellular pools. This might be achieved by 
either impairing translocation of IL-1b into specialized secretory lysosomes (3) or by acting on the 
activity of caspase-1 which is required for the maturation of pro-IL-1b into IL-1b (35). In contrast 
with our results, showing that IL-1b production was mainly controlled by PI3Ks at the post-
transcriptional level, it was shown that PI3K-dependent pathways inhibit the activation of the 
transcription factors that regulate TNF and tissue factor gene expression in LPS-stimulated THP-1 
cells (23). Furthermore, treatment with wortmannin up-regulates IL-1b mRNA in THP-1 monocytic 
cells activated by LPS (36). Thus, depending on the type of monocytic cell or the product, PI3Ks 
might control different mechanisms to limit pro-inflammatory factor expression. 
In contrast with LPS-activated monocytes, Ly294002 enhanced the total production of IL-1b 
in CEsHUT-activated monocytes, i.e., the decrease of pro-IL-1b intracellular levels was smaller than 
the corresponding increase in secreted IL-1b levels. This suggests that in this condition, PI3Ks 
control other mechanisms than IL-1b secretion. This could involve the rate of IL-1b gene 
transcription and/or the translation rate of IL-1b mRNA. Further dissection of the molecular 
mechanisms controlling the production of IL-1b should shed light on the respective contribution of 
these mechanisms. 
The present results reveal that IL-1b transcripts have a shorter half-life in CEsHUT- than in 
LPS-activated monocytes. Such instability of IL-1b transcripts indicates that the CEsHUT-induced 
transcription rate has to be higher to maintain steady-state levels that are comparable with those 
induce by LPS (see Fig. 6A). In agreement with this, b2 integrins that might play a part in the 
production of IL-1b by monocytes activated by cell-cell contact with stimulated T cells also 
induced very labile IL-1b transcripts in monocytes (37). Thus distinct post-transcriptional 
regulation of IL-1b transcript degradation upon monocyte activation by LPS or CEsHUT might 
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account for differences in IL-1b production. In contrast with IL-1b mRNA, the half-life of sIL-1Ra 
mRNA was longer in CEsHUT- than in LPS-activated cells (see Fig. 6D). This corroborates with the 
induced levels of sIL-1Ra mRNA, which are 2-fold higher in monocytes activated by CEsHUT than 
in LPS-activated cells after 9 h activation (see Fig. 5). Therefore, different post-transcriptional 
regulation of sIL-1Ra mRNA decay in monocytes activated by LPS or CEsHUT could account for 
the differences observed in the production of sIL-1Ra. Together these results suggest that depending 
on the pathogenic mechanism, the nature and amplitude of the inflammatory response is differently 
regulated. The premise that contact-mediated activation of monocytes induced the expression of 
stable sIL-1Ra transcript corroborates with the tremendous amount of sIL-1Ra which is often seen 
in the inflamed synovium (1). The high stability of IL-1b mRNA induced by LPS might favor 
inflammatory responses to infectious agents, in contrast, dysregulated over-production of IL-1b 
participates in the development of septic shock, systemic inflammatory diseases, and chronic 
inflammatory diseases such as rheumatoid arthritis (38). Because contact-mediated activation of 
monocytes by stimulated T cells is though to be relevant of chronic inflammation, i.e., a pathologic 
mechanism, the instability of the IL-1b transcript induced in the latter conditions might be part of a 
general protective mechanism set in by the cells attempting to resolve inappropriate inflammatory 
processes. 
Because Ly294002 inhibits all classes of PI3Ks, the identity of that/those involved in the 
mechanisms described here remains elusive. The expression of two PI3Ks of the class I is mainly 
restricted to cells of the hematopoietic system, suggesting that they could be good candidates, i.e., 
PI3Kg and/or PI3Kd (39). Interestingly, it has been recently claimed that PI3Ks-mediated 
machinery could be an ideal therapeutic target in inflammatory diseases (40), and trials in animal 
models of rheumatoid arthritis have shown that the blockade of PI3Kg suppresses joint 
inflammation (41). This was mainly due to the inhibition of leukocyte recruitment to inflammatory 
sites. This does not corroborate the present results and those from others showing that the activity of 
PI3Ks limits inflammatory responses (31-33). Since effects of PI3Kg blockade on cytokine 
production have not been reported, more investigations are required to determine the PI3K 
responsible for the control of cytokine production balance, and cautions should be taken in the 
clinical use of PI3K inhibitors. 
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In conclusion, the activation of PI3Ks in either acute or chronic inflammatory conditions leads 
to the tight control of IL-1b and IL-1Ra production by ruling different mechanisms. PI3Ks repress 
IL-1b production mainly by controlling secretory processes, although other mechanisms might be 
involved when monocytes are activated by cell-cell contact with stimulated T cells. PI3Ks control 
the induction of sIL-1Ra gene transcription in monocytes activated by LPS and direct cellular 
contact with stimulated T cells, but also in IFNb-treated monocytes suggesting that PI3K activation 
is required for the expression and production of sIL-1Ra. Thus the activation of PI3Ks in monocytes 
reduces IL-1b and enhances sIL-1Ra production, an activity that may lead to the resolution of the 
inflammatory responses.  
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Legends to figures 
Fig. 1. PI3K inhibition induces differential sIL-1Ra and IL-1b  production in human 
monocytes activated by CEsHUT or LPS. Isolated monocytes (5 x 104 cells/200 µl) were 
preincubated for 60 min in the presence or absence of 10 µM Ly294002 (Ly) and then stimulated or 
not with either CEsHUT (3 µg/ml proteins) or LPS (100 ng/ml) for 24 h in 96-well plates. 
Experiments were performed in the presence (CEsHUT) or absence (LPS) of polymyxin B (5 µg/ml). 
sIL-1Ra and IL-1b production was assessed in supernatants of triplicate cell cultures as described in 
Materials and Methods. Results obtained with monocytes from three different donors are presented 
as mean ± SD of percentage of sIL-1Ra and IL-1b production induced by CEsHUT or LPS in the 
absence of inhibitor; *: p < 0.05, and **:p < 0.01, as determined by Student’s t test. 
Fig. 2. CEsHUT and LPS induce Akt phosphorylation via PI3K activation. A) Isolated 
monocytes (4 x 106 cells/500 µl) were incubated or not with either CEsHUT (3 µg/ml proteins) or 
LPS (100 ng/ml) in 2-ml tubes for the indicated time. Experiments were performed in the presence 
(CEsHUT) or absence (LPS) of polymyxin B (5 µg/ml). Cell lysates were analyzed by Western blot 
as described in Materials and Methods with Abs to phosphorylated Ser473-Akt (P-S-Akt) and Abs to 
ERK1/2 as a loading control. B) Isolated monocytes (4 x 106 cells/500 µl) were treated or not with 
10 µM Ly294002 (Ly), 100 µM genistein (Geni.), and 1/1000 dilution of DMSO for 45 min and 
then stimulated with either CEsHUT or LPS as described above in 2-ml tubes for 60 min. 
Experiments were performed in the presence (CEsHUT) or absence (LPS) of polymyxin B (5 µg/ml). 
Cell lysates were analyzed by Western blot as described using Abs to phosphorylated Ser473-Akt 
and mAbs to b-tubulin as a loading control. The presented autoradiographies are typical of three 
different experiments.  
Fig. 3. Akt inhibition differentially regulates sIL-1Ra and IL-1b production in human 
monocytes activated by CEsHUT or LPS. Isolated monocytes were cultured as described in Fig. 1 
using 10 µM Akt inhibitor II (SH-5) instead of Ly294002 as indicated. sIL-1Ra and IL-1b 
production was assessed in supernatants of triplicate cell cultures. Results obtained with monocytes 
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from three different donors are presented as mean ± SD of percentage of sIL-1Ra and IL-1b 
production induced by CEsHUT or LPS in the absence of inhibitor; *: p < 0.05 as determined by 
Student’s t test. 
Fig. 4. Inhibitors of PI3Ks and Akt do not display cytotoxic effects on human monocytes 
activated by CEsHUT or LPS. Isolated monocytes (5 x 104 cells/200 µl) were pre-treated or not 
with 10 µM Ly294002 (Ly), 10 µM SH-5, 100 µM genistein (Geni.), and 1/1000 dilution of DMSO 
for 60 min and then stimulated with either CEsHUT (3 µg/ml proteins) or LPS (100 ng/ml) in 96-well 
plates. After 24 h activation, 20 µl/well of EZ4U dye solution was added and cells were cultured for 
additional 3 h as described in Materials and Methods. Experiments were performed in the presence 
(CEsHUT) or absence (LPS) of polymyxin B (5 µg/ml). Absorbance at 450 nm was assessed in 
supernatants of triplicate cultures. Results are presented as mean ± SD of optical density (OD). The 
presented results are typical of three different experiments.  
Fig. 5. Time-course of sIL-1Ra mRNA induction by CEsHUT or LPS. Isolated monocytes (3 × 
106 cells/3 ml) were preincubated for 60 min in the presence or absence of 10 µM Ly294002 (Ly) 
and then stimulated or not with either CEsHUT (3 µg/ml proteins) or LPS (100 ng/ml) in 6-well 
plates, as described in Materials and Methods. Experiments were performed in the presence 
(CEsHUT) or absence (LPS) of polymyxin B (5 µg/ml). At the indicated time total RNA was isolated 
and the expression level of sIL-1Ra mRNA was determined by quantitative real-time PCR analysis 
of triplicates normalized to the expression of the 18S mRNA. Results are presented as mean ± SD 
of percentage of relative sIL-1Ra expression induced by CEsHUT or LPS, the value of mRNA 
expression in 3 h-activated monocytes being arbitrarily considered as 100%. Results are 
representative of 3 distinct experiments.  
Fig. 6 . PI3Ks do not affect IL-1b  mRNA steady-state levels induced by CEsHUT or LPS. 
Isolated monocytes (3 × 106 cells/3 ml) were preincubated for 60 min in the presence or absence of 
10 µM Ly294002 (Ly) and then stimulated or not with either CEsHUT (3 µg/ml) or LPS (100 ng/ml) 
for 3 h (A) or the indicated time (B) in 6-well plates, as described in Materials and Methods. 
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Experiments were performed in the presence (CEsHUT) or absence (LPS) of polymyxin B (5 µg/ml). 
Total RNA was isolated and the expression level of sIL-1Ra mRNA was determined by quantitative 
real-time PCR analysis of triplicates normalized to the expression of the 18S mRNA. (A) Results 
are presented as mean ± SD of percentage of relative sIL-1Ra expression induced by CEsHUT or LPS 
from triplicate cultures. (B) Results are presented as mean ± SD of percentage of relative sIL-1Ra 
expression induced by CEsHUT or LPS. The value of mRNA expression in 3 h-stimulated monocytes 
being arbitrarily considered as 100%. Results are representative of 3 distinct experiments.  
Fig. 7. CEshut- or LPS-induced IL-1b and sIL-1Ra transcripts display different stability. 
Isolated monocytes (3 × 106 cells/3 ml) were preincubated for 60 min in the presence or absence of 
10 µM Ly294002 (Ly) before addition of either CEsHUT (3 µg/ml proteins) or LPS (100 ng/ml). 
Cells were then stimulated for 3 h before the addition or not of 10 µg/ml ActD (time = 0). Cell 
culture was stopped at the indicated time after ActD addition and IL-1b and sIL-1Ra mRNA levels 
were determined by quantitative real-time PCR analysis of triplicates normalized to the levels of the 
18S mRNA as described in Materials and Methods. Experiments were performed in the presence 
(CEsHUT) or absence (LPS) of polymyxin B (5 µg/ml). The relative expression levels of (A) IL-1b 
mRNA and (B) sIL-1Ra mRNA are presented as mean ± SD of percentage of relative cytokine 
expression induced by CEsHUT or LPS. The value of mRNA levels in 3 h-stimulated monocytes 
being arbitrarily considered as 100%. Results are representative of 3 distinct experiments.  
Fig. 8. PI3K inhibition enhances IL-1b  secretion in human monocytes activated by CEsHUT or 
LPS. Isolated monocytes (5 x 104 cells/200 µl) were preincubated for 60 min in the presence or 
absence of 10 µM Ly294002 (Ly) and then stimulated or not with either CEsHUT (3 µg/ml proteins) 
or LPS (100 ng/ml) for 24 h in 96-well plates. Experiments were performed in the presence 
(CEsHUT) or absence (LPS) of polymyxin B (5 µg/ml). IL-1b and pro-IL-1b production was assessed 
in supernatants and cell lysates, respectively, of triplicate cell cultures as described in Materials and 
Methods. Results obtained with monocytes from three different donors are presented as mean ± SD 
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of percentage of sIL-1Ra and IL-1b production induced by CEsHUT or LPS in the absence of 
inhibitor; *: p < 0.05, as determined by Student’s t test. 
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SUMMARY, DISCUSSION, AND CONCLUSIONS 
1. Summary 
As summarized in Figure 16, in this thesis we ruled out the controversial implication of the 
CD40L-CD40 interaction in T cell-contact-mediated activation of monocyte/macrophages, a 
mechanism that appears to play an important part in the initiation and persistence of chronic/sterile 
inflammatory diseases such as RA and MS (Figure 16A). Because other collaborators of our team 
currently carried out the identification of T cell surface molecules implicated in this mechanism, we 
then investigated the effects of IFNb, a molecule with beneficial outcome in MS and likely in RA, on 
T cell-contact activated monocyte function, in regard to cytokine production. In parallel, in order to 
compare two inflammatory conditions, we also assessed the effects of IFNb on monocyte 
inflammatory functions in activating conditions relevant to acute/infectious inflammation. We 
demonstrated that IFNb directed monocyte function towards an anti-inflammatory status in 
conditions of activation relevant to chronic, but not acute inflammation (Figure 16B). Therefore, our 
results both strengthen the hypothetical in vivo relevance of T cell contact-mediated activation of 
monocyte/macrophages and provide a rationale for the observation that IFNb-treated MS patients are 
not more prone to infection than normal individuals. Because an important anti-inflammatory feature 
of IFNb is the triggering of sIL-1Ra production by monocytes, we then addressed the question of the 
signaling pathways implicated in the induction of the latter by IFNb. Surprisingly, our data, ruled out 
a putative role of the STAT1 transcription factor, which was believed to be an absolute requisite for 
all IFNb-elicited effects. In contrast, we pinpointed the crucial role of PI3Ks in the transcriptional 
regulation of the sIL-1Ra gene (Figure 16C). This observation led us to investigate the functions of 
PI3Ks in the regulation of pro- and anti-inflammatory cytokine production by monocytes in 
conditions related to sterile and infectious inflammation. The latter study established that PI3Ks 
represent key effectors of cytokine homeostasis that might be uncontrolled in pathological conditions 
(Figure 16D). 
Since the results described in this thesis have been discussed in enclosed publications, this 
section is devoted to unresolved questions and future directions that should be assessed in order to 
better characterize the molecular basis of cell-cell contact.  
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2. Discussion 
I would like to emphasize part of the study assessing the implication of the CD40L-CD40 
interaction in T cell-contact signaling between stimulated T lymphocytes and distinct monocytic 
 
Figure 16. Schematic representation of major findings of this thesis. A) The CD40L-CD40 interaction does not rule pro-inflammatory cytokine 
production by monocyte/macrophages (Mf) activated by contact with stimulated T lymphocytes (sTL). B) While IFNβ differently affects IL-1β and 
TNF production induced by sTL or LPS, with both stimuli it potentiates that of sIL-1Ra, the latter being directly induced by IFNb. C) IFNb-
induced sIL-1Ra production is regulated at the transcriptional level by PI3Ks but not STAT1. D) Regardless the nature of stimulus, PI3Ks inflicts a 
breaking mechanism to maintain a proper inflammatory response, by acting on both pro- and anti-inflammatory cytokine expression/production 
machinery. 
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cells, dealing with peripheral blood monocytes and IFNg-macrophages, but not THP-1 cells, as they 
would be not relevant. 
2.1. Differential response of monocytes and IFNg-macrophages to contact-mediated 
activation by stimulated T cells  
We demonstrated that IFNg-macrophages are less responsive to activation by contact with 
stimulated T lymphocytes as compared with peripheral blood monocytes. As discussed in our paper, 
this observation might be the result of signaling pathway variations as a function of cell 
differentiation/maturation. This hypothesis was supported by the demonstration that although 
monocytes express CD40, only IFNg-macrophages responded to CD40LT in terms of TNF 
production. Signaling pathway modulations might be the consequences, among others, of qualitative 
or quantitative alterations in expression of IFNg-macrophage receptor(s) for the activating factor(s) 
expressed on stimulated T lymphocytes. These include a decreased surface expression, 
conformational rearrangement, and/or biochemical modification of an existing receptor. Indeed, 
monocyte/macrophage differentiation in vitro is characterized by the increase of macrophage specific 
activities associated with the decrease of some monocyte characteristics(613). For instance, IL-1b 
production and cell-surface specific receptors such as TLR4 are down-regulated upon differentiation 
from monocytes to macrophages(614). Alternatively, IFNg-macrophages may display a higher 
sensitivity to interactions with inhibitory molecule(s) that could be expressed at the surface of T 
lymphocytes. This hypothesis is supported by the observation that unstimulated T cells are capable to 
inhibit LPS-induced TNF production by monocytes, whereas the same T lymphocytes after 
stimulation are capable to induce TNF production by monocytes(365). This observation implies that 
stimulated T lymphocytes might express cell surface factor(s) that inhibit TNF production by 
monocytes, in addition to the expression of stimulatory ligands. However, in our hand, membranes 
isolated from unstimulated T cells failed to inhibit IL-1b production in monocytes activated by 
stimulated T lymphocytes (data not shown). The possibility still exists that IFNg-macrophages might 
display functional inhibitory signaling pathways through occupation of putative inhibitory 
receptor(s). These receptors might belong to the sialic acid binding immunoglobulin-like lectin 
(SIGLEC) family, or TIR family members such as ST2 and SIGIRR, and TNF-related apoptosis 
inducing ligand receptor (TRAILR)(615). For instance, one of the SIGLEC family member, CD33, is 
able to negatively control IL-1b and TNF production by human monocyte/macrophages(616). The 
relevance of such a premise could be examined by assessing whether contact with unstimulated T 
lymphocytes would impair the activation of IFNg-macrophages by either LPS or stimulated T 
lymphocytes. If this would result in inhibition with both stimuli, this would suggest that common 
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signaling pathways leading to cytokine production in both acute and chronic conditions might be 
used in macrophages, which are affected by inhibitory factors at the surface of T cells. 
2.2. Differential effects of IFNb  and IFNg in monocyte/macrophage functions 
On the basis of the study assessing the effect of IFNb on pro-inflammatory cytokine 
production by monocytes activated by either stimulated T lymphocytes or LPS, a number of 
similarities and discrepancies were emphasized between the effects of IFNb on 
monocyte/macrophage functions and those of IFNg reported in the literature. This depends on the 
stimulatory conditions. IFNg is currently portrayed as a critical initial signal for 
monocyte/macrophages inflammatory and effector functions, including in T cell-contact-dependent 
interactions(390). It is claimed in most studies that induction of monocyte/macrophage functions 
involves two initial signals, one of which is provided by IFNg, and the other by LPS, TNF or any 
stimulus. Our observation that IFNb enhanced monocyte inflammatory functions in response to LPS 
(Figure 16B) underlines the likeness between IFNg and IFNb. This is in sharp contrast with data 
obtained on monocyte inflammatory functions in the context of cell-cell contact. Indeed, while we 
demonstrated that IFNb impaired pro-inflammatory cytokine production by monocytes activated by 
cellular contact, it has been reported that stimulated T lymphocytes can induce IL-12 production by 
IFNg-primed monocytes if given as a second signal, whereas the very same T cells block IL-12 
production efficiently when given to nonprimed, resting monocytes before the stimulation 
challenge(617). This suggests that the prerequisite for IFNg priming would in vivo restrain 
monocyte/macrophage activation in influx areas of TH1 cells or cytotoxic T cells (i.e. IFNg 
producers). The capability of stimulated T lymphocytes to activate IFNg-primed 
monocyte/macrophages in antigen-nonspecific interactions might facilitate the activation of 
monocyte/macrophages infiltrating a lesion that does not provide macrophage-activating signal such 
as LPS(388). During the course of inflammation, the production of IFNg by stimulated T cells might 
provide the priming signal necessary to strengthen cytokine production by newly infiltrating 
monocyte/macrophages; this in turn might initiate the switch to a TH1-like/pro-inflammatory 
cytokine milieu characterizing chronic inflammation. I hypothesize that the presence of IFNb might 
reverse the effect of IFNg on monocyte effector and inflammatory functions. This is strengthened by 
a recent report showing that the increased expression of IFNb in RA synovium is associated with the 
activation of an immuno-modulatory mechanism that could inhibit synovial inflammation(618). In 
contrast with IFNb, IFNg potentiates LPS-induced IL-1b production by monocyte/macrophages, 
whilst inhibiting sIL-1Ra production, leading to a net pro-inflammatory bias in the LPS-induced 
response(619). Similarly, there are differences between IFNb and leptin and TH2 cytokines, 
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including IL-4, IL-10 and IL-13. The latter enhance the stimulatory effect of LPS on the production 
of sIL-1Ra by monocytes, whereas they decrease the synthesis of IL-1b(620-625). Taking as a 
whole, our results imply that IFNb shares features of both TH1 and TH2 cytokines.  
2.3. Molecular mechanisms possibly involved in the effects of IFNb  in cytokine homeostasis 
Although our results suggested that the ultimate effect of IFNb depends on the stimulus 
(Figure 16B), the molecular mechanisms involved are still elusive. Therefore, below I review some 
potential mechanisms that might give rise to such phenomenon. Upon contact-mediated activation of 
monocytes, the effect of IFNb on monocytes may result from an alteration of receptor(s) for either 
the activating or inhibitory ligand(s) expressed on T cells, respectively. Yet, IFNb might also act on 
different intracellular molecular mechanisms. Indeed, IFNb inhibits IL-1b and TNF production at 
both protein and messenger levels. IFNb may proceed trough several distinct molecular mechanisms 
to decrease mRNA levels in monocytes(626), one of them being the inhibition of transcription by 
IFN-inducible factors, such as CIS protein and SOCS proteins. It is tempting to claim that IFNb 
controls the expression or activity of a set of regulators of the signal transduction pathways exploited 
by T cell-contact interactions. IL-1b and TNF expression might also be regulated post-
transcriptionally by IFNb. The most probable cause of altered mRNA stability is a change in 
processing of the 3’-untranslated region’s AU-rich element (ARE) that controls RNA stability of 
many cytokines, including IL-1b and TNF. Further investigations are required to shed light on the 
underlying intracellular molecular mechanism(s) responsible for the effect of IFNb on cytokine 
production by monocyte activated by stimulated T lymphocytes.  
In LPS-activated monocytes, IFNb might increase IL-1b and TNF production by enhancing 
the transcription rate of both genes besides affecting transcript stability. The interaction of TLR4 
with LPS results in the induction of an array of immune response genes, which involves activation of 
the transcription factors, NF-kB and STAT1. For instance, LPS-induced CD40 expression in 
monocyte/macrophages involves, besides NF-kB activation, the endogenous production of IFNb 
through an autocrine loop, which contributes to the enhancement of CD40 expression by activating 
STAT1(627). An alternative mechanism that may explain how IFNb enhances cytokine production 
induced by LPS comes from the ability of IFNa to sensitize monocytes to microbial recognition. 
Indeed, IFNa pre-treatment enhances LPS responsiveness in monocytes by up-regulating the 
expression of TLR4 as well as several adapter molecules and kinases involved in its signaling(628). 
Since both IFNs share a common signaling receptor, it is tempting to hypothesize that IFNb, like 
IFNa, might similarly affect TLR4 signaling. It would be of interest to determine whether the long-
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lasting IFNb pre-treatment, which potentiates the effect of LPS on cytokine production, would 
achieve such molecular modifications of the TLR4 signaling. 
2.4. Downstream effectors of PI3K leading to sIL-1Ra transcription 
We demonstrated that while sIL-1Ra production was controlled at the transcriptional level by 
PI3K activity we ruled out any implication of STAT1 in this process (Figure 16C). This was 
surprising because STAT1 is part of the canonical IFNb signaling pathway and sIL-1Ra gene 
promoter contains STAT1 specific binding sites, as determined by a search for potential transcription 
factor binding (PATCHTM public 1.0, http://www.gene-regulation.com/index.html). However, 
examples of STAT1-independent sIL-1Ra induction have been described including by IL-1b, which 
signaling pathways were not shown to date to implicate STAT1 transcription factor. This study does 
not answer the question of the identity of the downstream components of the PI3K signaling pathway 
leading to sIL-1Ra expression. Because we demonstrated that IFNb-stimulated sIL-1Ra expression is 
abolished by the tyrosine kinase inhibitor genistein, we can speculate that JAk/STAT family 
members, other than STAT1, might be implicated in IFNb-induced sIL-1Ra production. Indeed, we 
demonstrated for instance that monocyte activation by IFNb triggered the activation of STAT3 
(629). This activation could subsequently lead to the formation of the transcriptional activator 
complex STAT3-STAT3(630-632), which functional binding site is found on sIL-1Ra gene 
promoter(165). Because PI3K activity controls the transcription of IFNb-induced sIL-1Ra gene in 
monocytes, the systematic knockdown, through small interfering RNA, of IFNb-inducible 
transcriptions factors, such as STAT3, might lead to the identification of potential downstream 
components of the PI3K pathway. Interestingly, while, leptin signaling pathway in monocytes 
includes different STATs, including STAT1, STAT3 and/or STAT4(620), the stimulation of sIL-1Ra 
expression by leptin is not inhibited by genistein(620). This observation suggests that JAk/STAT 
pathway is not required in leptin-induced sIL-1Ra production in monocytes, and consequently 
strengthens the premise that other signaling elements than STATs might be controlled by PI3Ks in 
IFNb-induced sIL-1Ra production by monocytes. The investigations of such signaling components 
may also partially elucidate by which mechanisms PI3Ks regulated sIL-1Ra production by 
monocytes activated by either LPS or stimulated T lymphocytes (Figure 16D). 
2.5. Roles of PI3Ks in cytokine homeostasis  
We demonstrated that the PI3K pathway in monocytes is critical to build-up an anti-
inflammatory state upon both chronic and acute inflammatory conditions, by both directly up-
regulating sIL-1Ra production and decreasing that of IL-1b (Figure 16D). This is particularly 
obvious in the case of septic-adapted monocytes, in which PI3Ks contribute to the repression of 
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inflammatory cytokine production, including IL-1b, and selectively mediate LPS-induced sIL-1Ra 
mRNA translation(578;602;633). Therefore, it would be of specific interest to determine whether 
PI3K activity would display similar effects in IFNg-macrophages than in monocytes, IFNg-
macrophages being representative of inflammatory macrophages. 
Recently, growing attention has been paid on specific PI3K isoforms that may regulate 
essential mechanisms implicated in inflammation such as leukocyte chemotaxis or mast cell 
degranulation. For instance, the blockade of class IB PI3K isoform (PI3Kg) in CIA suppress 
leukocyte recruitment and subsequent joint inflammation and damage(570). In contrast, in our 
model, the blockade of PI3K activity favors the secretion of pro-inflammatory mediators. Therefore, 
the identification of specific isoforms that are implicated in the regulation of cytokine production in 
human monocytes activated by stimulated T lymphocytes (or LPS) would be of an outstanding 
biological and therapeutic interest. However, with the exception of class IB isoform, the 
determination of specific function of class IA isoforms would be associated with numerous technical 
problems (See(1;634) also section 7.3.1). First, because optimal signaling through the PI3K pathway 
depends on a critical molecular balance between the regulatory and catalytic subunits(611), 
knockdown of class IA adaptor subunits would affect the expression of the p110 subunits and vice 
versa(1). Neutralizing antibodies of a given catalytic or regulatory isoform in monocytes would also 
have an impact on the functions of all isoforms. Therefore, the next alternative approach would 
consist to artificially express a mutated and catalytically dead isoform of PI3Ks in monocytes. 
However, to date, one of the major obstacles in delivering genes into human monocytes is the poor 
transduction or transfection efficiency under most currently available gene-transfer conditions(635). 
It has been reported that while monocytes could be generated in culture from CD34+ hematopoietic 
progenitor cells, the latter being permissive to gene transfer, the route of differentiation towards 
monocytes may result to monocyte phenotypic and functional variations. Nonetheless, encouraging 
perspectives are currently emerging considering that fresh peripheral blood monocytes can be 
transfected with mRNA by electroporation(636) and that PI3K isoform-specific inhibitors are 
starting to be commercially available. 
2.6. Intracellular mechanisms responsible for the induction of cytokines in T cell contact-
mediated activated monocytes 
The dissection of intracellular mechanisms induced by extract of whole membrane of 
stimulated T cells (CEsHUT) might be complicated by the multiplicity of the signals involved. 
However, we demonstrated that the induction of PI3K activation is very tightly regulated, i.e., only 
one activation wave of Akt phosphorylation was observed. This suggests that a very restricted 
number or only one stimulating factor at the surface of stimulated T cells is inducing the PI3K 
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pathway. We thus guess that CEsHUT can be used to dissect intracellular pathways controlling 
cytokine production. Since TLRs have been shown to play important part in acute 
inflammation(513), the involvement of such receptors or their downstream adaptor molecules in T 
cell-interaction signaling might be involved. In humans, MyD88 is a TLR signaling adaptor molecule 
that is used by all TLRs apart from TLR3, which signals through TRIF. MyD88 interacts with the 
IRAK family, leading to interaction with TRAF6, which ultimately leads to activation of NF-kB. 
Furthermore, MyD88 proved to be an adapter molecule triggering the activation of PI3Ks(527;589) 
which play a key regulatory role in the induction of sIL-1Ra and IL-1b production in monocytes (see 
results part 4). This strengthens our hypothesis of a role for MyD88 in T cell contact interactions-
induced signaling pathways. Since TLRs are a widespread way to activate monocyte/macrophages in 
inflammation, the receptor at the surface of monocyte/macrophages for activating factor expressed at 
the surface of stimulated T lymphocytes might be a member of the TLR family signaling through 
similar adaptors. This question might be addressed by silencing MyD88 and/or TRIF in human 
monocytes. This should shed light on the nature of the receptors involved in contact-mediated 
activation of monocytes. 
3. Conclusions 
Since cell-cell contact with stimulated T lymphocytes is a major pathway inducing IL-1 and 
TNF in monocyte/macrophages, it is likely to be relevant to chronic inflammatory diseases at the 
local site of inflammation where these cells are in close vicinity. Attempts at identifying the cell-
surface molecules - ligands and counter-ligands - involved in these processes are only at the initial 
stage, especially with regard to their hierarchy, the sequence of events and the possible cellular 
crosstalk. The elucidation of mechanisms by which the processes of monocyte-macrophage 
differentiation/maturation or monocyte immuno-modulation impairs the response of monocytic cells 
to activation by stimulated T lymphocytes, might shed light to molecular events distal to receptors 
that selectively control cytokine production. Furthermore, the caracterization at the molecular level 
of intracellular pathways that regulate the intricate relationships between T lymphocytes and 
monocyte/macrophages may give rise to the development of novel therapeutic approaches in chronic 
destructive, inflammatory diseases. 
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